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C H A P T E R  1
Adapted from Nederlands Tijdschrift voor Geneeskunde 2013; 157(39): A555
GENERAL INTRODUCTION
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INTRODUCTION
Inflammatory bowel disease (IBD), including ulcerative colitis (UC), Crohn’s disease (CD) and 
indeterminate colitis, is a group of chronic inflammatory disorders of the gastrointestinal 
tract with prevalences that vary between 37.5-248.6 per 100,000 in North America and 
4.9-505 per 100,000 in Europe.1 It is estimated that in The Netherlands currently between 
57,000 and 90,000 inhabitants suffer from IBD.2 The disease follows a relapsing course, 
characterized by a variety of symptoms such as abdominal pain, (hemorrhagic) diarrhea, 
weight loss and/or fatigue. In order to reduce symptoms and inflammation, but also to 
prevent long term complications, most patients are treated with medical therapy. First-line 
medical treatments for induction of remission are anti-inflammatory drugs such as topical 
and systemic steroids and 5-aminosalicylic acid. More severe IBD warrants maintenance 
treatment with immunosuppressive therapy, such as thiopurines, methotrexate or 
anti-TNFα therapy. 
Despite the wide therapeutic arsenal, both intra- and extra-intestinal complications 
of IBD still occur. For example, IBD patients may develop gastro-intestinal bleeding, toxic 
megacolon and/or colorectal cancer (CRC) often requiring surgery. Indeed, approximately 
70-80% of CD patients and 20-30% of UC patients eventually require gastrointestinal 
surgery.3, 4 Furthermore, extra-intestinal complications may occur, such as arthropathies, 
mucocutaneous (erythema nodosum and pyoderma gangrenosum) and ophthalmological 
(episcleritis and uveitis) manifestations as well as extra-intestinal malignancies. 
Both intestinal malignancies and several extra-intestinal malignancies occur more 
frequently in patients with IBD.5, 6 This can be mainly attributed to two causes including (1) 
chronic inflammation and (2) immunosuppressive medical therapy.7 Chronic inflammation 
is considered one of the key players in the development of intestinal malignancies and 
control of mucosal inflammation with anti-inflammatory and/or immunosuppressive 
maintenance therapy is therefore warranted. On the other hand, these medical therapies 
may promote or inhibit the development of (extra-)intestinal malignancies by impairing 
immunosurveillance of tumor cells or inducing DNA damage.8-11 Further evidence is required 
to optimize management strategies that can achieve reduction of chronic inflammation 
with an acceptable safety profile while reducing cancer risk.
INTESTINAL MALIGNANCIES - COLORECTAL CANCER
Incidence and prevalence
CRC is one of the most detrimental complications of IBD with significant morbidity and 
mortality.12 It occurs 1.5 to 2 times more frequently in IBD patients compared to the general 
population.13-15 Initially, high cumulative CRC incidences were found in a meta-analysis in 
2001 of 2% by 10 years, 8% by 20 years, and 18% by 30 years.5 However, lower CRC risks 
have been described in more recent years.15, 16 This might be attributed to inclusion bias 
since mainly single center studies rather than population-based cohorts were included in 
the previous meta-analysis.5 Furthermore, better anti-inflammatory treatment and improved 
management and surveillance strategies may contribute to a lower CRC risk.
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Risk factors
Several genetic, phenotypic and additional risk factors have been elucidated for CRC 
development in IBD. For example, those with longstanding, extensive colitis, post-
inflammatory pseudopolyps or strictures have an increased CRC risk. A genetic predisposition, 
such as a positive CRC family history, also increases the risk to develop CRC. In addition, 
patients with primary sclerosing cholangitis are at increased risk.13, 14 Anti-inflammatory and 
immunosuppressive therapies may also impact cancer risk. On one hand the reduction of 
chronic inflammation curtails cancer risk. Moreover, a specific anti-carcinogenic effect of 
5-ASA has been advocated on the basis of molecular data.16 By contrast, immunosuppressive 
therapy may stimulate carcinogenesis by impairing immunosurveillance of tumor cells 
or inducing DNA damage.8-11 Contradictory results have been reported in the literature 
regarding the protective or risk-enhancing effect of various therapeutic options.15, 17-20
Pathogenesis
The key genetic event that drives the onset and progression of CRC in general is the clonal 
outgrowth of mutated cells. As such, a sequential accrual of somatic mutations in for example 
p53 and KRAS contribute to cancer development. Similar molecular genetic events occur 
in sporadic and colitis-associated CRC, although the timing and sequence of events often 
differs.15 Furthermore, CRC develops in less than 10% of CRC patients in the context of an 
inherited genetic disorder such as familial adenomatous polyposis or Lynch Syndrome (LS) 
with germline mutations in respectively the adenomatous polyposis coli gene or mismatch 
repair (MMR) genes. 
Environmental factors, such as inflammation and altered microbiota, could trigger 
and impact carcinogenesis. Colitis-associated cancers for example, develop in chronically 
inflamed mucosa and are believed to develop via an inflammation-dysplasia-carcinoma 
sequence.21 Oxidative stress induces DNA damage resulting in the activation of pro-
carcinogenic genes and silencing of tumor-suppressor pathways, which could both induce 
and progress carcinogenesis. Moreover, a “field change” of cancer-associated molecular 
alterations may have been developed before there is any histological evidence of dysplasia 
due to chronic inflammation.15 For example, p53 mutations occur before the onset of 
dysplasia as a field change and normal cell populations are widely replaced according to this 
concept of “field cancerization”.22, 23
Outcome and management
Colitis-associated cancers behave more aggressively with a faster growth pattern and worse 
stage-specific survival compared to sporadic CRC.20 As such, IBD patients with CRC are 
younger and have more frequently multiple cancerous lesions. Given the increased CRC risk 
and worse outcome, endoscopic colonic surveillance is widely recommended to detect and 
potentially remove precancerous lesions and CRC. This is further supported by a reduced CRC 
incidence and CRC-related mortality among IBD patients undergoing surveillance, although 
these results may also be the consequence of optimized treatment strategies.24, 25 In case 
of multifocal low-grade dysplasia, high-grade dysplasia, or CRC, there is a generally well-
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accepted indication for colectomy with subsequently several surgical scenarios available 
as shown in Figure 1. The choice between different procedures depends on indication, 
comorbidity and patient’s wish.
A B C
Figure 1. Post-surgical scenarios after colectomy (Adapted from Netter’s Gastroenterology 2nd Ed.). (A) 
Ileostomy with rectal stump: after removal of the colon, the end of the small intestine is pulled through 
the abdominal wall of the belly and creates a stoma. A rectal stump is often left in situ. (B) Ileorectal 
anastomosis: after removal of the colon, the end of the small intestine is anastomosed to the rectum. (C) Ileal 
pouch-anal anastomosis: after removal of the colon and rectum, a new reservoir (the “pouch”) is constructed 
by folding the last part of the small intestine and anastomosing it with the anus.
Post-colectomy CRC risk
Although colectomy, with or without reconstructive surgery, substantially reduces CRC risk, 
IBD-associated CRC can still develop in the remaining bowel. Given this risk, endoscopic 
surveillance may also be necessary in the post-colectomy setting. However, current 
evidence is insufficient to make firm recommendations on this topic. A risk profile for cancer 
development in the remaining bowel parts, in combination with more knowledge on 
pathogenesis, prognosis and outcome would be helpful to guide these recommendations. 
More data on these separate items, including an appropriate interpretation, are needed to 
develop a post-surgical surveillance strategy.
INTESTINAL MALIGNANCIES – NEUROENDOCRINE 
TUMORS
Epidemiology and pathogenesis
In addition to increased CRC risk, IBD patients may have an increased risk to develop 
neuroendocrine tumors (NET) since inflammation may cause hyperstimulation of entero-
endocrine cells leading to hyperplasia and neoplasia.26-28 As such, the association between 
NET and IBD is described in 58 patients.29 Nevertheless, contradicting results regarding 
NET risk in IBD have been reported. Risks vary from a comparable risk until a relative risk 
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between 9 and 15 compared to the general population.26, 28, 30 In general, NET have a very low 
incidence (2-5 per 100,000 patients per year).31
Clinical characteristics
NET can arise from various anatomic locations, but most commonly originate from the lungs, 
gastrointestinal tract, and pancreas. As a consequence, heterogeneous site-specific symptoms 
exist in addition to symptoms caused by peptide release, such as flushing or carcinoid 
syndrome.31 NET in the gastrointestinal tract are frequently located submucosally, sometimes 
extending to the muscular layer. Symptoms include hematochezia, pain, and change in 
bowel habits.32 Main anatomic sites include the small intestine (44.7% of all gastrointestinal 
NET), followed in descending frequency by the rectum (19.6% of all gastrointestinal NET), 
appendix (16.7% of gastrointestinal NET) and colon (10.6% of all gastrointestinal NET; mainly 
in the descending colon followed by the cecal region; Figure 2).33
Diagnostics and outcome
NET are generally asymptomatic and most are detected during surveillance colonoscopy 
or after IBD-related surgery.34 This frequent incidental detection may result in an increased 
NET prevalence in IBD compared to the general population. Moreover, the real incidence 
in the general population may be underestimated.29 In general, NET follow an indolent 
clinical disease course with an excellent prognosis.35 Rectal NET are small and associated 
with a very low malignant potential, while colonic NET proximal to the rectum behave more 
aggressively.32 Coexistence of IBD and NET may result in a worse prognosis compared to 
non-IBD patients.29
Figure 2. Distribution of gastrointestinal NET.
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EXTRA-INTESTINAL MALIGNANCIES 
Epidemiology and pathophysiology
As IBD primarily affects the intestinal tract, intestinal cancers in IBD are studied thoroughly. By 
contrast, the risk of extra-intestinal cancer in IBD has obtained less attention, although extra-
intestinal manifestations are seen in 35% of patients, such as primary sclerosing cholangitis, 
nefrolithiasis, and rheumatologic, dermatologic and ophthalmologic disorders.6 Furthermore, 
immunosuppressive treatment regimens in IBD may contribute to the development of 
extra-intestinal malignancies, which is also shown in immunosuppressed post-transplant 
patients.36 Prescription of immunosuppressive and anti-TNFα therapies for IBD increased in 
recent decades with earlier introduction of these agents in the disease course.37 Together 
with the aging IBD population, this has resulted in a growing concern about extra-intestinal 
malignancies in IBD.
The overall risk to develop extra-intestinal malignancies in IBD is not increased in 
a meta-analysis consisting of 8 population-based cohort studies (17,052 patients).6 However, 
assessing individual cancer types, some cancers occurred more commonly in IBD compared 
to the background population. As such, CD patients had an increased risk of cancer of 
the upper gastrointestinal tract, lungs, urinary bladder, and skin. UC was associated with an 
increased risk of liver-biliary cancer and leukemia, but with a decreased risk of pulmonary 
cancer. Findings might be explained by smoking habits, extra-intestinal manifestations of 
IBD, and involvement of the upper gastrointestinal tract in CD. 
Renal cell carcinoma 
IBD patients may bear an increased risk to develop renal cell carcinoma (RCC). Indeed, urinary 
tract cancers seems to be more prevalent in IBD patients on thiopurines in a nationwide 
prospectively followed cohort.7 Moreover, RCC risk is increased in other autoimmune 
conditions, such as rheumatoid arthritis.38 In addition, RCC occurs more frequently in post-
transplantation patients exposed to immunosuppressive medication.36 
In general, RCC accounts for 2% of all cancers. Due to improved imaging techniques, 
they are increasingly discovered as incidentalomas (up to 40%).39-41 Similar to CRC and NET, 
there is evidence for a genetic etiology for RCC development, such as in Von Hippel-Lindau 
Syndrome. Furthermore, environmental and demographic factors, such as male gender, 
smoking and obesity, increase RCC risk. The classic triad of symptoms in RCC involves 
hematuria, abdominal pain, and a palpable mass in the flank or abdomen. However, small, 
localized tumors rarely produce symptoms and consequently escape clinical detection, 
similar to NET, resulting in often incidentally discovered RCC.42 Surgical kidney resection 
is the cornerstone of treatment for RCC. Depending on the stage of the disease, several 
systemic treatment options are available, such as immunotherapies and targeted therapies.
Clinical questions regarding extra-intestinal malignancies
Several important clinical questions with respect to IBD, IBD therapy and extra-intestinal 
cancer deserve further attention and research.10 First, it could be questioned which factors 
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contribute to the risk to develop extra-intestinal malignancies. For example, is medical therapy 
for IBD a risk factor for development of extra-intestinal cancer? Second, it remains unknown 
whether and how IBD (and IBD therapy) impacts risk of cancer recurrence, outcome and 
survival. Both questions have been extensively studied for CRC and some studies evaluated 
these issues for extra-intestinal malignancies in general. However, cancer site specific data, 
for example for RCC, are scarce or lacking while case-by-case management is encouraged 
based on the characteristics and expected evolution of the cancer, the probable impact of 
IBD therapy on cancer evolution, and IBD severity.8, 10
AIM
The long-term vision of my thesis is to optimize management and surveillance strategies in 
IBD patients at risk for/with solid intra- and extra-intestinal malignancies, both before and 
after cancer development. For this purpose, we formulated two main aims, including:
1. Epidemiological risk assessment of intra- and extra intestinal solid malignancies in 
IBD patients, including incidence, prevalence, and risk profile.
2. Translation of risk profiles into recommendations for daily clinical practice, including 
consequences for surveillance and IBD management.
As there are several types of malignancies, I limited this thesis to rare solid malignancies. 
Therefore, my thesis incorporates the following cancers in combination with IBD: LS related 
CRC, CRC in the rectal stump, CRC in the ileorectal anastomosis (IRA), CRC in the IPAA, 
colonic NET and RCC. Although these malignancies in IBD are rare, more knowledge in this 
field is of importance since these malignancies can occur in all IBD patients and thus data 
are relevant for the IBD population at large. Furthermore, these patients usually undergo 
oncologic treatment, requiring data regarding optimal cancer management in IBD. To 
improve outcome of both IBD and cancer, more data are needed that support (1) decision 
management for IBD in patients with cancer and (2) cancer management and surveillance 
in patients with IBD.
APPROACH
In order to address the abovementioned issues we used different study designs.
Retrospective case control and cohort studies based on PALGA searches
For epidemiological risk assessment we performed several PALGA searches. PALGA is 
the Dutch nationwide network and registry of histo- and cytopathology.43 This registry 
contains pathology reports generated in the Netherlands since 1971 and has complete 
national coverage since 1991 encompassing all pathology laboratories from all academic 
and non-academic hospitals in the Netherlands. Search terms such as “ulcerative colitis” 
and “Crohn’s disease” in combination with search terms for specific malignancies enabled 
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us to identify (nationwide) all IBD patients with that diagnosis. Subsequently, we identified 
IBD controls without that specific malignancy or without IBD (with or without PALGA), 
and performed several case control and cohort studies. As such, we assessed the risk and 
associated risk factors to develop NET, pouch neoplasia, and RCC in IBD patients and the risk 
to develop CRC in patients with both IBD and LS. 
Systematic review and meta-analysis
We performed a systematic review of observational studies for further epidemiological risk 
assessment, determining prevalence, incidence and risk factors to develop post-colectomy 
neoplasia in IBD. In addition, a meta-analysis was conducted if sufficient data were available 
for pooling purposes. As such, we determined a pooled CRC incidence and prevalence, and 
compared these among subgroups (rectal stump, IRA, IPAA). Furthermore, we analyzed risk 
factors for developing post-colectomy neoplasia in a pooled model. A systematic review 
and meta-analysis compares and collects all available evidence and is considered one of 
the highest grades of evidence. By using this approach for epidemiological risk assessment 
of post-colectomy neoplasia development, we assessed, summarized and interpreted all 
available data. In turn, these calculated CRC risk percentages aid in guiding endoscopic 
surveillance intervals. Thus, this approach provided us with an ideal starting point for 
translation of the available epidemiological evidence into daily clinical practice. 
Interpretation and discussion
Study results require interpretation and implementation in order to translate findings 
into clinical practice. To interpret our data and the available data in literature, we shaped 
and discussed our opinion in several articles. In some, we integrated risk assessment, 
interpretation and consequences in one manuscript. In other situations, we expressed our 
opinion in separate articles, for example in a letter to the editor or in a viewpoint. As such, 
we gave our opinion on surveillance pouchoscopy in reply to a systematic review of IPAA 
cases with pouch neoplasia. Furthermore, we formulated our vision on pouch surveillance 
in a viewpoint. 
OUTLINE
The background and framework for the thesis is described in Chapter 1. It provides 
background information about intra- and extra intestinal cancers in IBD and shows the gaps 
of knowledge. 
Part I describes cancer risk for several types of cancer. In Chapter 2 we assessed the risk 
to develop CRC in patients with both IBD and LS as genetic predisposition with concurrent 
inflammation might increase CRC risk. Chapter 3 evaluates the risk to develop NET in IBD. 
Since prevalences of NET could be increased due to frequent gastrointestinal surgery with 
incidental NET detection, we compared NET prevalences between IBD and others with 
gastrointestinal surgery (diverticulitis and ischemia). In Chapter 4 we determined the risk 
of RCC development in IBD. By adopting a case control study design we established a risk 
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profile to develop RCC and investigated the impact of IBD and IBD therapy on outcome and 
survival.
Part II evaluates CRC risk in IBD patients who underwent a colectomy. In the different 
post-surgical scenarios after colectomy, including the permanent end ileostomy and rectal 
stump, IRA and IPAA, risk profiles for CRC development are established. Chapter 5 describes 
the cumulative incidence of pouch dysplasia and carcinoma in IBD. Furthermore, risk factors 
for pouch cancer development are identified. In Chapter 6 we performed a systematic review 
and meta-analysis assessing prevalence, incidence and risk factors for CRC development 
in the rectal stump, IRA and IPAA. Chapter 7 translates the results of the two preceding 
chapters into surveillance recommendations for daily clinical practice. 
Part III contains de general discussion including future perspectives (Chapter 8). 
Subsequently, we summarized our main findings.
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ABSTRACT
Lynch Syndrome and inflammatory bowel disease (IBD) are associated with an increased 
colorectal cancer (CRC) risk due to genetic and inflammatory factors. It is unknown whether 
CRC risk is further increased in patients who suffer from both Lynch Syndrome and IBD. We 
therefore aimed to establish CRC risk in patients with both Lynch Syndrome and IBD.
We established a cohort of Lynch Syndrome patients based on two Lynch Syndrome 
referral centers in The Netherlands. This cohort was linked to PALGA (Dutch nationwide 
Pathology Registry) to identify those having IBD. Subsequently, we compared phenotypes 
of patients suffering from both Lynch Syndrome and IBD (cases) to Lynch Syndrome patients 
without IBD (controls) by adopting a retrospective cohort study approach.
15/1046 (1.4%) Lynch Syndrome patients also carried a diagnosis of IBD. Despite a younger 
age in the case group (median 38.0 y versus 52.0 y, p = 0.001), the rate of CRC development 
was not significantly different between cases (4/15, 26.7%) and controls (311/1031, 30.2%). 
Cases developed CRC at a younger age compared to controls (median 36.0 y versus 46.0 y, 
p = 0.045). However, cumulative CRC incidence was similar in both groups (p = 0.121). All 
CRC patients in the case group had ulcerative colitis, resulting in a higher cumulative CRC 
incidence for this IBD subgroup compared to controls (p < 0.001).
Concurrence of Lynch Syndrome and IBD raises the risk for CRC at a younger age, 
especially in those with ulcerative colitis.
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INTRODUCTION
Lynch Syndrome (LS) and inflammatory bowel disease (IBD) are associated with an increased 
colorectal cancer (CRC) risk due to genetic (LS) and inflammatory (IBD) factors. Reported 
lifetime risk of CRC development in LS ranges from 22 to 74%, resulting in an approximately 
4 to 15 times increase in CRC risk compared to the general population.1, 2 The mean age of 
CRC diagnosis in LS is 44–61 years compared with 69 years in sporadic cases of CRC.1 IBD 
patients bear a 1.7 times greater CRC risk in comparison with the general population, which 
is further exacerbated by additional risk factors such as IBD diagnosis at younger age and 
greater disease extent.3 Recommendations for endoscopic surveillance have been adapted 
to reflect these higher CRC risks. Although relevant for surveillance and treatment strategies, 
it is unknown whether CRC risk is further increased in patients who suffer from both LS 
and IBD.
The literature contains a few cases of LS patients with IBD who developed CRC.4, 5 In 
a case series of 12 patients with both LS and concomitant IBD, four patients developed CRC 
at the age ranging from 32 to 47 years.5 Two other case reports described a 28- and 51-
year-old LS patient with in respective ulcerative colitis (UC) and Crohn’s disease (CD) who 
developed CRC.4, 6 Although CRC arose at a relatively young age in these patients, no firm 
conclusions regarding CRC risk can be drawn based on these single cases as they comprise 
a high risk of selection bias and lack a control group.
The molecular mechanism that drives CRC in LS has been investigated in experimental 
models.7, 8 MSH2 deficient or MLH1 deficient mice (recapitulating human LS) were treated 
with dextran sodium sulfate to induce an inflammatory colitis. Mismatch repair (MMR) 
deficient mice with colitis developed significantly more colorectal neoplastic lesions 
compared to those without colitis. In the same vein, combination of a MSH2 deficiency and 
inflammation resulted in accelerated carcinogenesis.7
As a corollary from described cases and mice models, we hypothesize an increased and 
accelerated CRC risk for LS patients with IBD compared to those with LS only. In the current 
study, we aimed to establish CRC risk in patients with both LS and IBD. 
PATIENTS AND METHODS
Study design
We established a Dutch cohort of LS patients derived from two referral centers. Patients 
in the LS cohort who developed IBD were identified by linkage with PALGA, the Dutch 
Pathology Registry with national coverage.9 Subsequently, we compared LS patients with 
IBD (cases) and LS patients without IBD (controls) by adopting a retrospective cohort study 
approach in order to establish CRC risk.
The study was approved by the Privacy Commission and Scientific Council of PALGA 
and by the Medical Ethics Review Committee region Arnhem - Nijmegen (Registration 
number 2013/468).
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Patient identification
Patients with confirmed mutations in the MMR genes associated with LS in either 
the Radboud University Medical Center (Nijmegen, The Netherlands) or Academic Medical 
Center (Amsterdam, The Netherlands) were eligible for inclusion. LS associated mutations 
included heterozygous germline mutations in MLH1, MSH2 (and EPCAM deletion-mediated 
MSH2 methylation), MSH6 or PMS2, excluding patients with bi-allelic MMR gene mutations. 
All carriers who were tested and/or treated at the Gastroenterology and Human Genetics 
department between 1998 and 2014 in those two centers were included.
For the identification of IBD patients in the established LS cohort, we linked the identified 
LS patients to PALGA, the Dutch Pathology Registry. PALGA (Dutch nationwide network and 
registry of histo- and cytopathology) contains pathology reports generated in the Netherlands 
since 1971 and has complete national coverage since 1991 encompassing all pathology 
laboratories from all academic and non-academic hospitals in the Netherlands.10, 11 Via 
a trusted third party (ZorgTTP), which replaces all identifiable data by unique pseudonyms, 
we extracted data from PALGA without jeopardizing privacy.12 We obtained all pathology 
reports of the gastrointestinal tract from patients in the LS cohort and made an initial 
selection of patients with both LS and possible IBD (Figure 1). 
Cases with both IBD and LS were further confirmed or excluded after careful evaluation 
of individual medical records. Diagnoses of UC, indeterminate colitis or CD were based on 
a combination of endoscopic, radiologic and histological evidence.13 We excluded patients 
with infectious colitis or transient periods with atypical inflammation from the IBD group. 
Uncertainties regarding IBD diagnosis were resolved by discussion and consensus with two 
investigators (L.D. and L.S.) and a third expert gastroenterologist (F.H.).
Figure 1. Patient flowchart.
227
CO
LO
REC
TA
L C
A
N
CER RISK IN
 PATIEN
TS W
ITH
 IBD
 A
N
D
 LYN
CH
 SYN
D
RO
M
E
Data collection
One author (L.S.) extracted data from anonymized medical records for patients with both 
LS and IBD. Extracted variables included age, gender, smoking behavior, primary sclerosing 
cholangitis, MMR gene mutation, age at LS diagnosis, IBD characteristics, and the history 
of (extra-)intestinal neoplasia including microsatellite instability (MSI). Age was defined as 
the age during the PALGA search or, if deceased, the age at death. We collected the following 
IBD characteristics: age at IBD diagnosis, IBD phenotype according to the Montreal 
classification, and medical and surgical treatment. Exposure to 5-aminosalicylic acids, 
thiopurines, anti-TNFα agents, cyclosporine or methotrexate was defined as “used” or 
“not used”. 
For all patients included in the LS cohort, data were extracted from local prospectively 
registered LS databases and the PALGA database. Extracted variables from these databases 
included: gender, MMR gene mutation, age at LS diagnosis and history of colorectal 
neoplasia. Both synchronous CRC at the time of diagnosis as well as metachronous CRC 
during follow-up (interval > 6 months since first CRC) were recorded.14
Histopathological reassessment 
One expert gastrointestinal pathologist (I.N.) reassessed all gastrointestinal neoplasia 
specimens from patients with both LS and IBD, while blinded to clinical, endoscopic and 
radiographic features. This reassessment included the grade and type of neoplasia, classified 
according to Riddell into indefinite for dysplasia, low grade dysplasia (LGD), high grade 
dysplasia or adenocarcinoma.15 Revised results were used for further analyses. 
Immunohistochemistry and MSI status
The MMR mutation and, if not determined before, MSI status were (re)assessed in neoplasia 
specimens from patients with both LS and IBD. Immunohistochemistry was performed with 
antibodies against MLH1 (1:40, Clone G168-15, BD Biosciences, NJ, USA), MSH2 (1:40, Clone 
GB12, Merck Millipore Calbiochem®, Darmstadt, Germany), MSH6 (1:500, Clone EPR3945, 
Abcam, Cambridge, UK) and PMS2 (1:100, Clone A16-4, BD Biosciences, NJ, USA) on formalin-
fixed paraffin-embedded tissue with colorectal neoplasia to determine the MMR mutation. 
For determination of the MSI status, we performed a multiplex PCR comprising five 
mononucleotide repeat markers (NR-27, NR-21, NR-24, BAT-25 and BAT-26).16 Lesions were 
defined as MSI when three or more of the five markers showed instability.16, 17 
Since hypermethylation of the MLH1 promotor causes MSI as well, we evaluated 
the methylation status of this promotor region in all neoplasia specimens. For this purpose 
a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) kit 
(SALSA MLPA ME011-B2, MRC Holland, Amsterdam, The Netherlands) was used according to 
manufacturer’s protocol. Products were analyzed on a 3730 Analyzer (Applied Biosystems, 
Foster City, CA, USA).
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Statistics
Descriptive statistics were performed for LS patients with IBD. Categorical variables were 
expressed as numbers with percentages and continuous variables were expressed as 
means (if normally distributed) or medians (if not normally distributed) with a minimum – 
maximum range.
Subsequently, cases and controls were compared with univariable analysis. χ2 test 
or Fisher exact test (if expected cell counts were < 5) were used for categorical data and 
independent Student t test (if normally distributed) or Mann-Whitney U test (if not normally 
distributed) were used for continuous data. Cumulative CRC incidences were counted with 
1 minus Kaplan-Meier curves and compared with log rank analysis.
A P value of < 0.05 (2 sided) was considered to be statistically significant. All missing 
values were considered to be at random and were excluded from analyses. All statistical 
analyses were performed with IBM SPSS statistics version 20.0 (SPSS Inc, Chicago, IL).
RESULTS
Patient identification
We established a LS cohort consisting of 1046 patients (Figure 1) with a known MMR 
deficiency. Linkage with PALGA and further evaluation of patient records showed that 
15/1046 (1.4%) LS patients also carried a confirmed diagnosis of IBD. 
LS patients with IBD
Characteristics of the 15 cases with both LS and IBD, including 8 (53.3%) with UC, 6 (40.0%) 
with CD and 1 (6.7%) with indeterminate colitis are shown in Table 1. Median age at IBD-
diagnosis was 30 years (range 10-63) and median duration of IBD until our PALGA search (or 
until death if deceased) was 7 years (range 0-19). Six out of 15 cases (40%) were diagnosed 
with LS prior to IBD diagnosis. Disease extent in UC involved the complete colon in 62.5% 
(5/8) and the left-sided colon in 37.5% (3/8). CD patients had either ileal involvement (50%, 
3/6) or ileocolonic involvement (50%, 3/6; 2/3 with < 50% affected colon). In the single 
patient with indeterminate colitis, lesions were restricted to the cecal region. Three patients 
without CRC underwent surgery due to disease activity, including one CD patient with an 
ileocecal resection, one CD patient with both an ileocecal resection and subtotal colectomy, 
and one UC patient with restorative proctocolectomy and ileoanal pouch construction. 
LS patients with IBD versus LS patients without IBD
The comparison between LS patients with and without IBD is shown in Table 2. Despite 
a younger age at study inclusion in the case group (median 38.0 y versus 52.0 y, p = 0.001), 
the percentage of patients who developed CRC did not significantly differ between cases 
(4/15, 26.7%) and controls (311/1031, 30.2%; p = 1.000). The 4 cases developed CRC at 
a younger age compared to controls (median 36.0 y versus 46.0 y, p = 0.045). However, 
cumulative CRC incidence was similar between both groups (p = 0.121). All CRC patients 
had UC resulting in a higher cumulative CRC incidence for the UC subgroup (4/8, 46.4% at 
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Table 1. IBD characteristics of 15 patients with both LS and IBD.
Variable
IBD and LS cases
(n = 15)
Male sex 7 (46.7)
Ever smoked 3 (20.0)
Primary sclerosing cholangitis 0 (0.0)
Age at IBD diagnosis, median (range) 30 (10-63)
IBD type
 Ulcerative colitis 8 (53.3)
 Crohn’s disease
 Indeterminate colitis
6 (40.0)
1 (6.7)
Ulcerative colitisa
 Extend
  Proctitis (E1)
  Left-sided colitis (E2)
  Pancolitis (E3)
0 (0.0)
3 (37.5)
5 (62.5)
Crohn’s diseasea
 Extend 
  Ileum (L1)
  Colon (L2)
  Ileocolonic (L3)
 Upper digestive (L4)
 Perianal disease activity
 Phenotype 
  Non stricturing/penetrating (B1)
  Stricturing (B2)
  Penetrating (B3)
  Stricturing and penetrating
3 (50.0)
0 (0.0)
3 (50.0)
0 (0.0)
0 (0.0)
2 (33.3)
2 (33.3)
1 (16.7)
1 (16.7)
Medical therapy prior to CRC diagnosis
 Steroids
 5-aminosalicylic acids 
 Thiopurines
 Methotrexate
 Cyclosporine 
 Anti-TNFα therapy
9 (60.0)
11 (73.3)
4 (26.7)
0 (0.0)
2 (13.3)
3 (20.0)
Gastrointestinal surgery 7b (46.7)
All values are expressed as n (%) unless otherwise noted.
a Classified according to the Montreal classification.
b 4/7 patients underwent surgery due to CRC development.
age of 38) compared to controls (311/1031, 7.0% at age of 38, p < 0.001). The distribution of 
mutated mismatch repair genes between cases and controls was similar (p = 0.414). 
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LS patients with IBD and colorectal neoplasia
Eight of 15 LS patients with IBD developed a LS-associated neoplasia, including 4 CRC, 
3 colorectal dysplasia and 1 endometrial/urothelial cell carcinoma. Histopathological 
reassessment did not change these results. An overview of the patients who developed 
a colorectal neoplasia is displayed in Table 3. All 4 patients with CRC had UC, either 
pancolonic (3 patients) or left-sided (1 patient). Two patients developed CRC prior to LS and 
IBD diagnoses. CRC was diagnosed in 1 patient (case 1 in Table 3) after absence of surveillance 
colonoscopies during 5 years. Subsequently, 3 metachronous CRC developed 3 years later 
following an incomplete colonoscopy due to poor bowel preparation. Only one (with LGD) 
out of 7 patients who developed colorectal neoplasia used azathioprine for more than 12 
years until end of follow-up. One out of 4 CRC patients died 11 months after CRC diagnosis, 
whereas 3 patients were alive after respectively 3, 4 and 12 years of follow-up. 
Two patients had multiple adenocarcinomas. The first patient (case 1 in Table 3) 
developed after an IBD-history of 12 years 3 synchronous adenocarcinomas in his rectum 
resulting in a rectum and os coccygis amputation with an end colostomy. After this resection, 
LS diagnosis was made. Three years later, 3 new synchronous colorectal adenocarcinomas 
were detected in the colostomy, sigmoid colon and appendix. The patient underwent a total 
colectomy and chemotherapy, and was alive with metastatic disease 3 years after his last CRC. 
The second patient (case 2 in Table 3) had 3 synchronous CRC in her sigmoid colon before 
LS and IBD diagnosis. A subtotal colectomy was performed and no metastasis developed 
in 4 years of follow-up. The percentage of patients with multiple CRC was not significantly 
different between cases and controls (2/4 (50%) versus 66/311 (21.2%), p = 0.205; Table 2). 
However, duration of follow-up after first CRC was shorter in the case group (median 6.5 
y (4-11) versus 11 y (0-38)), although not significantly different (p = 0.262). Nevertheless, 
Table 2. Comparison between cases with both LS and IBD, and LS controls without IBD
Variable
IBD and LS
(n = 15)
LS controls
(n = 1031) P value
Male sex 7 (46.7) 474 (45.3) 0.916
Agea, median (range) 38 (26-69) 52 (18-100) 0.001
MMR mutation 0.414
 MLH1 5 (33.3) 256 (24.8)
 MSH2 2 (13.3) 310 (30.1)
 PMS2 1 (16.7) 128 (12.4)
 MSH6 7 (46.7) 337 (32.7)
Colorectal cancer
 Multiple CRCb
 Synchronous CRC
 Metachronous CRC
Age at diagnosis CRC, median (range)
4 (26.7)
2 (50)
2 (50)
1 (25)
36 (34-42)
311 (30.2)
66 (21.2)
19 (20.7)
52 (16.7)
46 (16-86)
1.000
0.205
0.023
0.523
0.045
All values are expressed as n (%) unless otherwise noted.
a Age is defined as the age during the PALGA search or, if deceased, the age at death.
b Both patients with synchronous and/or metachronous CRC.
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the total number of CRC was remarkable in patients with both LS and IBD (cases: 1 patient 
with 3 CRC, 1 patient with 6 CRC; controls: 47 patients with 2 CRC, 17 patients with 3 CRC, 2 
patients with 4 CRC).
All colorectal neoplastic lesions from patients with both LS and IBD were MSI. Remarkably, 
one patient with UC and a MLH1 MMR deficiency who developed 3 synchronous CRC 
showed hypermethylation of the MLH1 promotor region in all 3 CRC. This was not observed 
in the other patients with both LS and IBD who developed colorectal neoplasia.
DISCUSSION
The key finding of our study is that patients with both LS and IBD developed CRC at a younger 
age compared to LS patients without IBD, although cumulative CRC incidence was similar. 
Our unique cohort highlights that CRC specifically developed in LS patients with UC rather 
than CD and that this subgroup has a higher cumulative CRC incidence.
Although other studies comparing LS patients with and without IBD are lacking, our 
findings are confirmed by previous reports. As such, one series from a single center reported 
4 patients with CRC out of 12 patients (33%) with both LS and IBD at the age ranging from 32 
to 47 years, which is in line with our results (4 CRC out of 15 patients with LS and IBD, 27%; 
age 34-42).5 Only 1 patient in this case series who developed CRC had CD (ileitis), supporting 
our finding that especially LS patients with UC bear an increased CRC risk. However, almost 
none of the CD patients had colonic involvement both in literature and in our study, not 
allowing us to draw conclusions on CRC risk for colonic CD. 
The higher cumulative CRC incidence and younger onset in LS patients with UC may 
be caused by the interaction of MMR deficiencies and inflammation. Inflammation can 
induce DNA damage and inactivate or repress MMR responses.18 In LS patients with already 
affected MMR systems, these consequences of the inflammatory process may further 
facilitate carcinogenesis. This is supported by data from two MMR deficient (MLH1, MSH2) 
mice models (recapitulating human LS), that suggest increased and accelerated colorectal 
carcinogenesis in dextran sodium sulphate induced colitis.7, 8 In our study 2 patients had 
multiple CRC, which might be the result of an increased and/or accelerated carcinogenesis. 
By contrast, both in our study and in literature, CRC sometimes developed prior to IBD 
diagnosis and/or mucosal inflammation did not involve CRC location.19 Possible explanations 
may be a delayed diagnosis of IBD (mucosal inflammation can be present years before IBD 
diagnosis) or the absence of inflammatory involvement in the underlying CRC pathway in 
these specific cases.
Another linkage between the carcinogenesis in LS and IBD might be a defect in MMR 
genes. As such, a specific polymorphism in MSH2 (frequency background population: 10%) 
was associated with high grade dysplasia and CRC in UC patients, although not confirmed in 
a second study.20, 21 In addition to MMR deficiencies, MSI can be the result of inflammation-
induced promotor hypermethylation of MLH1. Contrasting sporadic CRC, low frequencies of 
MLH1 promotor hypermethylation are found in IBD- and LS-associated CRC.22, 23 Moreover, 
various clinical features of IBD-associated CRC (for example young age and no female 
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predominance) resemble LS-associated CRC and differ from sporadic-CRC.22 In our series, all 
cases with a colorectal neoplasia had MSI. 
The prevalence of concomitant IBD in our LS cohort (15/1046; 1.4%) is in line with another 
study that determined a prevalence of 1.5% (5/329), which is relatively high compared to 
the highest reported IBD prevalence in the general population in Europe (507/100,000 
persons; 0.5%).24 This may be the result of routine endoscopic surveillance in LS patients 
resulting in increased detection of latent IBD. However, 6/15 (40%) patients with both LS 
and IBD in our cohort received their IBD diagnosis prior to their LS diagnosis. An alternative 
hypothesis might be a shared genetic pathway, a view that is shared by others since mucosal 
abnormalities are found in LS patients.25 Two studies described an association between 
various MLH1 haplotypes with different MLH1 polymorphisms and IBD.9, 26 Used markers in 
these studies were close to a susceptibility locus for IBD as determined in a genome-wide 
association study.27 
Several clinically relevant conclusions can be drawn from our study results. First, as patients 
with LS and IBD can develop CRC at a very young age, careful compliance to the existing 
LS and IBD surveillance recommendations is advised.28, 29 This importance is underlined by 
the observation that inadequate bowel preparation and inadequate surveillance intervals 
were the most important risk factors for interval CRC in general IBD patients.30 Our first case 
(case 1, Table 3), who developed multiple CRC following insufficient follow-up, underlines 
this. Whether or not current surveillance intervals are sufficient is difficult to assess, since 
the interval CRC in our cases developed while surveillance guidelines regarding preparation 
and intervals were not followed. Second, a diagnosis of CRC in patients with both LS and IBD 
requires a colectomy given the risk of recurrence as well as multiple CRC as evidenced by our 
described cases. Moreover, colorectal dysplasia may already warrant colectomy, although 
another case series described 4 LS patient with IBD and LGD who underwent prophylactic 
colectomy not revealing malignancy.5 Finally, our data emphasize that IBD patients with CRC 
at young age could also have LS. An already existing diagnosis of IBD, prohibiting further 
MSI testing, may be a confounding factor for LS diagnosis in these patients as also reported 
in literature.22 Therefore, careful evaluation of young IBD patients with CRC considering 
LS is of major importance since it has clinical implications for the genetic counseling of 
these patients. Importantly, hypermethylation of the MLH1 promotor region often causing 
MSI in non-LS patients, does not exclude a diagnosis of LS in patients with IBD (case 2, 
current study).31
This study has some limitations. Although we established the largest LS cohort with 
concomitant IBD thus far, the first limitation includes the relatively small number of cases. 
This could have resulted in sampling bias and in type II error in the comparison between 
LS patients with and without IBD. Second the retrospective nature of this study may have 
resulted in missing variables. We took great care and achieved to limit the proportion of 
missing variables. Third, patients came from 2 LS referral centers which contribute to an 
element of selection bias. Indeed, the relatively young age of our cohort (cases median 
38 years; controls median 52 years), probably results from earlier and more aggressive 
surveillance in this population. Finally, data regarding surveillance frequency are lacking, 
which is relevant to CRC detection and development. 
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In conclusion, patients with both LS and IBD in our cohort developed CRC at a younger 
age, which might be the result of combined inflammation and MMR deficiencies. Especially 
UC patients were at increased CRC risk and strict adherence to surveillance guidelines in 
these patients should be encouraged. 
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ABSTRACT
Inflammatory bowel disease (IBD) patients may bear an increased neuroendocrine tumor 
(NET) risk. These tumors are mostly reported as coincidental findings during surgery. We 
aimed to determine the prevalence of colonic NET in a Dutch nationwide IBD cohort and 
calculate the prevalence rate ratios (PRR) compared with the general Dutch population. Our 
second aim was to investigate whether a high bowel surgery rate in IBD could result in a high 
PRR for NET. 
The Dutch Pathology Registry (PALGA) was searched to identify all IBD patients with 
colonic NET in The Netherlands between 1991 and 2011. We determined the prevalence and 
PRR of colonic NET in a 20-year period. For our second aim, we compared NET prevalence 
in colonic resection specimens between IBD cases and non-IBD controls (diverticulitis 
and ischemia). 
We identified 51 IBD patients who developed colonic NET resulting in a prevalence of 
60.4–89.3 per 100,000 patients in a 20-year period with a PRR of 2.8–4.1. However, adjusted 
for resection type, sex and age, a higher NET prevalence was shown in diverticulitis (OR 5.52, 
95% CI 3.47–8.78) and ischemia (OR 1.97, 95% CI 1.09–3.58) compared with IBD. 
Our key finding is that NET are more prevalent in IBD patients compared with the general 
population (PRR 2.8–4.1). This might be attributed to a high rate of incidental NET as IBD 
patients frequently undergo intestinal surgery. A lower adjusted NET prevalence in colonic 
resection specimens for IBD compared to ischemia and diverticulitis supports this hypothesis.
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INTRODUCTION
Colorectal cancer (CRC) risk is increased in patients with inflammatory bowel disease (IBD).1, 2 
As IBD duration, extent and severity of disease drive CRC risk, it is assumed that chronic 
intestinal inflammation is an important contributing factor.3 In addition to an increased CRC 
risk, IBD patients also carry a risk to develop other types of neoplasia such as neuroendocrine 
tumors (NET). Several authors have reported cases of both IBD and NET resulting in 
the hypothesis that inflammation may cause hyperstimulation of enteroendocrine cells 
leading to hyperplasia and neoplasia.4–6 However, convincing epidemiological evidence of 
an association between IBD and NET is lacking so far.
NET risk in IBD patients has been poorly investigated and reported results are variable. 
Two studies including, respectively, 590 and 111 IBD patients, found an increased risk of 
NET development compared to the background population.5, 7 By contrast another study 
among 705 IBD cases did not detect an increased prevalence.6 However, all these data were 
collected from single tertiary referral centers introducing referral and selection bias and as 
such may not be representative for the IBD population at large. Furthermore, high surgery 
rates in IBD (25–30% in ulcerative colitis [UC] and 70–80% in Crohn’s disease [CD]) may lead 
to high NET risks, as these tumors are mostly detected by coincidence during surgery.8, 9 
Therefore, the comparison of NET risks across studies is difficult given the variable rates of 
bowel surgery in control groups in the aforementioned studies.
To resolve the discrepancy in reported NET prevalence we designed a nationwide study 
to determine the prevalence of colonic NET in a Dutch IBD cohort. Research questions were 
restricted to the colon as both UC and CD are located to this part of the gastrointestinal tract 
and colonic tissue is available for most IBD patients. First, we aimed to investigate whether 
IBD patients have an increased colonic NET prevalence compared with the general Dutch 
population. Second, we hypothesized that an increased NET prevalence in IBD patients is 
explained by a high rate of colonic resections and thus a high rate of incidental findings. 
We therefore compared NET prevalence between IBD cases and non-IBD controls, both with 
a colonic resection.
MATERIAL AND METHODS
Study design and data sources
We established a cohort consisting of all IBD patients with concomitant colonic NET in 
The Netherlands assembled over 20 years using the nationwide Dutch pathology database 
PALGA.10 Subsequently, the prevalence of NET was calculated by dividing these IBD patients 
with colonic NET by the total Dutch IBD population.11, 12 
For our first aim, we compared the determined NET prevalence in the IBD population 
with the reported NET prevalence in the general Dutch population.13 The NET prevalence 
in the general population was provided by the Dutch Cancer Registry of which data are 
also based on PALGA. Using this registry, a previous study reported NET and carcinoma 
prevalence in The Netherlands between 1990 and 2010 according to different sites.13 
To investigate our second hypothesis, we compared the NET prevalence in IBD cases 
and non-IBD controls, both with one or more colonic resections. Control groups included 
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diverticulitis and ischemia patients since these patients frequently undergo a colonic 
resection but evidence for an increased NET risk is lacking. 
Patient identification
PALGA, the nationwide network and registry of histopathology and cytopathology, was 
searched to identify all patients with concomitant IBD and colonic NET between 1991 
and 2011 in The Netherlands. The PALGA registry contains pathology reports generated in 
The Netherlands since 1971 and has complete national coverage since 1991 encompassing 
all pathology laboratories from all academic and nonacademic hospitals in The Netherlands.10 
With approval of their Privacy Commission and Scientific Council, we performed a PALGA 
search with the following search terms: “ulcerative colitis”, “Crohn’s disease”, “indeterminate 
colitis”, “chronic idiopathic inflammatory bowel disease”, or “colonic inflammation” combined 
with ”carcinoid”, “neuroendocrine tumor”, or “neuroendocrine carcinoma”, located in the “colon”, 
“appendix” or “ileocecal region” (Figure 1).
For our second aim, we identified diverticulitis and ischemia patients with colonic NET. 
A second PALGA search in the same period was performed. Search terms for NET were 
combined with “diverticulitis”, or “diverticulosis” to identify diverticulitis patients with NET, 
and with “circulatory insufficiency” and “ischemia” to identify ischemia patients with NET. In 
addition, we estimated for our second aim total IBD, diverticulitis and ischemia populations 
with a colonic resection. In two years within the inclusion period, we identified all IBD, 
diverticulitis and ischemia patients who had a colonic resection using PALGA and linearly 
extrapolated the results to all years of inclusion (1991–2011). Since on one hand anti-TNFα 
agents might decrease the need for surgery and however, increasing IBD incidences over 
time might elevate the number of colonic resections, we chose to evaluate the number 
of resections in one separate year before and after anti-TNFα approval in the late nineties. 
For this reason we evaluated the number of resections in 1995 (without the availability of 
anti-TNFα agents) and in 2005 (with the availability of anti-TNFα agents) for estimating total 
Figure 1. Schematic overview of the PALGA search strategy for patient identification. a This inclusion period 
applies to the search strategies with NET.
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populations.14, 15 Patients were allowed to be included in more than one group since each 
group is considered to be an independent sample of the total population. 
Inclusion and exclusion criteria
Patients with UC, colonic CD, indeterminate colitis (IC), diverticulitis or colonic ischemia 
who developed a NET or who had a colonic resection in 1995 or 2005 were eligible for 
inclusion. Diagnoses of IBD, diverticulitis or ischemia were confirmed or excluded after 
careful evaluation of individual pathology reports. NET included both well and poorly 
differentiated NETs and carcinomas (NET grade 1 to 3 according the WHO 2010 criteria).16 
We included microcarcinoids (tumor size between 0.5 and 5 mm) and excluded mixed 
adenoneuroendocrine carcinomas.17 Primary tumors had to be located in a colonic biopsy 
or resection specimen, which was defined as any partial or complete colonic resection 
including an appendectomy and ileocecal resection. NET cases diagnosed in a colonic 
biopsy or polypectomy were excluded from the comparison between IBD, diverticulitis 
and ischemia patients, as total populations in this comparison were based on patients who 
underwent a colonic resection. Furthermore, we excluded patients in whom a diagnosis of
IBD, diverticulitis or ischemia was made after NET development, or after their colonic 
resection. Patients who developed NET prior to 1991 or after 2010 were also excluded. 
Data extraction
Two authors (L.D. and W.V.) extracted data from PALGA and from anonymized pathology 
reports. Extracted variables included gender, type of IBD, age at IBD onset, colonic resection 
type, NET location, TNM stage according to the WHO 2010 criteria18 and age at colonic 
resection or NET diagnosis. The age of IBD onset was defined by the first biopsy or resection 
specimen suggesting IBD. Colonic resection type was divided into four categories taken 
the length of the resection specimen and the NET incidence at the different anatomical 
sites into account.13 Categories included ileocecal resection (including appendectomy), 
rectosigmoid resection, partial colonic resection (including hemicolectomy) and total 
colonic resection.
Total Dutch IBD population
Based on different approaches, we estimated the total IBD population in The Netherlands 
between 1991 and 2011 for prevalence calculations. Our first approach included the use of 
a report by the Dutch national Institute for Public Health and Environment, which estimated 
a total Dutch IBD population of 57,000 in 2007 based on general practitioners registrations.11 
For our second approach, we extrapolated the highest reported IBD prevalence of northern 
Europe from a recent publication of the European Crohn’s and Colitis Organisation 
Epidemiology Committee (507/100,000) to The Netherlands (n = 516,655,799), resulting in 
a total Dutch IBD cohort of 84,445 patients in 2011.12,19 The range (57,100–84,445) of estimated 
IBD patients is a result of increasing IBD prevalence and variably reported prevalence rates of 
IBD due to geographical and methodological differences.
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Statistics
We calculated the prevalence of NET in a 20-year period (1991–2011) in the nationwide 
IBD population by dividing the IBD patients with NET by the total Dutch IBD population. 
Subsequently, the calculated NET prevalence in the IBD population was compared to the NET 
prevalence in the general Dutch population resulting in a prevalence rate ratio (PRR).
Next, we compared the prevalence of NET during a 20-year period in colonic resection 
specimens between IBD cases and non-IBD controls. For this purpose, the total number, 
type and age of colonic resections determined in two years (1995 and 2005) were linearly 
extrapolated to a 20-year period (1991–2011). Confounders for NET development were 
univariately compared within the NET group and the total group with a colonic resection 
using χ2 test. We performed a binary logistic regression model adjusted for gender, age 
and resection type to compare NET prevalence in colonic resection specimens between 
diseases. To verify the robustness of the analyses based on linear extrapolation between 
1995 and 2005, we performed two additional sensitivity analyses. In the first, we assumed 
yearly a similar number of patients as in 1995, to estimate the total population during 
a 20-year period (estimated total population = number of patients in 1995 x 20). Likewise, 
we estimated total populations for our second sensitivity analysis using the total number 
of patients in 2005. All missing values were considered to be at random and were excluded 
from analyses. A P values below 0.05 was considered statistically significant. All statistical 
analyses were performed with Statistical Analysis Software version 9.2 (SAS Institute, Cary, 
NC) or IBM SPSS statistics version 20.0 (SPSS, Chicago, IL).
RESULTS
IBD patients with NET
Our PALGA search identified 51 IBD patients who developed colonic NET, including 22 
UC patients, 25 CD patients and 4 patients with IC (Figure 2). Median age of IBD and NET 
diagnoses were respectively 40 and 48 years. Tumors were localized in the appendix (n = 
531; 72.1%), rectosigmoid colon (n = 56; 14.0%), descending colon (n = 53; 7.0%) and cecum 
(n = 53; 7.0%). In 8 patients NET locations were not further specified than ileocecal region 
(n = 53) or colon (n = 55). Detection of NET was performed with a colonic resection in 46 
patients and with colonic biopsies in 5 patients. Tumor stages were distributed as follows: 
36.1% (13/36; n = 515 missing) were stage I, 11.1% (4/36) were stage I or II, 25.0%
(9/36) were stage II, 19.4% (7/36) presented with lymph node metastases (stage III) 
and 8.3% (3/36) presented with distant metastases (stage IV).
NET prevalence and PRR
An estimated total Dutch IBD population between 57,100 and 84,445 patients resulted in 
a 20-year NET prevalence between 60.4 and 89.3 per 100,000 patients (Table 1). Compared 
with a 20-year colonic NET prevalence of 21.9 per 100,000 patients in the general population, 
this yields a PRR between 2.8 and 4.1.
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Figure 2. Patient inclusion flowchart. The light gray box represents the patients included for the comparison 
of NET PRR between IBD, diverticulitis and ischemia patients. 
Table 1. Prevalence rate ratio of NET for IBD patients compared to the general population.
IBD Population Total Dutch population
PRR
Cases
(n)
Prevalence in  
a 20-y period
(n/100,000 patients)
Casesa
 (n)
Prevalence in  
a 20–y period
(n/100,000 patients)
A IBD 51 89.3 3440 21.9 4.1
 Ulcerative colitisb 26 81.7 3440 21.9 3.7
 Crohn’s disease 25 99.2 3440 21.9 4.5
B IBD 51 60.4 3440 21.9 2.8
 Ulcerative colitisb 26 55.2 3440 21.9 2.5
 Crohn’s disease 25 67.0 3440 21.9 3.1
A: Estimated IBD prevalence of 57,100 patients as reported by the Dutch national Institute for Public Health and 
Environment.11
B: Estimated IBD prevalence of 84,445 patients based on literature.12 
a The number of NET cases in the general Dutch population is previously determined.13
b 4 patients with indeterminate colitis are included in the UC subgroup.
IBD versus diverticulitis and ischemia
An inclusion flowchart of the patients included for the comparison of NET prevalence 
between different cohorts with a colonic resection is displayed in Figure 2. As patients were 
excluded in whom NET was detected with colonic biopsies, we included 46 out of 51 IBD 
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patients with NET, 60 out of 63 diverticulitis patients with NET and 21 out of 23 ischemia 
patients with NET. Extrapolation of the total number of patients with one or more colonic 
resections in 1995 and 2005 resulted in 14,840 IBD, 38,430 diverticulitis and 5460 ischemia 
patients (Figure 2). This resulted in a significantly lower 20-year prevalence of NET in colonic 
resection specimens for diverticulitis (0.16%) compared with IBD (0.31%; odds ratio [OR] 0.50, 
95% confidence interval [CI] 0.34–0.74) and ischemia (0.39%; OR 0.41, 95% CI 0.25–0.67). No 
statistically significant different prevalence of NET was observed between IBD and ischemia 
(OR 1.24, 95% CI 0.74–2.08).
Patient characteristics of the included patients are depicted in Table 2. Both NET patients 
and all colonic resection patients were significantly younger in the IBD group (p < 0.05). 
All IBD patients with a colonic resection underwent more frequently ileocecal resections 
(p < 0.05) compared with diverticulitis and ischemia patients while in NET patients 
the resection types were equally distributed across groups (p = 0.154). This resulted in 
a different prevalence of NET in colonic resections across subgroups, especially in those 
based on resection type (Table 3). A multivariate binary logistic regression model 
was performed to adjust for these potential confounders. A higher adjusted 20-year 
NET prevalence was shown in diverticulitis patients (OR 5.52, 95% CI 3.47–8.78) and 
ischemia patients (OR 1.97, 95% CI 1.09–3.58) compared with IBD. Similar results were 
found in our sensitivity analyses based on extrapolation of data from 1995 or 2005 only 
(data not shown).
NET prevalence in IBD subtypes
As the comparison with the general population demonstrated a slightly increased NET 
prevalence for CD than for UC patients (Table 1), we subsequently compared NET prevalence 
in colonic resection specimens across IBD subtypes. No statistical different NET prevalence 
was found in CD versus UC colonic resection specimens (OR 0.59, 95% CI 0.32–1.07). However, 
a multivariate analysis adjusted for resection type showed a significantly lower 20-year NET 
prevalence for CD compared with UC patients (OR 0.30, 95% CI 0.13–0.68).
DISCUSSION
The key finding of this study is an increased colonic NET prevalence in IBD patients in 
comparison with the general population with a PRR between 2.8 and 4.1. However, adjusted 
for resection type, gender and age, a lower NET prevalence was shown in IBD patients with 
a colonic resection compared to diverticulitis and ischemia patients with a colonic resection. 
This latter finding suggests that the increased NET prevalence in IBD patients could be 
attributed to incidental findings as a result of frequent colonic resections.
Previous studies are in line with the increased NET risk for IBD patients in comparison 
with the general population. Although data were retrospectively collected from single 
tertiary referral centers, one study reported a relative risk of approximately 9 for rectal 
carcinoid development and another reported an OR of approximately 15 for carcinoid tumor 
development.5,7 This increased risk accords with our study in which we calculated a population 
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Table 3. NET prevalence in colonic resections during a 20-year period displayed for different subgroups
Variable
NET prevalence in colonic resections (%) Multivariate analysis
(Final binary logistic 
regression model;
odds ratio, 95% CI)IBD Diverticulitis Ischemia
Disease type
 Ischemia n/a n/a 0.385 1.97 (1.09–3.58)
 IBD 0.310 n/a n/a 1.00
 Diverticulitis n/a 0.156 n/a 5.52 (3.47–8.78)
Gender
 Female 0.373 0.153 0.456 1.00
 Male 0.230 0.160 0.323 0.86 (0.59–1.25)
IBD type
 Ulcerative colitis 0.414 n/a n/a n/a
 Crohn’s disease 0.243 n/a n/a n/a
 Indeterminate colitis 0.769 n/a n/a n/a
Age at colonic resection
 < 50 y 0.266 0.292 0.244 1.00
 50 – 70 y 0.411 0.136 0.513 1.62 (1.03–2.54)
 > 70 y 0.391 0.127 0.335 1.63 (0.97–2.73)
Colonic resection type
 Ileocecal resection 0.414 5.250 1.122 1.00
 Rectosigmoid resection 0.145 0.029 0.171 0.10 (0.06–0.18)
 Partial colonic resection 0.567 0.172 0.176 0.01 (0.01–0.02)
 Total colonic resection 0.205 0.952 0.606 0.32 (0.17–0.61)
based NET PRR between 2.8 and 4.1 for IBD patients. Comparing the determined colonic NET 
prevalence in IBD with the highest reported NET prevalence by the WHO results in similar 
PRR (2.9–4.2).20 The calculated PRR might be an underestimation as cases only comprise CD 
patients with colonic disease activity while the total Dutch IBD population included all CD 
patients regardless of disease localization.
The increased PRR of NET in IBD may be attributed to incidental findings in resection 
specimens, as hypothesized by previous studies.6, 21, 22 This is supported by the lower colonic 
NET prevalence in multivariate analysis for IBD patients with a resection compared to 
diverticulitis and ischemia patients with a resection. Similar comparisons have not been 
made in literature before and only case reports regarding NET in diverticulitis or ischemia 
patients are available.23–33 Prevalence rates of carcinoid tumors in appendectomy specimens 
were similar in IBD patients compared with non-IBD controls, supporting our findings.6 
Another study reported 9 cases (5 CD and 4 UC), all discovered incidentally, in 2284 patients 
undergoing intestinal surgery for IBD resulting in a prevalence of 0.26% which was nearly 
identical to a rate of 0.27% in non-IBD patients undergoing intestinal surgery.6, 22, 34, 35 
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Prevalence rates are similar to our results (0.33%) and are further supported by another 
study that identified 3 carcinoids among 1000 CD patients undergoing intestinal surgery 
(0.33%).21 Finally, the relatively high percentage of stage I (36.1–47.2%) and low percentage 
of stage IV (8.3%) NET in our IBD patients compared to all gastrointestinal NET (23.8% 
stage I, 23.8% stage IV) underscores a high percentage of incidental NET in our 
IBD population.36
Whether a relationship exists between chronic mucosal inflammation and NET 
development could not be extracted from our data. The significantly higher colonic NET 
prevalence in UC may indicate a role of inflammation. By contrast, most of reported IBD 
cases with NET in the literature arose in areas of uninflamed intestine suggesting absence 
of a firm correlation between local inflammation and NET development.5 However, patients 
could have previously had inflammation in these areas, for example before start of medical 
therapy, or distant inflammatory mediators might play a role.
NET usually have an excellent prognosis if diagnosed at an early stage and treated 
adequately.37 Although rare, NET may clinically simulate IBD, especially in CD patients with 
ileal involvement. Thus, an accurate and timely diagnosis of NET is extremely important.21 
NET are often detected incidentally during surgery and a different approach might have 
been considered if NET was already suspected clinically. Results of our study may improve 
the awareness of NET coexistence in IBD patients, especially in those who need to undergo 
intestinal surgery. Furthermore, the increased tumor risk in IBD patients as a consequence of 
incidental findings could also be investigated in future research for other (extra)-intestinal 
malignancies in IBD patients.
Strengths of this study include the nationwide approach and the comparison of NET 
prevalence across patient groups with frequent colonic resections. Although the size of our 
IBD cohort with NET is limited (n = 551), we established to our best knowledge the largest 
cohort thus far. This study also has some limitations. First, diagnoses of IBD, diverticulitis and 
ischemia were made on the basis of individual pathology reports rather than on clinical and 
endoscopic features. Reasons for surgery were unknown and thus it was unclear whether 
a NET was detected as an incidental finding. However, these limitations consistently 
applied to all cases, controls and total populations. Furthermore, NET diagnosis could be 
missed as a result of sampling bias. Since IBD is already associated with CRC, pathologists 
may have a higher cancer suspicion when assessing colonic specimens, with subsequently 
less sampling bias compared to diverticulitis and ischemia. Third, colonic resection types 
differed among case and control groups, which may influence NET risk. To address this 
issue, we performed a multivariate analysis adjusting for this confounder. Third, bias 
may be introduced by the extrapolation of data. However, due to feasibility reasons this 
was inevitable to determine total IBD, diverticulitis and ischemia populations and thus to 
address our research question. Finally, NET criteria and WHO grading systems changed 
during the inclusion period impeding the opportunity to analyze well differentiated NET 
and poorly differentiated neuroendocrine carcinomas separately. 
In conclusion, we identified an increased colonic NET prevalence in IBD patients in 
comparison with the general population, resulting in a PRR between 2.8 and 4.1. This finding 
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may be attributed to a high rate of incidental NET as IBD patients frequently undergo 
intestinal surgery. A lower adjusted 20-year NET prevalence for IBD compared with ischemia 
and diverticulitis supports this hypothesis. 
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ABSTRACT
Immunosuppressive therapy may impact cancer risk in inflammatory bowel disease (IBD). 
Cancer specific data regarding risk and outcome are scarce and data for renal cell carcinoma 
(RCC) are lacking. We aimed (1) to identify risk factors for RCC development in IBD patients 
(2) to compare RCC characteristics, outcome and survival between IBD patients and 
the general population.
A PALGA (Dutch Pathology Registry) search was performed to establish a case group 
consisting of all IBD patients with incident RCC in The Netherlands (1991–2013). Cases were 
compared with two separate control groups: (A) with a population-based IBD cohort for 
identification of risk factors (B) with a RCC cohort from the general population to compare 
RCC characteristics and outcomes. 
180 IBD patients with RCC were identified. Pancolitis (OR 1.8–2.5), penetrating Crohn’s 
disease (OR 2.8), IBD related surgery (OR 3.7–4.5), male gender (OR 3.2–5.0) and older age at 
IBD onset (OR 1.0–1.1) were identified as independent risk factors for RCC development. IBD 
patients had a significantly lower age at RCC diagnosis (p < 0.001), lower N-stage (p = 0.025), 
lower M-stage (p = 0.020) and underwent more frequently surgical treatment for RCC (p < 
0.001) compared to the general population. This translated into a better survival (p = 0.026; 
HR 0.7) independent of immunosuppression.
IBD patients with a complex phenotype are at increased risk to develop RCC. They are 
diagnosed with RCC at a younger age and at an earlier disease stage compared to the general 
population. This translates into a better survival independent of immunosuppressive or 
anti-TNFα therapy.
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INTRODUCTION
Inflammatory bowel disease (IBD), including ulcerative colitis (UC), Crohn’s disease (CD) and 
indeterminate colitis is a chronic inflammatory disorder of the gastrointestinal tract. Patients 
with this disease have an increased risk for both intestinal and various extraintestinal 
malignancies.1, 2 This risk is mainly attributed to two drivers: chronic inflammation and 
drug-induced immunosuppression.3 Particularly immunosuppressive medication such 
as thiopurines and methotrexate may play a role in the development of extra-intestinal 
malignancies by impairing immunosurveillance of tumor cells or inducing DNA damage.4-7 
The potential associated cancer risk is an important growing concern given the need for 
prolonged immunosuppressive therapy in IBD, especially in view of the aging IBD population. 
Various extra-intestinal malignancies, such as lymphoproliferative disorders and non-
melanoma skin cancers occur more frequently in IBD patients compared to the general 
population, mainly in those using immunosuppression.2, 6, 8-12 Although only limited evidence 
is available, it has been suggested that immunosuppression in IBD patients may increase 
the risk for a variety of solid malignancies, such as renal cell carcinoma (RCC). Indeed, RCC 
occurs more frequently in post-transplantation patients exposed to immunosuppressive 
medication.13 In addition, the risk for urinary tract cancers in IBD patients on thiopurines 
seems to be elevated.3
It is unknown whether and how IBD therapy impacts risk of cancer recurrence, outcome 
and survival. Aggregate data failed to demonstrate an effect of immunosuppression and 
anti-TNFα agents on recurrence of any cancer in IBD patients.5 By contrast, cancer specific 
data on recurrence and outcome are scarce. For example, only eight case reports of IBD 
patients with RCC have been described and led to speculation on a putative association with 
immunosuppressive therapy.14-19 As such, more data are needed to estimate RCC risk and to 
guide the subsequent individual IBD therapy.
To this end we established a nationwide cohort of IBD patients with incident RCC. We had 
a dual aim: (1) to identify risk factors for RCC development, and in particular to investigate 
the impact of IBD therapy on RCC development (2) to compare RCC characteristics, outcome 
and survival between IBD patients and the general population, including the impact of 
immunosuppression and anti-TNFα agents.
MATERIALS AND METHODS
Study design and data sources 
In order to study risk factors and the clinical course of RCC in IBD patients, we performed two 
retrospective nationwide case control studies. We established a case group consisting of all 
IBD patients who developed RCC in The Netherlands assembled over 22 years, using PALGA 
(Dutch nationwide network and registry of histo- and cytopathology).34 Subsequently, these 
cases were included in the following two case control studies: 
The first case control study aimed for the identification of risk factors to develop RCC. 
Controls were randomly sampled from IBDSL, a population-based IBD registry.35
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The second case control study was performed to compare RCC characteristics and 
outcomes between IBD patients and the general population. Controls were identified from 
the ECR and included patients from the general population who developed RCC.36
The study was approved by the Privacy Commission and Scientific Council of PALGA 
and by the Medical Ethics Review Committee region Arnhem - Nijmegen (Registration 
number 2013/419).
Case identification
PALGA was searched in order to identify all IBD patients with concomitant RCC in 
The Netherlands from January 1991 until May 2013. The PALGA registry contains pathology 
reports generated in the Netherlands since 1971 and has complete national coverage 
since 1991 encompassing all pathology laboratories from all academic and non-academic 
hospitals in the Netherlands.34 We performed a PALGA search with the following search terms: 
“ulcerative colitis”, “Crohn’s disease”, “indeterminate colitis”, or “chronic idiopathic inflammatory 
bowel disease” combined with all “primary carcinomas of the kidney” or “metastasis of kidney 
cancer”. Cases were further confirmed or excluded after careful evaluation of the individual 
pathology reports and/or medical records (Figure 1).
All patients with UC, CD or indeterminate colitis who developed a histologically 
confirmed RCC following IBD diagnoses were included. The diagnosis of IBD was based on 
a combination of clinical, endoscopic, histological and radiographic criteria.37 The following 
exclusion criteria were used: no diagnosis of IBD, no diagnosis of RCC, RCC diagnosis before 
IBD diagnosis and RCC diagnosis before 1991.
Controls (A) – IBD South Limburg cohort
Controls for the identification of risk factors to develop RCC were randomly selected 
from IBDSL. IBDSL is a prospectively followed, population-based IBD registry in an area in 
the southeast of The Netherlands between Germany and Belgium, called South-Limburg. 
This area has a population of approximately 645.000 inhabitants with a low migration rate 
and covers one academic and two general district hospitals.38 Adult patients in this area with 
a diagnosis of UC or CD based on a combination of endoscopic, radiologic and histological 
evidence are included in this cohort since 1991.38 It includes 2807 IBD patients (40.9% CD, 
59.0% UC), which represents 93% of the regional IBD population.35 We randomly included 
patients with an IBD diagnosis between 1991 and 2011. An unmatched study design 
was chosen given the relatively large number of cases, allowing adjustment for possible 
confounders as well as to avoid missing potential risk factors.39
Controls (B) – Eindhoven cancer registry
Controls to compare RCC characteristics and outcomes were identified from the ECR, maintained 
by the Netherlands Comprehensive Cancer Organization. The registry prospectively collects 
data on all newly diagnosed cancers in the southern part of The Netherlands since 1955.36 
This area includes 10 general hospitals and 6 regional pathology laboratories, comprising 
approximately 2.3 million inhabitants (15% of the Dutch population).40 Tumor characteristics 
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Figure 1. Patient inclusion flowchart.
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and patient characteristics are routinely extracted from medical records by specially trained 
administrators of the cancer registry. By means of an independent case ascertainment 
method, the completeness of the registration is estimated to exceed 95%.41 We included 
all patients with a histologically confirmed RCC between 1991 and 2010 from the ECR 
as controls.
Data extraction
Two authors (L.D and L.N) extracted demographic and clinical variables from anonymized 
medical records for patients included in the case group. Extracted data included gender, 
date of birth, smoking history (ever/never), primary sclerosing cholangitis, IBD characteristics 
and RCC characteristics. We collected the following IBD characteristics: type of IBD, date of 
diagnosis, phenotype according to the Montreal Classification, and medical and surgical 
treatment. Exposure to 5-ASA, thiopurines, anti-TNFα agents, cyclosporine or methotrexate 
was defined as “used” or “not used” since dosage/duration could not be reliably retrieved for 
all cases. RCC characteristics included: date of diagnosis, location, tumor stage according to 
the TNM classification (7th edition), differentiation grade according to Fuhrman42, whether 
the tumor was incidentally detected or not, treatment, outcome and survival.
Incidentally diagnosed cancers were considered to be tumors discovered during 
investigations performed for reasons other than for RCC related symptoms including 
palpable tumor, haematuria (both macroscopic and microscopic), flank pain and signs of 
cachexia related to the disease.21 RCC outcome included disease free survival (duration 
since RCC diagnosis until recurrence or death) and overall survival (duration since RCC 
diagnosis until death). Histopathological subtype could not be obtained reliably due to 
the great variability of morphology reporting standards since 1991. Similar variables with 
corresponding definitions were extracted from registries (IBDSL and ECR) for patients 
included in the control groups. 
Statistics
For both case control studies we compared potential risk factors, RCC characteristics and/or 
outcomes between cases and controls with a univariable analysis. χ2 test or Fisher exact test 
(if expected cell counts were < 5) were used for categorical data and independent Student t 
test (if normally distributed) or Mann-Whitney U test (if not normally distributed) were used 
for continuous data. Variables with a P value of < 0.1 in univariable analyses were included in 
a multivariable model. As the control group in a case control study should reflect the entire 
source population that gave rise to the cases, we did not exclude IBD patients who developed 
RCC from the control groups.43 These patients were in both models analyzed as cases. 
For case control study A, identifying independent risk factors to develop RCC, we 
performed a multivariable logistic regression model with backward sampling. This model 
was adjusted for the duration of follow-up (fixed variable), which was defined as the time 
since IBD onset until the date of RCC diagnosis (cases) or the end of follow-up or death 
(controls). For case control study B, comparing RCC outcome between IBD cases and 
the general population, we made Kaplan Meier survival curves and performed log rank 
461
REN
A
L CELL C
A
RCIN
O
M
A
 RISK A
N
D
 O
U
TCO
M
E IN
 IBD
analysis. Subsequently confounder correction was performed with Cox regression model 
with forward sampling. A covariate was considered as a confounder when the beta coefficient 
of the variable of interest (IBD yes/no) changed by 10% or more.44 A P value of < 0.05 (2 
sided) was considered to be statistically significant. All missing values were considered to 
be at random and were excluded from analyses. All statistical analyses were performed with 
IBM SPSS statistics version 20.0 (SPSS Inc, Chicago, IL).
RESULTS
Patient identification
We identified 180 IBD patients who developed RCC in 69 of 87 hospital organizations in 
the Netherlands (Figure 1).20 Twenty-seven potential cases could not be verified and were 
excluded. To identify risk factors for RCC development we established a control group of 
1800 IBD patients randomly selected from the IBD South Limburg Cohort (IBDSL; Case 
control study A). For the comparison of RCC characteristics and outcomes we identified 
a second control group using the Eindoven Cancer Registry (ECR). This search yielded 4388 
patients with RCC in the general population (Case control study B).
Risk factors for RCC development - Case control study A
Potential clinical and demographic risk factors for RCC development were compared 
univariable between IBD cases who developed RCC and IBDSL control patients (Table 1). Male 
gender, Montreal E3 pancolitis, perianal disease activity, a stricturing and/or penetrating 
CD phenotype, and IBD related surgery occurred statistically significantly more frequent 
in the case group (p < 0.001 for all comparisons). Furthermore, cases had a statistically 
significantly longer duration of follow-up since IBD diagnosis (p < 0.001), but used less 
thiopurines (p = 0.047) and anti-TNFα agents (p = 0.006) during follow-up. We considered 
differences in inclusion period (IBD diagnosis since 1950 (cases) versus IBD diagnosis since 
1991 (controls)) as a reason for these differences, since widespread use of thiopurines and 
the introduction of anti-TNFα therapy occurred in the last decade of inclusion. Using similar 
inclusion periods of IBD diagnosis for both cases and controls (since 1991) almost abolished 
treatment differences (5-aminosalicylic acids (5-ASA), 89.6% (cases) versus 89.8% (controls), 
p = 0.954; thiopurines, 35.6% versus 40.2%, p = 0.432; methotrexate, 0.0% versus 5.3%, 
p = 0.049; cyclosporine, 4.1% versus 1.5%, p = 0.102; anti-TNFα therapy, 15.1% 
versus 19.7%, p = 0.326).
A multivariable logistic regression model that took the duration of follow-up since IBD 
diagnosis into account was made separately for UC and CD patients to identify independent 
risk factors for RCC development. Included variables were: gender, age at IBD diagnosis, 
extend of UC and CD, perianal disease activity, CD phenotype and IBD related surgery. As 
prescribed medical therapy might be different and/or not reliable in early years of inclusion, 
we did not include these variables in this model. Therefore, we performed a sensitivity 
analysis including patients with an IBD diagnosis since 1991 in both the case and control 
group. Medical therapy was included in this logistic regression model.
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Table 1. Univariable comparison of potential risk factors and confounders between cases (IBD patients who 
developed RCC) and controls (randomly selected IBD patients from IBDSL) for the identification of risk factors 
to develop RCC (case control study A).
Variable
IBD and RCC cases 
(n = 180)
IBDSL
(n = 1800)
Missing values
(cases/IBDSL) P value
Male gender 114 (63.3) 837 (46.5) 0 < 0.001
Ever smokeda 38 (62.3) 421 (62.5) 11/122 0.979
Age at IBD diagnosis (y), median 43 39 3/1 0.106
IBD typeb
 Ulcerative colitis 93 (56.4) 1004 (55.8)
 Crohn’s disease 72 (43.6) 796 (44.2) 0 0.885
Ulcerative colitis
 Extend
  Proctitis (E1)
  Left-sided colitis (E2)
  Pancolitis (E3)
14 (17.5)
24 (30.0)
42 (52.5)
243 (24.4)
472 (47.5)
279 (28.1) 10/13 < 0.001
Crohn’s disease
 Extend 
  Ileum (L1)
  Colon (L2)
  Ileocolonic (L3)
 Upper digestive (L4)
 Perianal disease activity
 Phenotype 
  Non stricturing/penetrating (B1)
  Stricturing (B2)
  Penetrating (B3)
  Stricturing and penetrating
27 (38.6)
19 (27.1)
24 (34.3)
2 (2.8)
21 (30.0)
19 (27.9)
16 (23.5)
15 (22.1)
18 (26.5)
223 (28.1)
183 (23.0)
389 (48.9)
65 (8.2)
119 (14.9)
437 (54.9)
171 (21.5)
96 (12.1)
92 (11.6)
2/1
1/0
2/0
4/0
0.054
0.106
0.001
< 0.001
Medical therapy prior to RCC diagnosis
 5ASA
 Thiopurines
 Methotrexate 
 Cyclosporine 
 Anti-TNFα therapy
145 (94.2)
49 (32.0)
3 (2.0)
5 (3.3)
16 (10.5)
1605 (89.8)
717 (40.2)
95 (5.3)
26 (1.1)
350 (19.7)
26/13
27/17
29/10
27/10
28/25
0.083
0.047
0.074
0.091
0.006
IBD related surgery 86 (48.0) 508 (28.3) 1/8 < 0.001
Calendar year of IBD diagnosis, median 1989 2003 3/1 < 0.001
Duration of follow-up since IBD  
diagnosis (y), median 
19 7 3/30 < 0.001
All values are expressed as n (%) unless otherwise noted.
a Smoking data were only available for patients with Crohn’s Disease.
b Indeterminate colitis was not considered in this comparison since these patients were excluded from IBDSL.
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Table 2 shows the final logistic regression models after backward elimination of the non-
significant variables for both UC and CD patients. Patients with a more complex phenotype 
including Montreal E3 UC (OR 1.8–2.5, 95% CI 1.0–5.3), penetrating CD (OR 2.8, 95% CI 
1.3–5.8) and/or IBD related surgery (OR 3.7–4.5, 95% CI 1.6–8.2) were at increased risk for RCC 
development. Furthermore, male gender (OR 3.2–5.0, 95% CI 1.7–13.2) and older age at IBD 
diagnosis but not age by itself (OR 1.0–1.1, 95% CI 1.0–1.1) were identified as independent 
risk factors. Use of 5-ASA (OR 0.2, 95% CI 0.0–0.7) protected against RCC development. 
Table 2. Final multivariable regression model for the identification of independent risk factors to develop RCC.
Model Variable Coefficient β
Odds ratio 
(95% CI) P value
Ulcerative colitis Male gender 1.169 3.218 (1.715-6.040) < 0.001
(all cases, n = 1061) IBD related surgery
Age at IBD diagnosis
1.499
0.023
4.477 (2.433-8.238)
1.023 (1.006-1.042)
< 0.001
0.009
Montreal E3 colitisa 0.598 1.818 (1.045-3.163) 0.034
Ulcerative colitis Male gender 1.609 4.999 (1.889-13.226) 0.001
(sensitivity analysis, n = 1015) IBD related surgery
Age at IBD diagnosis
1.306
0.028
3.692 (1.578-8.641)
1.029 (1.006-1.051)
0.003
0.011
Montreal E3 colitisa 0.922 2.513 (1.2005.262) 0.015
5-ASA -1.746 0.174 (0.044-0.687) 0.013
Crohn’s disease Age at IBD diagnosis 0.035 1.035 (1.014-1.057) 0.001
(all cases, n = 845) Penetrating disease 1.021 2.776 (1.320-5.836) 0.007
Crohn’s disease Age at IBD diagnosis 0.049 1.051 (1.028-1.074) < 0.001
(sensitivity analysis, n = 811)
Similar inclusion periods of IBD diagnosis (since 1991) for cases and controls were used in the sensitivity analysis 
(case control study A). 
a Reference category is patients with Montreal E1 or E2 colitis.
RCC characteristics and survival - Case control study B
Univariable comparisons of RCC characteristics between IBD cases and the general 
population are shown in Table 3. IBD patients had a statistically significantly lower age at RCC 
diagnosis (p < 0.001), lower N-stage (p = 0.025), lower M-stage (p = 0.020) and underwent 
more frequently surgical treatment for RCC (p < 0.001). This may be attributed to a high 
percentage of incidentally diagnosed cancers in the case group (n = 80/180, 51.3%).
Figure 2 displays the overall survival curves of the case and control group. IBD patients 
had a statistically significant better overall survival compared to the general population 
(p < 0.001). However, age at RCC diagnosis, T-stage, M-stage, surgical treatment and 
calendar year of RCC diagnosis emerged as confounders in a Cox model. Adjusted for these 
confounders, a protective effect of IBD on overall survival was still present (p = 0.026; HR 0.7; 
95% CI 0.5–1.0).
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Table 3. Univariable comparison of RCC characteristics between cases (IBD patients who developed RCC) and 
controls (RCC patients in the general population derived from ECR) (case control study B).
Variable
IBD and RCC cases  
(n = 180)
ECR 
(n = 4388)
Missing values
(cases/ECR) P value
Male gender 114 (63.3) 2659 (60.6) 0 0.461
Age at RCC diagnosis (y), median 62 (27-83) 66 0 < 0.001
Location
 Left-sided
 Right-sided
89 (50.6)
87 (49.4)
2119 (48.7)
2230 (51.3) 4/39 0.631
Grade
 1-2
 3-4
88 (72.7)
33 (27.3)
1214 (69.3)
539 (30.7) 59/2635 0.442
T stage
 T1-T2
 T3-T4
130 (76.9)
39 (23.1)
2509 (70.9)
1032 (29.1) 11/847 0.089
N stage
 N0
 N+
160 (94.1)
10 (5.9)
3281 (88.6)
423 (11.4) 10/684 0.025
M stage
 M0
 M1
155 (87.1)
23 (12.9)
2962 (80.0)
742 (20.0) 2/684 0.020
Surgery 168 (93.9) 3318 (75.6) 1/0 < 0.001
Calendar year of RCC diagnosis, 
median
2003 2007 0 < 0.001
All values are expressed as n (%) unless otherwise noted.
Figure 2. Overall survival curves of the general and IBD population following RCC diagnosis.
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RCC survival related to medical IBD therapy
Based on received IBD medication, we performed subgroup survival analysis for IBD cases 
with RCC. Patients who used immunosuppression (including thiopurines, methotrexate 
and cyclosporine) and/or anti-TNFα therapy before or after RCC diagnosis had a statistically 
significantly better disease free survival following RCC diagnosis compared to those who 
did not (Figure 3). Especially patients who were treated with immunosuppression and/
or anti-TNFα agents after RCC diagnosis, showed a better disease free survival. However, 
a multivariable Cox analyses adjusted for the confounders TNM stage and age at RCC 
diagnosis, abolished this protective effect of immunosuppressive and anti-TNFα therapy 
(immunosuppression before RCC diagnosis, p = 0.946; immunosuppression after RCC 
diagnosis, p = 0.386; anti-TNFα therapy before RCC diagnosis, p = 0.673; anti-TNFα therapy 
after RCC diagnosis, p = 0.502). Similar survival curves were found for the effect of IBD 
therapy on overall survival (data not shown).
Following a similar strategy as for the identification of risk factors we performed 
a sensitivity analysis focusing on patients who carried an IBD diagnosis since 1991. We 
determined the effect of medical therapy on disease free and overall survival. All survival 
analyses and Cox models showed similar results as shown above (data not shown).
DISCUSSION
One of the key findings of our study is that IBD patients with a complex phenotype (including 
Montreal E3 UC, penetrating CD and/or IBD related surgery) are at increased risk to develop 
RCC. They are younger at diagnosis and carry a lower RCC stage compared to the general 
population. This translates into a better disease free and overall survival. The second key 
finding of our study is that immunosuppressive and anti-TNFα therapy does not adversely 
affect disease free and overall survival in IBD patients following RCC diagnosis. 
A better survival in our IBD cohort with RCC may be caused by frequent abdominal imaging 
in these patients, which leads to incidental findings such as RCC. Due to the widespread 
use of imaging techniques, the incidental detection of RCC in the general population 
significantly increased in recent decades to approximately 40%.21-23 This compares to 51% for 
incidentally detected RCC in our IBD cohort. Previous studies have shown that patients with 
these incidentally detected RCC are diagnosed at an earlier stage, which is translated into 
a better survival after correction for confounders (TNM stage, age at RCC diagnosis, calendar 
year).22-24 This is in line with our study in which IBD patients (including a high proportion of 
incidentally diagnosed cancers) received earlier RCC diagnosis and had a better survival.
We found that patients with a more complex IBD phenotype are at increased risk 
to develop RCC. A more frequent and intensive use of the health care system, including 
abdominal imaging, may be associated with this phenomenon. Indeed, another study found 
that IBD patients exposed to anti-TNFα agents (generally prescribed for patients with a more 
complex IBD phenotype) developed RCC at a younger age and received earlier RCC surgery 
compared to IBD patients unexposed to anti-TNFα therapy or patients having rheumatoid 
arthritis.25 Other risk factors for RCC development were male gender and older age at IBD 
onset (not age by itself ), but not the use of medical therapy. One could hypothesize that with 
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Figure 3. Disease free survival curves in IBD subgroups with RCC based on IBD medication received.
increasing age, potential cancer risk factors accumulate until IBD onset with subsequently 
accelerated carcinogenesis. As such, patients who develop IBD later in life are at increased 
risk to develop early colorectal cancer (< 8 y) and more widespread colorectal neoplasia.26, 27 
The role of immunosuppression and/or anti-TNFα agents in relation to cancer development 
remains to be clarified as the literature reports contradictory results.3, 5, 28
Results of our study demonstrated no adverse effect of immunosuppression and/or 
anti-TNFα therapy on both disease free and overall survival following RCC. These therapies 
were mainly (re)started or continued after RCC diagnosis in patients with low stage RCC and 
as a corollary these patients showed a better disease free and overall survival (Figure 3). For 
example, 32 out of 41 patients (82.1%) who used immunosuppressive therapy and 17 out 
of 21 patients (81.0%) with anti-TNFα therapy after RCC diagnosis had a T1 RCC. Adjustment 
for TNM stage abolished the protective effect of immunosuppressive and anti-TNFα therapy 
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and no differences on survival were subsequently found. These findings are in line with 
the only available, prospective study in IBD patients, which showed no negative impact of 
immunosuppressive agents on recurrent cancer of any type.5 Other data originates from 
observational studies including patients with rheumatoid arthritis or solid organ transplants. 
No difference in any new or recurrent malignancy incidence was observed in rheumatoid 
arthritis patients exposed or unexposed to anti-TNFα agents.7, 29 A study in post-transplant 
setting demonstrated a recurrence rate of 0% for incidentally diagnosed RCC and of 30% for 
symptomatic RCC, although a formal comparison to a control group was lacking.30 
Despite concerns regarding a cancer inducing effect of anti-TNFα therapy, TNFα blockers 
have been previously considered as a therapeutic strategy for RCC.31, 32 Previous studies 
showed that TNFα can act as an autocrine tumor growth factor and that its presence is 
associated with poor prognosis. Indeed, phase I/II trials in RCC demonstrated an anti-tumor 
effect of anti-TNFα treatment.32 However, the most recent phase II trial in 2010 showed no 
beneficial effect of anti-TNFα therapy in metastatic RCC.31 Similarly, results of our study did 
not show a better survival of metastatic RCC in patients treated with anti-TNFα agents (data 
not shown). 
Our study has important clinical implications for the evidence-based management 
of IBD therapy in patients with a history of RCC. As no adverse effect of IBD therapy on 
disease free and overall survival was observed, our data suggest that these agents could 
be considered following RCC. Cancer specific data are lacking to date, although case-by-
case management is encouraged based on the characteristics and expected evolution of 
the cancer, the probable impact of IBD therapy on cancer evolution, and IBD severity.4, 
7 The impact of dose, duration and time interval following RCC remains to be assessed in 
larger prospectively followed cohorts. In addition, more cancer specific data are needed for 
other types of cancer to develop individualized evidence-based management strategies in 
IBD patients with cancer.
The present study has several limitations. First, the retrospective nature of data collection 
could have influenced the completeness and accuracy of the extracted data. For example, 
medication use was difficult to ascertain from older medical records. To address this issue, 
we performed sensitivity analyses including patients with similar calendar years of IBD 
diagnosis or RCC diagnosis in the case and control group, disseminating missing values 
and errors across groups. Second, the use of multiple databases and registries resulted in 
different ways of data collection and the absence of some variables. For example, potential 
risk factors and confounders, such as smoking behavior, hypertension, body mass index and 
incidental detection of RCC, were not available in IBDSL or the ECR. Given this limitation 
some of our results need to be interpreted with caution. However, it was inevitable to use 
multiple databases to address our research questions. Finally, selection bias may have been 
introduced as we used different registries and databases. For example, cases were identified 
nationwide whereas controls with RCC and controls with IBD were ascertained from two 
different registries in the south of The Netherlands. However, previous studies confirmed 
that these population-based registries are representative of the Total Dutch population.33
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In conclusion, we identified a complex IBD phenotype as a risk factor to develop 
RCC. IBD patients were diagnosed with RCC at a younger age and at an earlier disease 
stage compared to the general population, which translated into a better disease free 
and overall survival following RCC. Immunosuppressive and anti-TNFα therapy did not 
adversely affect this better survival. This observation may aid physicians in guiding IBD 
therapy following RCC diagnosis and treatment.
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ABSTRACT
Although restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) substantially 
reduces the risk of colorectal cancer in patients with inflammatory bowel disease (IBD), 
subsequent pouch neoplasia can develop. There are few data on the incidence of and risk 
factors for neoplasia, so there is no consensus on the need for pouch surveillance. We aimed 
to determine the cumulative incidence of pouch neoplasia in patients with IBD and identify 
risk factors for developing pouch neoplasia. 
We searched the Dutch Pathology Registry (PALGA) to identify all patients with IBD and 
IPAA in The Netherlands from January 1991 to May 2012. We calculated the cumulative 
incidence of pouch neoplasia and performed a case-control study to identify risk factors. 
Demographic and clinical variables were analyzed with univariable and multivariable Cox 
regression analyses. 
We identified 1200 patients with IBD and IPAA; 25 (1.83%) developed pouch neoplasia, 
including 16 adenocarcinomas. Respective cumulative incidences at 5, 10, 15, and 20 years 
were 1.0%, 2.0%, 3.7%, and 6.9% for pouch neoplasia and 0.6%, 1.4%, 2.1%, and 3.3% for 
pouch carcinoma. A history of colorectal neoplasia was the only risk factor associated with 
pouch neoplasia. Hazard ratios were 3.76 (95% confidence interval, 1.39–10.19) for prior 
dysplasia and 24.69 (95% confidence interval, 9.61–63.42) for prior carcinoma. 
The incidence of pouch neoplasia in patients with IBD without a history of colorectal 
neoplasia is relatively low. Prior dysplasia or colon cancer is associated with an approximate 
4- and 25-fold increase in risk, respectively, of developing pouch neoplasia.
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INTRODUCTION
Despite medical progress, approximately 30% of ulcerative colitis (UC) patients eventually 
require a colectomy because of refractory disease, intolerance to medication, or complications 
of the disease.1 In those cases, restorative proctocolectomy with ileal pouch-anal anastomosis 
(IPAA) is the preferred surgical treatment to restore intestinal continuity and fecal continence. 
Dysplasia or cancer of the colon is one of the UC-related complications that may necessitate 
a colectomy. It is well established that the risk of colorectal cancer (CRC) is increased in 
patients with inflammatory bowel disease (IBD).2 The risk of CRC is especially increased in 
cases of multi-focal low-grade dysplasia (LGD) or high-grade dysplasia (HGD), and these are 
generally well-accepted indications for proctocolectomy. Restorative proctocolectomy with 
IPAA substantially reduces the risk to develop CRC; however, malignant degeneration of 
the pouch may still arise.
The incidence and prevalence of pouch neoplasia in patients with IBD are probably 
low. According to the latest review, only 42 pouch adenocarcinomas have been described 
in the literature.1 A previous study reported a cumulative incidence of pouch neoplasia of 
1.9% after 15 years and 5.1% after 25 years.3 However, these data were collected in a single 
tertiary pouch referral center and may not be representative of the general IBD population 
with IPAA. Furthermore, the relatively low incidence makes it difficult to assess risk factors for 
development of pouch neoplasia. 
Given the paucity of data regarding the risk of pouch neoplasia, there is no consensus 
on the necessity and potential interval of pouch surveillance. The aim of our study was to 
establish the cumulative incidence of pouch neoplasia in a nationwide cohort of patients 
with IBD and IPAA. Furthermore, we aimed to identify risk factors for pouch neoplasia to 
contribute to a recommendation for a more targeted pouch surveillance program in patients 
with IBD.
Patients and methods
Design
We studied the cumulative incidence of pouch neoplasia using a nationwide established 
Dutch cohort of patients with IBD. Risk factors for developing pouch neoplasia were 
identified by adopting a case-control study approach.
Patient identification
PALGA, the nationwide network and registry of histopathology and cytopathology, was 
searched, with approval of their Privacy Commission and Scientific Council, to identify all 
patients with IBD and IPAA in The Netherlands. PALGA contains pathology reports generated 
in The Netherlands since 1971 and has complete national coverage since 1991 encompassing 
all pathology laboratories from all academic and nonacademic hospitals in The Netherlands.4 
A search of PALGA was performed with the following search terms: “ulcerative colitis”, “Crohn’s 
disease”, “indeterminate colitis”, and “chronic idiopathic inflammatory bowel disease” combined 
with “pouch” or a (Dutch) synonym. The search was performed from January 1991 to May 
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2012. Cases were further confirmed or excluded after careful evaluation of the individual 
pathology reports.
Verification cohort
To verify the coverage of our PALGA search, we compiled a verification cohort. This 
cohort consisted of patients with IBD and IPAA from the Radboud University Nijmegen 
Medical Centre who had at least one outpatient medical contact at the Department of 
Gastroenterology and Hepatology between 2004 and May 2012. Next, we verified whether 
pathology reports from examination of gastrointestinal tissue were available in the medical 
records. Using these pathology reports, we verified whether patients were likewise identified 
through the PALGA search.
Inclusion and exclusion criteria
Patients with IPAA were identified with PALGA, and those with a diagnosis of ulcerative 
colitis, indeterminate colitis, or Crohn’s disease based on the colonic resection specimen 
were included. The following exclusion criteria were used: familial adenomatous polyposis, 
absence of a diagnosis of IBD or IPAA, Kock pouch, ileorectal anastomosis, ileoneorectal 
anastomosis, or missing follow-up. Furthermore, patients were excluded if the colectomy 
specimen was not available or if no distinction could be made for the type of pouch 
or anastomosis despite careful evaluation of the pathology reports. Of note, none of 
the exclusion groups contained patients with IPAA and pouch neoplasia.
Patients who developed pouch neoplasia, including pouch dysplasia and pouch 
adenocarcinoma, were identified as cases. Pouch malignancies other than adenocarcinomas 
were excluded from the case group. Controls for the case-control study were randomly 
selected (using a 1:3 ratio) from the entire population with IBD and IPAA (identified with 
PALGA) at the 6 centers that provided the majority (69%) of cases. Because the control group 
in a case-control study should reflect the entire source population that gave rise to the cases, 
we did not exclude patients with pouch neoplasia from the control group.5
Histopathologic assessment
Pouch neoplasia was defined as dysplasia or carcinoma in the pouch or anal transitional zone 
(ATZ; the area between the dentate line and anastomosis, with or without mucosectomy), 
classified according to Riddell as IND, LGD, HGD, or adenocarcinoma.6 For the patients 
with a diagnosis of pouch dysplasia, the pouch biopsy specimens with dysplasia were 
reevaluated by an expert gastrointestinal pathologist (I.D.N.) blinded to clinical, endoscopic, 
and radiographic features. The gradation of dysplasia was reassessed, and eventually revised 
results were used for analysis. The category IND after reevaluation was excluded from 
the case group in the analysis.
Statistics
Cumulative incidences were counted with 1 minus Kaplan–Meier curves. Time to event was 
calculated from the date of pouch construction to the development of pouch neoplasia 
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(cases) or the end of follow-up for patients who did not develop a neoplasia (controls). 
End of follow-up was defined as the last gastroenterology-related medical contact, pouch 
excision, or patient’s death. The median time to develop pouch carcinoma and the median 
survival time, including a minimum to maximum range, were derived from
Kaplan–Meier curves. For the variables collected from the total cohort, log-rank analyses 
were performed to compare the incidence of pouch neoplasia in those subgroups. 
χ2 test or Fisher exact test (if expected cell counts were < 5) for categorical data and 
independent Student t test for continuous data were used to compare cases and controls 
on all selected possible risk factors. Variables with a P value of < 0.1 in univariate analyses 
were included in a multivariate Cox proportional hazard model with backward sampling 
to determine which risk factors are independently associated with developing a pouch 
carcinoma. A P value of < 0.05 (2 sided) was considered to be statistically significant. Cases 
in the control group were analyzed as cases in the Cox model, resulting in hazard ratios that 
can be interpreted as relative risks. All missing values were considered to be completely at 
random and were excluded from analyses. All statistical analyses were performed with IBM 
SPSS statistics version 20.0 (SPSS Inc, Chicago, IL).
RESULTS
Patients
We identified 1200 patients with IBD and IPAA with a median follow-up time of 6.5 years using 
PALGA. Fortyfive of the 1200 patients (3.75%) had an initial histological diagnosis of pouch 
neoplasia (Figure 1). This group consisted of 12 patients with IND, 17 patients with LGD, and 
16 patients with adenocarcinoma. In the latter group, 4 carcinomas were considered to be 
recurrence of CRC and 2 carcinomas arose after pouch excision. One of the patients with 
a recurrence previously underwent an incomplete CRC resection and a pouch carcinoma 
was detected 1 month after pouch construction. In the other 3 cases, recurrences occurred 
within 1 to 2 years after treatment of CRC. The 2 patients with adenocarcinoma after 
pouch excision for chronic pouchitis or perianal symptoms developed carcinomas 5 and 
6 years after pouch excision. Identified pouch malignancies other than adenocarcinoma 
included one B-cell non-Hodgkin lymphoma, and this case was excluded from the analysis. 
The control group was established by random selection of 100 patients from the nationwide 
cohort. The medical record of one patient could not be retrieved, which resulted in 
a final control group of 99 patients. This control group included 4 cases with a diagnosis 
of pouch neoplasia.
Verification cohort
Our verification cohort consisted of 93 patients with IBD and IPAA who visited the outpatient 
clinic at the Radboud University Nijmegen Medical Centre between 2004 and May 2012. 
Eighty-eight of the 93 patients (95%) were identified on the initial search of PALGA, and 
the remaining 5 patients (5%) escaped identification by our search. These 5 patients 
never underwent a pouch biopsy or the PALGA search terms were not mentioned in 
the pathology reports.
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Figure 1. Flowchart showing patient inclusion.
Histopathologic reassessment
All pouch biopsy specimens with dysplasia except one were available for reassessment. 
Re-review of the specimens shifted the grades of dysplasia in 22 of 29 cases. Reassessment 
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resulted in downgrading of dysplasia in 18 patients and upgrading in 4 patients. This resulted 
in the identification of 4 cases with IND, 8 cases with LGD, 1 case with HGD, and 16 cases with 
adenocarcinoma (Figure 1).
Cumulative incidences
Figure 2 depicts the cumulative incidences of pouch neoplasia (both dysplasia and 
carcinoma), pouch dysplasia (LGD and HGD), and pouch carcinoma. The cumulative 
incidences of pouch neoplasia were 1.0%, 2.0%, 3.7%, and 6.9% at 5, 10, 15, and 20 years, 
respectively. The respective cumulative incidences at 5, 10, 15, and 20 years for pouch 
dysplasia were 0.3%, 0.5%, 1.6%, and 3.7% and for pouch carcinoma were 0.6%, 1.4%, 2.1%, 
and 3.3%.
Figure 2. Cumulative incidences of pouch neoplasia (both carcinoma and dysplasia), pouch carcinoma, and 
pouch dysplasia.
Risk factors for pouch neoplasia
Table 1 lists the basic variables extracted from PALGA, including age at colectomy, sex, type 
of IBD, and prior colorectal neoplasia. A history of colorectal neoplasia significantly differed 
between cases and controls. For this variable, we performed log-rank analyses. Patients with 
prior colorectal dysplasia or carcinoma had higher cumulative incidences of pouch neoplasia 
compared with patients without a history of colorectal neoplasia (P < 0.001, log-rank test, 
Figure 3). After 15 years, the combined cumulative incidence of pouch dysplasia and 
carcinoma was 29.5% in the subgroup with prior CRC and 2.2% in the subgroup without 
prior neoplasia (Figure 3). 
Clinical and demographic characteristics that were derived from the medical records 
are described in Table 2. Age at pouch construction, duration of IBD, primary sclerosing 
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Table 1. Comparison of the extracted variables from PALGA between patients with pouch neoplasia (both 
carcinoma and dysplasia) and patients without pouch neoplasia.
Variable
Pouch 
neoplasia
( n = 25)
Without  
pouch neoplasia
(n = 1175)
Univariate analyses 
(P value)
Missing 
value 
(n)
Age at colectomy (y), mean + SD 39.7 + 9.9 35.9 + 12.4 0.123 0
Female sex 8 (32.0) 559 (47.6) 0.157 0
IBD type
 Ulcerative Colitis 20 (80.0) 1033 (87.9)
 Crohn’s disease 2 (8.0) 44 (3.7)
 Indeterminate colitis 3 (12.0) 98 (8.3) 0.190 0
Prior colorectal neoplasia 
 Without 10 (40.0) 1026 (87.4)
 Dysplasia 6 (24.0) 107 (9.1)
 Adenocarcinoma 9 (36.0) 41 (3.5) < 0.001 1
All values are expressed as n (%) unless otherwise noted.
Figure 3. Cumulative incidences of pouch neoplasia of subgroups categorized by the presence or absence of 
prior colorectal dysplasia or cancer, which differ significantly with log-rank analyses (p < 0.001).
cholangitis, and again a history of colorectal neoplasia were significantly different between 
patients with and without pouch neoplasia (p = 0.019, p = 0.001, p = 0.030, and p < 0.001, 
respectively). Table 3 shows the results of the multivariate Cox model with all hazard ratios 
before elimination of nonsignificant variables as well as the final model after backward 
elimination. Both prior colorectal dysplasia and carcinoma emerged as risk factors with 
respective hazard ratios of 3.76 (95% confidence interval, 1.39–10.19; p = 0.009) and 24.69 
(95% confidence interval, 9.61–63.42; p < 0.001). Most cases of prior colorectal neoplasia 
were located in the rectosigmoid colon (Table 4). 
Inclusion of patients with a recurrence of CRC and thus a prior CRC may give a distorted 
picture of the identified risk factor “prior colorectal neoplasia.” Patients who developed 
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adenocarcinoma after pouch excision may contribute to this effect. To verify the identified 
risk factors, we performed a sensitivity analysis excluding these patients. A new Cox model 
confirmed our earlier findings and showed prior colorectal dysplasia and carcinoma as 
the only risk factors, with respective hazard ratios of 4.17 (95% confidence interval, 1.50–
11.62; p = 0.006) and 20.28 (95% confidence interval, 6.71–61.30; p < 0.001).
Table 2. Comparison between patients with pouch neoplasia (both carcinoma and dysplasia) and the control 
group for possible risk factors and confounders extracted from the medical records.
Variable
Pouch 
neoplasia
(n = 25)
Control 
group
(n = 99)
Univariate 
analyses
(P value)
Missing 
value
(n)
Female sex 8 (32.0) 41 (41.4) 0.494 0
Age at IBD diagnosis (y), mean + SD 25.7 + 11.6 25.7 + 12.5 0.984 10
Age at pouch construction (y), mean + SD 39.8 + 9.9 33.0 + 13.3 0.019 0
IBD type
 Ulcerative Colitis 20 (80.0) 89 (89.9)
 Crohn’s Disease 2 (8.0) 3 (3.0)
 Indeterminate colitis 3 (12.0) 7 (7.1) 0.296 0
Extended colitis (Montreal E3) 22 (91.7) 78 (89.7) 1.000 13
IBD duration from diagnosis to pouch construction
(y), mean + SD
13.3 + 8.2 6.9 + 6.1 0.001 10
Prior colorectal neoplasia (LGD, HGD, carcinoma) 15 (62.5) 12 (12.4) < 0.001 3
J-pouch configuration 18 (85.7) 79 (85.9) 1.000 11
Anastomosis type
 Handsewn with mucosectomy 4 (19.0) 17 (18.7)
 Stapled without mucosectomy 17 (81.0) 74 (81.3) 1.000 12
Pouchitis (chronic or relapsing) 6 (24.0) 26 (26.3) 1.000 0
Cuffitis 4 (16.0) 10 (10.1) 0.479 0
Crohn’s disease of the pouch 2 (8.0) 2 (2.0) 0.181 0
Primary sclerosing cholangitis 4 (16.0) 3 (3.0) 0.030 0
Ever smoked 8 (38.1) 17 (23.6) 0.262 31
Family history of colorectal carcinoma 0 (100) 0 (100) Not computable 54
Pouch duration (y)a, mean + SD 8.6 + 6.1 8.4 + 7.0 0.883 0
Surveillance frequency (average/year) 0.43 + 0.42 0.52 + 0.57 0.470 15
Surveillance intervals
 No surveillance pouchoscopy
 > 1 pouchoscopy every 3 y
 > 1 pouchoscopy every 5 y
 > 1 pouchoscopy every 10 y
 < 1 pouchoscopy every 10 y
3 (12.0)
8 (32.0)
3 (12.0)
3 (12.0)
8 (32.0)
14 (14.1)
26 (26.3)
12 (12.1)
29 (29.3)
18 (18.2) 0.332 0
All values are expressed as n (%) unless otherwise noted.
a Pouch duration of cases and controls was calculated from the date of proctectomy to the development 
of pouch neoplasia (cases) or end of follow-up (controls). End of follow-up for controls was defined as the last 
gastroenterology-related medical contact, pouch excision, or patient’s death.
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Characteristics and outcomes of pouch neoplasia 
The identified cases of pouch carcinoma and dysplasia were further analyzed, and an 
overview is presented in Table 4 and Supplementary Table 1. The median time to develop 
a pouch carcinoma after diagnosis of IBD was 20 years (range, 14–38 years) and 7.0 years 
(range, 0–22 years) after pouch construction. LGD developed at a median time of 19 years 
(range, 9–34 years) after diagnosis of IBD and 7.0 years (range, 0–18 years) after pouch 
construction. Ten of 16 pouch carcinomas were located at the ATZ, and 3 of 8 cases of pouch 
dysplasia arose at the ATZ.
The endoscopic characteristics at the time of detection of pouch neoplasia were not 
consistent. Dysplasia and cancer were seen in patients with ulcerated lesions, polypoid 
lesions, and mass-like lesions, but patients without endoscopic abnormalities also had 
neoplasia (Table 4 and Supplementary Table 1). For instance, 4 of 16 patients with pouch 
carcinoma did not have any visible lesions on endoscopy.
Pouch dysplasia rarely progressed during follow-up, and as a result only 3 carcinomas 
(19%; stage I, n = 2; stage II, n = 1) were preceded by HGD, LGD, and/or IND. In patients with 
IND or LGD, only 2 of 14 patients progressed to carcinoma during follow-up, whereas 9 of 14 
patients with dysplasia had regression on subsequent biopsy specimens. One patient with 
HGD also showed regression, and no dysplasia was found on subsequent biopsy specimens. 
In our cohort, 3 patients with pouch dysplasia were not followed up by pouchoscopy. In one 
patient in the latter group, LGD was detected in the excised pouch specimen. 
Most pouch carcinomas were detected at an advanced stage of disease, resulting in a high 
mortality rate (Table 4). Nine of 16 patients died with a median survival of 11 months (range, 
1–20 months) after diagnosis of pouch carcinoma. Three additional patients were lost to 
follow-up. Two of these patients had metastatic disease at last followup. Pouch carcinomas 
did not recur in 4 patients during a median follow-up of 12 months (range, 11–124 months) 
after diagnosis of pouch carcinoma.
DISCUSSION
The key finding of our study is the relatively low incidence of pouch carcinoma, especially in 
patients without a history of colorectal neoplasia. Only 16 of 1200 patients with IPAA (1.3%) 
were identified with pouch carcinoma in our nationwide IBD cohort. Of note, most of these 
carcinomas developed at the ATZ (63%). The cumulative incidence of developing pouch 
carcinoma reached 3.3% after 20 years. Furthermore, a history of colorectal dysplasia and 
carcinoma raised the risk of pouch neoplasia by 4- and 25-fold, respectively. After 15 years, 
the cumulative incidence of pouch neoplasia was 29.5% in the subgroup with a prior CRC 
and 2.2% in the subgroup without a prior neoplasia.
The relatively low incidence of pouch carcinoma (cumulative incidence of 3.3% after 20 
years) in IBD is in line with the findings of another large cohort study. This study evaluated
3202 patients with IBD and IPAA and reported a cumulative incidence of pouch carcinoma 
of 2.4% after 20 years.3 Similarly, this cohort study detected 23 patients (0.72%) with pouch 
dysplasia, while a meta-analysis showed a pooled prevalence of pouch dysplasia of 1.13% in 
2040 patients.3, 9 This is in line with data presented in the current study (pouch dysplasia in 9 
of 1200 patients [0.75%]). 
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Prior colorectal neoplasia is a risk factor for development of pouch neoplasia.3, 
10–12 The majority of cases identified in our cohort (69%) as well as by the most recent 
review1 (57%) had a history of colorectal neoplasia. Most pouch carcinomas (63% in our 
cohort) developed at the ATZ. Although it seems reasonable to remove colonic tissue by 
mucosectomy, this strategy does not protect against pouch neoplasia.3, 13, 14 A possible 
explanation is the presence of residual colonic mucosa islets that may remain even after 
“complete” mucosectomy.15 It could be hypothesized that this residual colonic mucosa bears 
an increased risk of malignant degeneration, especially in patients with prior colorectal 
neoplasia. The short interval between pouch construction and development of carcinoma 
in some patients and the ATZ location of most pouch carcinomas raises the issue whether 
some pouch carcinomas represent recurrence of CRC rather than a primary pouch carcinoma. 
Other previously purported risk factors for developing pouch neoplasia include pouchitis,3, 
15–17 long duration of IBD,3, 10–12 and primary sclerosing cholangitis.3, 18, 19 None of these factors 
were identified as a risk factor in our study.
A thorough understanding of the natural history of pouch neoplasia is fundamental 
to the development of an effective strategy for pouch surveillance. In colonic IBD, 
the surveillance strategy is based on the concept of an inflammation-dysplasia-carcinoma 
sequence.20 Whether this sequence also applies to pouch neoplasia is unknown. The fact 
that pouchitis was not identified as a risk factor as well as the high regression rates and 
low progression rates of pouch dysplasia both in the literature and in our study suggest 
that this hypothesis does not hold for pouch carcinogenesis.1, 21 On the other hand, one 
study identified concurrent LGD or HGD in 10 of 11 (90.9%) pouch carcinomas in the pouch 
excision specimens.3 In addition, many clinicopathological and molecular features in pouch 
carcinoma are shared with IBD-associated CRC, which is in favor of the inflammation-
dysplasia-carcinoma sequence.22
The underlying purpose of our study was to contribute to a recommendation for a more 
targeted pouch surveillance program in patients with IBD. Importantly, our nationwide 
study provides the opportunity to generate data that reflect the IPAA population at large, 
in contrast to prior studies that stem from tertiary referral centers. Data from the present 
study suggest that pouch surveillance with close inspection of the ATZ should be considered 
in patients with IPAA who have a history of colorectal neoplasia. However, it is unknown 
whether surveillance will indeed detect carcinoma at a less advanced stage and result in an 
improved prognosis. Most pouch carcinomas in our study were not preceded by dysplasia, 
and resection of dysplastic lesions might not contribute to the prevention of pouch 
carcinoma. Furthermore, our data suggest a limited role for pouch surveillance in patients 
without a history of colorectal neoplasia. This is supported by the relatively low incidence 
of pouch neoplasia in patients without prior colorectal neoplasia (cumulative incidence of 
2.2% after 15 years), especially in comparison with the lifetime incidence of approximately 
5% for developing CRC in the general population.23
The present study has some limitations. First, the retrospective nature of the study 
and use of data primarily not intended for research resulted in missing variables. Second, 
the relatively small number of cases might result in a type II error in determining risk factors. 
In addition, the current study could represent a slight overestimation of the actual cumulative 
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incidences. The exclusion of patients because of incomplete documentation of the presence 
of IPAA, as well as pouch patients who never underwent pouch biopsies (and thus escaped 
identification by our search), could contribute to this effect. However, our verification cohort 
suggests that only few patients were missed and none of these patients had a diagnosis 
of pouch neoplasia. It is debatable whether patients with recurrences of CRC and pouch 
carcinomas after pouch excision should be part of the case group. Because we aimed to 
formulate a comprehensive surveillance strategy that identifies all pouch carcinomas, we 
included these carcinomas in our case group. This may influence the identification of risk 
factors, but sensitivity analyses excluding these patients resulted in identification of similar 
risk factors. Finally, patients were not subjected to a standardized endoscopic surveillance 
program. Pouchoscopies were performed by both gastroenterologists and surgeons without 
standardized biopsy protocol and well-defined intervals. Although the average pouchoscopy 
rate was once per 5 years and the surveillance intervals were the same between the case 
and control groups, it is unknown whether a more standardized surveillance program would 
have picked up more cases of pouch dysplasia in general and before pouch carcinoma. Many 
cases of dysplasia regressed; this, combined with the absence of a standardized endoscopic 
surveillance strategy, may have contributed to missed cases of pouch dysplasia. The slightly 
larger sample size of the pouch carcinoma group compared with the pouch dysplasia group 
might also reflect missed detection of dysplasia. Patients with a prior CRC could have had 
a pouchoscopy more frequently; however, this was not seen in the patients included in 
the case-control study (data not shown).
In conclusion, the incidence of pouch neoplasia in patients with IBD without prior 
colorectal neoplasia is relatively low. A history of dysplasia and CRC raises the risk of pouch 
neoplasia significantly. Our data suggest that a limited surveillance program is sufficient for 
patients with IPAA without a history of colorectal neoplasia. A targeted surveillance program 
should be considered in patients with a prior colorectal neoplasia. However, prospective 
studies are required to evaluate the effects of such a surveillance strategy.
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ABSTRACT
Colorectal neoplasia can still develop after colectomy for inflammatory bowel disease. 
However, data on this risk are scare, and there have been few conclusive findings, so no 
evidence-based recommendations have been made for postoperative surveillance. We 
conducted a systematic review and meta-analysis to determine the prevalence and incidence 
of and risk factors for neoplasia in patients with inflammatory bowel disease who have 
undergone colectomy, including the permanent-end ileostomy and rectal stump, ileorectal 
anastomosis (IRA), and ileal pouch-anal anastomosis (IPAA) procedures.
We searched PubMed, Embase, Web of Science, and Cochrane Library through May 
2014 to identify studies that reported prevalence or incidence of colorectal neoplasia after 
colectomy or specifically assessed risk factors for neoplasia development. Studies were 
selected, quality was assessed, and data were extracted by 2 independent researchers.
We calculated colorectal cancer (CRC) prevalence values from 13 studies of patients 
who underwent rectal stump surgery, 35 studies of IRA, and 33 studies of IPAA. Significantly 
higher proportions of patients in the rectal stump group (2.1%; 95% confidence interval 
[CI], 1.3%–3.0%) and in the IRA group (2.4%; 95% CI, 1.7%–3.0%) developed CRC than in 
the IPAA group (0.5%; 95% CI, 0.3%–0.6%); the odds ratio (OR) for CRC in the rectal stump 
or IRA groups compared with the IPAA group was 6.4 (95% CI, 4.3–9.5). A history of CRC 
was the most important risk factor for development of CRC after colectomy (OR for 
patients receiving IRA, 12.8; 95% CI, 3.31–49.2 and OR for patients receiving IPAA, 15.0; 
95% CI, 6.6–34.5).
In a meta-analysis of published studies, we found the prevalence and incidence of CRC 
after colectomy to be less than 3%; in patients receiving IPAA it was less than 1%. Factors that 
increased risk of cancer development after colectomy included the presence of a residual 
rectum and a history of CRC. These findings could aid in development of individualized 
strategies for post-surgery surveillance.
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INTRODUCTION
Although the magnitude of the colorectal cancer (CRC) risk in inflammatory bowel disease 
(IBD) patients is still under debate, it is well-established that both ulcerative colitis (UC) and 
Crohn’s disease (CD) patients with colonic involvement have an increased risk to develop 
CRC. It is one of the most detrimental complications of IBD, with significant morbidity and an 
associated mortality rate of approximately 15%.1 To reduce CRC risk, endoscopic surveillance 
guidelines have been developed that allow detection and potential removal of precancerous 
lesions. This strategy might reduce the increased CRC incidence in IBD patients and improve 
mortality rates.2 However, IBD surveillance guidelines have been written on the basis of 
research in patients with an intact colon.3, 4
Although therapeutic options have expanded during the last decade, bowel surgery still 
plays an important role in the management of IBD. Indeed, the cumulative risk of intestinal 
surgery for UC patients is 25%–30% and even higher for CD patients (70%–80%).5, 6 For UC 
or extensive colorectal CD, staged restorative proctocolectomy is the surgical treatment of 
choice. The series of surgical procedures start with subtotal colectomy and ileostomy with 
a residual rectum left in situ. This initial approach will keep options for reconstructive surgery 
open.1 Ileal pouch-anal anastomosis (IPAA) is the preferred reconstructive procedure after 
colectomy in UC patients.1, 5 In patients with extensive colonic CD, ileorectal anastomosis 
(IRA) is the first restorative option to consider.6 For several reasons including comorbidities 
and concerns about fertility, treating physicians and patients may reconsider restorative 
surgery, and these patients usually continue with a permanent ileostomy and rectal stump. 
Colectomy, with or without reconstructive surgery, substantially reduces the risk to 
develop colorectal neoplasia. However, neoplasia of the residual rectum or ileoanal pouch 
may still arise and is associated with a poor prognosis. The latter underlines the importance of 
preventative strategies such as endoscopic surveillance. In recent years, data have expanded 
regarding prevalence, incidence, and risk factors for colorectal neoplasia after colectomy. 
Lack of a comprehensive approach and interpretation of these data has led to the absence 
of endoscopic surveillance recommendations for these patients. Thus, integrated data on 
CRC risk in postsurgical IBD patients are needed to further aid development of surveillance 
guidelines. We therefore conducted a systematic review and meta-analysis that aimed to 
determine prevalence, incidence, and risk factors regarding colorectal dysplasia and cancer 
after colectomy in 3 groups of IBD patients including (1) patients with a permanent ileostomy 
and rectal stump, (2) patients with IRA, and (3) patients with IPAA.
METHODS
Search strategy
Medline, Embase, the Cochrane Library, and Web of Science were independently searched 
with the help of a clinical librarian until May 2014 by 2 authors (L.D., L.N.) to identify studies 
that evaluated the colorectal neoplasia risk after colonic resection in IBD patients. We used 
the medical subject headings (MeSH) “Inflammatory bowel disease” OR “Ulcerative colitis” 
OR “Crohn’s disease”, combined with “Surgical anastomosis” OR “Colectomy” OR “Restorative 
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proctocolectomy” and combined with “Colorectal neoplasms” OR “Rectal neoplasms” OR “Colon 
neoplasms” OR “Anus neoplasms”. Simultaneously, a title/abstract search was performed with 
similar search terms and synonyms. The full search strategy is described in Supplementary 
Table 1. No restrictions regarding language, year of publication, or publication type were 
imposed. A manual search for references in the initially selected articles (Figure 1) was 
performed to identify additional relevant articles. The reporting checklist proposed by 
the Meta-analysis of Observational Studies in Epidemiology was used as a guideline in this 
systematic review and meta-analysis. 
Inclusion and exclusion criteria
Studies were eligible for inclusion if the authors reported a series of IBD patients who 
underwent colonic resection and if occurrence of postoperative neoplasia in the residual 
rectum or pouch was described. In addition, we included studies that specifically assessed 
risk factors for neoplasia development after colectomy. Studies including patients with 
a Hartmann procedure or segmental resection and studies not defining the total IBD patient 
group were excluded. Furthermore, we excluded case reports, case series, studies including 
< 20 patients, and conference abstracts because these might not be representative for 
the target population. In case of duplicate publication or similar data from same institutions, 
the most recent and complete data sets were considered. Multiple studies from one 
institution were both considered if less than 25% of the inclusion years overlapped.
Quality assessment of retrieved articles
On the basis of the guidelines for critically appraising studies of prevalence or incidence, we 
composed a list of parameters for quality judgment.7 These comprise whether the study was 
single center or population based, the number of patients (more or less than 100; a calculated 
sample size of 114 patients would be needed to show a prevalence of 5% with an error rate 
of 4%; a smaller sample size would give a higher risk of bias), duration of follow-up (cutoff 
mean or median 1 year), proctectomy or pouch excision rate, whether a clear pathologic 
classification system was used for grading neoplasia, whether the study was retrospective or 
prospective, and whether the study was consecutive. Two authors (L.D., L.S.) independently 
determined a quality score for each study, with a maximum of 7 points. Disagreement was 
resolved by discussion and consensus with a third reviewer (F.H.).
Data extraction
Different parameters were independently extracted by 2 authors (L.D., L.S., in consensus 
with F.H.) from the original articles including demographics, IBD characteristics, neoplasia 
prevalence and incidence, and risk factors such as a history of preoperative colorectal 
neoplasia, primary sclerosing cholangitis (PSC), pouchitis, and type of pouch anastomosis. 
IBD characteristics included the type and duration of IBD. For each group of IBD patients 
(rectal stump, IRA, and IPAA), the prevalence of colorectal neoplasia was calculated by 
dividing the cases by the total patient group at risk. Patients with either adenocarcinoma, 
including carcinoma in situ, or dysplasia were included as cases. The first group with a rectal 
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Figure 1. Flowchart showing inclusion of articles for analysis.
a Twelve articles are included in both the rectal stump group and the IRA group. 
b One article is included in both the IRA group and the IPAA group. 
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stump was defined as the group of patients who underwent a colonic resection including 
the hepatic and splenic flexure and who received a permanent ileostomy. A rectal or 
rectosigmoidal stump was still in situ and at risk for neoplasia development. Patients who 
were lost to follow-up, postoperatively deceased, or undergoing secondary reconstruction 
of IRA or IPAA were not included in this group. The IRA and IPAA groups included all patients 
who underwent IRA or IPAA in 1 or more stages, respectively. Patients with an ileosigmoidal 
or cecorectal anastomosis were also included in the IRA group. In accordance with the rectal 
stump group, patients who were lost to follow-up or postoperatively deceased were 
excluded from the IRA and IPAA groups.
Statistics
We performed a meta-analysis to estimate pooled prevalences and cumulative incidences 
of colorectal neoplasia after colectomy. Random-effect models were used because of 
heterogeneity of studies. We assessed publication bias with the visual inspection of a funnel 
plot and used the Egger test to analyze funnel plot asymmetry.8 Subsequently, we compared 
prevalences between subgroups (for example UC versus CD) with a logistic regression model 
calculating odds ratios (ORs). 
To analyze potential risk factors for developing CRC after colectomy, ORs were separately 
calculated for each study and subsequently pooled with a random-effect model. Risk factors 
that comprised continuous data were analyzed in a pooled model by calculating a weighted 
mean difference.
To compare equality of follow-up duration between the 3 groups, we used one-way 
analysis of variance. Correlations between duration of follow-up and prevalence were 
analyzed with Spearman correlation coefficient. A P value less than 0.05 was considered 
statistically significant. All statistical analyses were performed by using StatsDirect Statistical 
Software version 2.8.0 (StatsDirect, Sale, Cheshire, UK), Statistical Analysis Software version 
9.2 (SAS Institute, Cary, NC), or IBM SPSS statistics version 20.0 (SPSS Inc, Chicago, IL).
RESULTS
Study selection
The systematic study selection flowchart is depicted in Figure 1. Sixteen, 68, and 56 articles 
were included in the rectal stump group, the IRA group, and the IPAA group, respectively. 
Because of duplicate data, 2 studies in the rectal stump group, 32 studies in the IRA group, 
and 18 studies in the IPAA group were not used for prevalence calculations (references for 
excluded studies are listed in Supplementary Material). For both the rectal stump group 
and the IRA group we included 1 article and for the IPAA group 5 articles that specifically 
assessed risk factors.
Study characteristics and quality assessment
Summarized quality scores for all included studies are depicted in Supplementary Tables 2–4 
for the rectal stump group, IRA group, and IPAA group. Full quality assessment is displayed 
in Supplementary Tables 5–7. 
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The mean quality score of selected studies in the rectal stump group was 2.3 out of 7. All 
studies included retrospective, single-center cohort studies. Sample sizes were insufficient, 
and none of the studies mentioned the pathologic classification system that was used to 
evaluate rectal neoplasia. Proctectomy rates differed between 46% and 95%, resulting in 
a reduced number of patients at risk to develop rectal neoplasia. However, there was no 
correlation between proctectomy rates and cancer prevalence (P = 0.510).
Studies included in the IRA group had better overall quality, with average quality score of 
4.0. This was mainly caused by better documentation and longer duration of follow-up, lower 
proctectomy rate, and larger number of included patients per study. Higher proctectomy 
rates were not correlated with lower cancer prevalence (P = 0.311).
Included articles on the IPAA group had a mean quality score of 3.0. The difference in 
quality score with the IRA group might be attributed to absence of the pouch excision rate, 
which was not reported in most articles. No correlation between follow-up duration and 
prevalence was observed (P = 0.515).
Ileostomy and rectal stump
Prevalence and incidence
A pooled analysis including 1011 IBD patients demonstrated a carcinoma prevalence of 
the rectal stump of 2.1% (95% confidence interval [CI], 1.3–3.0; Supplementary Table 2, 
Supplementary Figures 1 and 4). This value represents the prevalence in a variable duration 
of reported follow-up between 0.25 and 40 years. None of the included studies evaluated 
dysplasia development. One study specifically assessed the cumulative rectal cancer 
incidence in UC patients with a rectal stump or secondary IRA (constructed in 2 stages), 
resulting in an incidence of 12.6% after 24 years after surgery.9
Risk factors
Only 1 study assessed risk factors for the development of rectal stump cancer.10 This 
retrospective case-control study included 12 rectal stump carcinomas and 18 control 
patients without rectal stump neoplasia and identified PSC and IBD duration until subtotal 
colectomy as risk factors. The study design of this case-control study was not sufficient to 
identify a history of colorectal neoplasia as risk factor because these patients were excluded 
from the control group. 
We detected no difference in carcinoma prevalence of the rectal stump between 
UC and CD (2.2%, 95% CI, 1.3%–3.4% versus 2.1%, 95% CI, 0.6%–4.4%; OR 1.4, 95% CI, 
0.4–5.0, p = 0.574).
Ileorectal anastomosis
Prevalence and incidence
A pooled rectal carcinoma prevalence of 2.4% (95% CI, 1.7%–3.3%) was calculated in the IRA 
group, including 2762 patients with a variable duration of reported follow-up between 1 
and 35 years (Supplementary Table 3, Supplementary Figures 2 and 5). Development of 
rectal dysplasia after IRA was described in 16 studies including 1425 patients, resulting in 
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a pooled dysplasia prevalence of 2.5% (95% CI, 1.2%–4.2%). Because the year of publication 
and the duration of follow-up may influence the prevalence, we performed subgroup 
analysis on the basis of these variables. There was a statistically significant lower carcinoma 
prevalence (OR, 2.3; 95% CI, 1.3–4.1; p = 0.003) in studies published after 1990 (1.6%; 95% CI, 
0.8%–2.6%) compared with earlier studies (3.2%; 95% CI, 2.1%–4.4%). No differences were 
found between studies with a duration of follow-up of at least 8 years (start surveillance 
colonoscopies), compared with studies with a shorter duration of follow-up (2.0%, 95% CI, 
0.9%–3.4% versus 2.4%, 95% CI, 1.3%–3.7%; OR, 1.1, 95% CI, 0.5–2.2; p = 0.899).
Three studies reported a cumulative incidence of rectal carcinoma in the IRA group 
after onset of IBD.11–13 A pooled analysis showed cumulative incidences of 0%, 5% (95% CI, 
3.0%–7.5%), and 10% (95% CI, 7.0%–12.0%) after 10, 20, and 25 years after IBD onset, 
respectively. One study estimated cumulative incidences after IRA construction. After 5, 10, 
15, and 20 years, respectively, cumulative incidences were 0%, 2%, 5%, and 14% for rectal 
carcinoma and 7%, 9%, 20%, and 25% for rectal dysplasia.14
Risk factors
UC, a history of CRC, and IBD duration emerged as risk factors for developing rectal carcinoma 
after IRA construction. None of the included studies specifically evaluated PSC as a risk factor. 
UC patients, including patients with indeterminate colitis, were more likely to develop rectal 
carcinoma after IRA construction compared with CD patients. A higher pooled carcinoma 
prevalence of the rectum was estimated in UC patients versus CD patients (3.2%, 95% CI, 
2.3%–4.3% versus 0.7%, 95% CI, 0.2%–1.6%) with OR of 10.3 (95% CI, 2.5–41.9; p = 0.001).
A forest plot evaluating prior CRC as a risk factor to develop rectal carcinoma after 
IRA construction is displayed in Figure 2A. Three studies were available for meta-analysis 
because they reported prior CRC both in the patients who developed rectal carcinoma 
and in the patients who did not.11, 12, 15 A pooled OR of 12.8 (95% CI, 3.3–49.2) favors 
prior CRC as risk factor to develop rectal carcinoma in patients with IRA. This is further 
supported by another study that described rectal neoplasia after subtotal colectomy in 17 
CD patients with a history of CRC.16 Six of 17 patients (28.6%) developed rectal carcinoma 
after subtotal colectomy, which is significantly higher than a pooled prevalence of 2.4% 
(P < 0.001). A history of colorectal dysplasia could not be assessed as risk factor because 
of insufficient data.
A longer duration of IBD also predisposes development of rectal carcinoma after 
colectomy and IRA. Others have reported an increasing risk over time in which none of the 22 
rectal carcinomas after IRA developed within IBD duration of 10 years (3534 patient-years of 
follow-up). Beyond 10 years, the risk was 1 in 185 patient-years between 10 and 20 years of 
IBD duration and 1 in 117 patient-years in patients with IBD history of more than 20 years.12 
Furthermore, 1 study showed that patients who developed rectal cancer had a statistically 
significant longer duration of IBD compared with patients who did not develop rectal cancer 
(P = 0.030).14 Nine studies reported IBD duration until rectal carcinoma development, and 
none of the 49 patients developed cancer within 10 years of IBD duration.9, 12, 14, 17–22
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Figure 2. (A) Forest plot displaying effect of CRC before colectomy on development of rectal carcinoma after 
IRA. I2 (inconsistency) = 0%. (B) Forest plot displaying effect of CRC before colectomy on development of IPAA 
carcinoma. I2 (inconsistency) = 7.1%.
A
B
Ileal pouch-anal anastomosis
Prevalence and incidence
The pooled prevalence of carcinoma in the ileoanal pouch was 0.5% (95% CI, 0.3%–0.6%; 
Supplementary Table 4, Supplementary Figures 3 and 6). This analysis included 8403 
patients with a variable duration of follow-up. Thirty-one articles including 7647 patients 
reported pouch dysplasia development, resulting in a pooled pouch dysplasia prevalence of 
0.8% (0.5%–1.3%). Even studies that only included high-risk patients, such as patients with 
chronic pouchitis, prior CRC, long pouch duration (> 8 years), or PSC, showed relatively low 
pouch neoplasia prevalence (0.9%–4.6%).23–26
Three studies reported cumulative incidences of pouch carcinoma after IPAA 
construction, resulting in a pooled cumulative incidence of 0.4% (95% CI, 0.1%–0.9%), 0.9% 
(95% CI, 0.2%–1.9%), 1.4% (95% CI, 0.04%–3.0%), 2.7% (95% CI, 2.1%–3.4%), and 3.4% (95% 
CI, 2.8%–4.0%) after 5, 10, 15, 20, and 25 years, respectively.11, 27, 28 Cumulative incidences of 
pouch dysplasia were reported in 2 of these studies. A pooled analysis showed cumulative 
incidences of pouch dysplasia after IPAA of 0.6% (95% CI, 0.2%–1.2%), 0.9% (95% CI, 
0.8%–1.8%), 1.5% (95% CI, 1.2%–1.9%), and 3.0% (95% CI, 2.0%–5.0%) after 5, 10, 15, and 
20 years, respectively.27, 28
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Risk factors
Risk factors for pouch neoplasia development are a history of colorectal neoplasia and IBD 
duration. There was insufficient evidence available to evaluate a stapled anastomosis, PSC, 
and pouchitis as risk factors.
Prior colorectal neoplasia is the most important risk factor for developing pouch 
neoplasia. A pooled analysis including 5216 patients showed that patients with prior 
CRC had a statistically significant increased risk to develop pouch carcinoma (OR, 15.0; 
95% CI, 6.6–34.5; Figure 2B) compared with patients without a history of CRC.11, 23, 27–30 
Moreover, an analysis excluding patients with prior CRC showed that prior colorectal 
dysplasia was also a risk factor for developing pouch carcinoma (OR, 4.4; 95% CI, 1.9–10.1; 
Supplementary Figure 7).11, 23, 27–29 A systematic review of all described pouch carcinoma cases 
in IBD patients reported that 57.1% of these cases (28 of 49) had prior colorectal neoplasia. 
IBD duration might also be considered as a risk factor because patients who developed 
pouch neoplasia had a significantly longer IBD duration before pouch construction 
compared with patients who did not develop pouch neoplasia in the univariate analysis 
of the 2 largest cohort studies. A pooled analysis of these 2 studies including 4403 patients 
showed that patients with pouch neoplasia had 5.1 years (95% CI, 2.5–7.6) longer IBD history 
before pouch construction (P < 0.001).27, 28 Mean pouch duration before cancer was 10.8±7.3 
years in all cases described in the literature.31
Patients with a hand-sewn anastomosis with mucosectomy carry a higher risk to develop 
pouch carcinoma compared with patients with a stapled anastomosis as shown in a pooled 
meta-analysis (OR, 2.9; 95% CI, 1.3–6.6; Supplementary Figure 8). However, no statistical 
difference was reached when comparing stapled and hand-sewn anastomosis for pouch 
neoplasia development (OR, 1.7; 95% CI, 1.0–3.1; Supplementary Figure 9).
Less conclusive evidence is available regarding the role of PSC and pouchitis in pouch 
neoplasia development. One small study including 22 patients with IPAA found that patients 
with PSC had a higher risk to develop atrophic pouch mucosa.32 Pouchitis was associated 
with atrophic pouch mucosa development in 2 other studies.33, 34 These patients with PSC 
or pouchitis might indirectly carry an increased risk to develop pouch neoplasia because 
atrophic pouch mucosa is associated with pouch neoplasia development.35 By contrast, both 
PSC and pouchitis were not identified as risk factors for pouch neoplasia development in 
the 2 largest IBD cohorts with IPAA (n = 120028 and n = 320327).
Comparison of rectal and pouch neoplasia in the rectal stump, ileorectal 
anastomosis, and ileal pouch-anal anastomosis
A summary of the prevalence, incidence, and risk factors for each group is shown in Figure 3. 
Pooled prevalences of both rectal carcinoma and rectal dysplasia in patients with a residual 
rectum (rectal stump or IRA) were significantly higher compared with pouch carcinoma and 
pouch dysplasia (IRA and rectal stump carcinoma versus pouch carcinoma, OR, 6.4, 95% 
CI, 4.3–9.5, p < 0.001; IRA carcinoma versus pouch carcinoma, OR, 7.1, 95% CI, 4.8–10.7, 
p < 0.001; IRA dysplasia versus pouch dysplasia, OR, 3.3, 95% CI, 2.1–5.2, p < 0.001; rectal 
stump carcinoma versus pouch carcinoma, OR, 4.5, 95% CI, 2.5–7.9, p = 0.049). Prevalence 
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Figure 3. Summary chart of prevalence, incidence, and risk factors for colorectal neoplasia in the rectal stump, 
IRA, and IPAA. NA, not available.
of rectal carcinoma in the rectal stump group versus the IRA group did not show significant 
differences (OR, 0.6, 95% CI, 0.4–1.0, p = 0.074). Because the duration of follow-up after 
colectomy might influence the prevalence, we compared this between the 3 groups. No 
differences in ollow-up duration were observed between the rectal stump, IRA, and IPAA 
groups (p = 0.544). In addition, no increasing trend of pooled prevalences over time was 
observed when analyzed per 5-year mean or median duration of follow-up (Figure 4).
DISCUSSION
One of the key findings that can be derived from our systematic review is a low overall 
carcinoma prevalence and incidence in IBD patients after (reconstructive) colonic surgery. 
The cancer prevalence appeared to be dependent on the type of surgery and was highest 
in IRA patients (2.4%), followed by patients with a rectal stump (2.1%), and lowest in IPAA 
patients (0.5%). Prior CRC was the most important risk factor for developing rectal or pouch 
carcinoma (IRA group: OR, 12.8; IPAA group: OR, 15.0). Furthermore, we identified IBD 
duration and a diagnosis of UC as risk factors.
The calculated prevalences and cumulative incidences of rectal and pouch carcinoma 
need to be placed in perspective. The lifetime incidence for developing CRC in the general 
population approaches 5%.36 Although the cumulative incidence of rectal carcinoma after 
IRA is based on only 1 study, 5% equals the cumulative rectal carcinoma risk 15 years after 
IRA construction. The pooled cumulative incidence of pouch carcinoma 25 years after IPAA 
construction (3.4%) is below the general lifetime CRC risk. None of the reported rectal 
carcinomas in the IRA group developed within 10 years after IBD onset. Pouch carcinomas 
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Figure 4. Pooled prevalences of carcinoma in the rectal stump, IRA, and IPAA groups when analyzed per 5-year 
mean or median duration of follow-up after colectomy. 
developed after mean 10.8 years after IPAA. Furthermore, for proper interpretation of 
prevalences and incidences we should take a declining CRC risk over time into account 
because of improved IBD treatment strategies and advanced endoscopic procedures. This 
may have resulted in lower CRC prevalences and incidences for rectal stump, IRA, and 
IPAA patients in recent years. Moreover, prevalences and incidences may even be lower 
because mainly single-center studies rather than population-based cohorts were available 
for analysis.
A history of colorectal neoplasia before IRA or IPAA surgery is the most important risk 
factor for subsequent development of rectal and pouch carcinoma (IRA: OR, 12.8; IPAA: OR, 
15.0). This is underlined by a shorter pouch duration before cancer diagnosis in IPAA patients 
with prior dysplasia or cancer compared with those without prior pouch neoplasia.31 
Furthermore, the majority of the carcinomas in the IPAA group arose from therectal mucosa 
rather than from the ileal pouch mucosa.31 Therefore, it could be speculated that residual 
colonic mucosa is the main contributor to an increased risk to develop colorectal neoplasia, 
especially in patients with prior colorectal neoplasia.
As a corollary, one may hypothesize that the total amount of colorectal mucosa in situ may 
correlate with the subsequent risk to develop rectal or pouch carcinoma. The significantly 
lower cancer prevalence in the IPAA group compared with the groups with a rectum in situ 
fuels this hypothesis. In line with this, patients with a complete colon in situ may bear an 
even higher risk for colorectal neoplasia. This is supported by other authors who showed 
a lower risk of CRC per patient-year in patients after IRA compared with patients with 
an intact colon.12 On the other hand, patients with a stapled anastomosis, leaving a few 
centimeters rectal mucosa in situ, were not carrying a higher risk compared with patients 
with a hand-sewn anastomosis with mucosectomy. The presence of residual colonic mucosal 
islands that remain even after “complete” mucosectomy might form an explanation for this 
latter observation.37
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UC patients had approximately 10-fold increase in risk to develop rectal carcinoma after 
IRA construction in comparison with CD patients. This might suggest an association with 
the inflammatory process, because the rectum is more frequently involved in UC patients. 
On the other hand, pouchitis, inflammation of the pouch, was not identified as a risk factor. 
However, pouchitis is variable and often poorly defined, making it difficult to assess this 
potential risk factor. 
Our findings may impact clinical practice because they could provide guidance in 
developing a postsurgical endoscopic surveillance strategy. Similar to the guidelines for CRC 
screening, direct evidence regarding the benefit of colorectal surveillance is not available.3, 
4 To this end, the identified risk factors may assist in recommendations on surveillance. 
The current British surveillance guidelines distinguish low-risk (no high-risk factors) and 
high-risk groups (PSC, prior colorectal neoplasia, atrophic mucosa) after colectomy and 
recommend surveillance intervals of 5 years and 1 year, respectively.4 On the basis of 
our findings, we believe that the presence of a residual rectum after surgery is the major 
determinant for cancer development. Furthermore, the cancer risk is determined by 
a history of preoperative colorectal neoplasia, the duration of IBD, and a UC rather than a CD 
diagnosis. All these factors should be assessed by the clinician and taken into account in 
a postoperative surveillance strategy. IPAA patients, especially those without prior colorectal 
neoplasia, have a low cancer risk, and a very limited surveillance program might be sufficient 
for these patients.
One of the limitations of this review is that the included studies have a high risk of bias, 
especially those in the rectal stump group. Most studies were retrospective single-center 
studies introducing selection and recall bias. Furthermore, neoplasia development was often 
one of the secondary outcomes, and study heterogeneity was significant across studies. For 
example, some studies offered routine surveillance after colectomy, whereas other studies 
only performed an endoscopic procedure on indication. In addition, the included studies had 
a highly variable duration of follow-up, and the year of publication of the included studies 
varied between 1956 and 2014, which may also introduce bias. In older studies, diagnosis of 
IBD, detection of dysplasia and carcinoma, and IBD treatment differed from current practice. 
More recent treatment strategies such as thiopurines and biologicals may have decreased 
the burden of chronic colonic inflammation and have led to a reduction of cancer risk. In 
addition, advancing endoscopic visualization techniques may have further reduced cancer 
rates over time. Indeed, we observed statistically lower carcinoma prevalence in studies 
published after 1990.
In conclusion, we found significantly lower carcinoma prevalence in the IPAA group 
(0.5%) compared with the rectal stump group (2.1%) and IRA group (2.4%). A history of 
CRC was the most important risk factor, with 15.0-fold (IPAA) and 12.8-fold (IRA) increase 
in risk. Furthermore, IBD duration and UC rather than a diagnosis of CD emerged as risk 
factors for rectal or pouch neoplasia. These findings may aid in developing individualized 
postsurgical endoscopic surveillance strategies to optimize prevention of CRC development 
in IBD patients.
6N
EO
PLA
SIA
 RISK A
FTER CO
LEC
TO
M
Y IN
 IBD
 – A
 SYSTEM
ATIC REVIEW
 A
N
D
 M
ETA
-A
N
A
LYSIS 
108
ACKNOWLEDGMENTS
The authors thank Prof J.P.H. Drenth for his multiple critical revisions of the manuscript. For 
the statistical support, the authors thank Dr W. Kievit and H.M.M. Groenewoud, MSc.
6N
EO
PLA
SIA
 RISK A
FTER CO
LEC
TO
M
Y IN
 IBD
 – A
 SYSTEM
ATIC REVIEW
 A
N
D
 M
ETA
-A
N
A
LYSIS 
109
REFERENCES
1. Connelly TM, Koltun WA. The surgical 
treatment of inflammatory bowel disease-
associated dysplasia. Exp Rev Gastroenterol 
Hepatol 2013;7:307-322.
2. Ananthakrishnan AN, Cagan A, Cai T, et al. 
Colonoscopy is associated with a reduced risk 
for colon cancer and mortality in patients with 
inflammatory bowel diseases. Clin Gastroenterol 
Hepatol 2015;13:322-329.
3. Farraye FA, Odze RD, Eaden J, et al. AGA technical 
review on the diagnosis and management of 
colorectal neoplasia in inflammatory bowel 
disease. Gastroenterology 2010;138:746-774, e1-e4; 
quiz e12-e13.
4. Cairns SR, Scholefield JH, Steele RJ, et al.; British 
Society of Gastroenterology, Association of 
Coloproctology for Great Britain and Ireland. 
Guidelines for colorectal cancer screening and 
surveillance in moderate and high risk groups 
(update from 2002). Gut 2010;59:666-689.
5. Andersson P, Soderholm JD. Surgery in 
ulcerative colitis: indication and timing. Dig 
Dis 2009;27:335-340. 
6. Martin ST, Vogel JD. Restorative procedures in 
colonic crohn disease. Clinics in Colon and Rectal 
Surgery 2013;26:100-105.
7. Loney PL, Chambers LW, Bennett KJ, et al. 
Critical appraisal of the health research 
literature: prevalence or incidence of a health 
problem. Chronic Dis Can 1998;19:170-176.
8. Egger M, Davey Smith G, Schneider M, et al. 
Bias in meta-analysis detected by a simple, 
graphical test. BMJ 1997;315:629-634.
9. Johnson WR, Hughes ESR, McDermott FT. 
The outcome of patients with ulcerative colitis 
managed by subtotal colectomy. Surg Gynecol 
Obstet 1986;162:421-425.
10. Lutgens M, van Oijen MGH, Vleggaar FP, 
et al. Risk factors for rectal stump cancer 
in inflammatory bowel disease. Dis Colon 
Rectum 2012;55:191-196.
11. Andersson P, Norblad R, Soderholm JD, et al. 
Ileorectal anastomosis in comparison with 
ileal pouch anal anastomosis in reconstructive 
surgery for ulcerative colitis: a single institution 
experience. J Crohns Colitis 2014;8:582-589.
12. Baker WNW, Ritchie JK, Aylett SO, et al. 
Cancer of rectum following colectomy and 
ileorectal anastomosis for ulcerative colitis. Br J 
Surg 1978;65:862-868.
13. Grundfest SF, Fazio V, Weiss RA, et al. The risk 
of cancer following colectomy and ileo-rectal 
anastomosis for extensive mucosal ulcerative-
colitis. Ann Surg 1981;193:9-14.
14. Moreira AD, Kiran RP, Lavery I. Clinical outcomes 
of ileorectal anastomosis for ulcerative colitis. 
Br J Surg 2010;97:65-69.
15. Oakley JR, Jagelman DG, Fazio VW. Complications 
and quality of life after ileorectal anastomosis for 
ulcerative colitis. Am J Surg 1985;149:23-30.
16. Maser EA, Sachar DB, Kruse D, et al. High rates of 
metachronous colon cancer or dysplasia after 
segmental resection or subtotal colectomy in Crohn’s 
colitis. Inflamm Bowel Dis 2013;19:1827-1832.
17. Gruner OPN, Flatmark A, Naas R. Ileorectal 
anastomosis in ulcerative colitis: results in 57 
patients. Scand J Gastroenterol 1975;10:641-646.
18. Khubchandani IT, Kontostolis SB. Outcome 
of ileorectal anastomosis in an inflammatory 
bowel-disease surgery experience of 3 decades. 
Arch Surg 1994;129:866-869.
19. Paoluzi OA, Paolo MC, Ricci F, et al. Ileo-rectal 
anastomosis in ulcerative colitis: results of 
a long-term follow-up study. Italian Journal of 
Gastroenterology 1994;8:392-397. 
20. Pastore RL, Wolff BG, Hodge D. Total abdominal 
colectomy and ileorectal anastomosis for 
inflammatory bowel disease. Dis Colon 
Rectum 1997;40:1455-1464.
21. Ribet M, Wurtz A, Paris JC. Ileorectal 
anastomosis after colectomy for ulcerative 
colitis: a long-term study of 73 cases [French]. 
[La conservation du rectum dans la chirurgie 
de la recto-colite hemorragique (etude 
a long terme de 73 operes)]. Gastroenterol Clin 
Biol 1981;5:1140-1145.
22. Stettler C, Larvol L, Girault T, et al. Is ileorectal 
anastomosis still a valid option in the surgical-
treatment of ulcerative-colitis: analysis of 
the functional, endoscopic and histologic 
results of 74 cases. Gastroenterol Clin 
Biol 1993;17:175-180.
6N
EO
PLA
SIA
 RISK A
FTER CO
LEC
TO
M
Y IN
 IBD
 – A
 SYSTEM
ATIC REVIEW
 A
N
D
 M
ETA
-A
N
A
LYSIS 
110
23. Imam MH, Eaton JE, Puckett JS, et al. 
Neoplasia in the ileoanal pouch following 
colectomy in patients with ulcerative colitis 
and primary sclerosing cholangitis. J Crohns 
Colitis 2014;8(10):1294-1299.
24. Tsunoda A, Talbot IC, Nicholls RJ. Incidence of 
dysplasia in the anorectal mucosa in patients 
having restorative proctocolectomy. Br J 
Surg 1990;77:506-508.
25. Kuiper T, Vlug MS, van den Broek FJC, et al. 
The prevalence of dysplasia in the ileoanal 
pouch following restorative proctocolectomy 
for ulcerative colitis with associated dysplasia. 
Colorectal Dis 2012;14:469-473.
26. Vento P, Lepisto A, Karkkainen P, et al. Risk of 
cancer in patients with chronic pouchitis after 
restorative proctocolectomy for ulcerative 
colitis. Colorectal Dis 2011;13:58-66.
27. Kariv R, Remzi FH, Lian L, et al. Preoperative colorectal 
neoplasia increases risk for pouch neoplasia 
in patients with restorative proctocolectomy. 
Gastroenterology 2010;139:806-812, e1-e2.
28. Derikx LA, Kievit W, Drenth JPH, et al. Prior 
colorectal neoplasia is associated with 
increased risk of ileoanal pouch neoplasia in 
patients with inflammatory bowel disease. 
Gastroenterology 2014;146:119-128.
29. Branco BC, Sachor DB, Heimann TM, et al. 
Adenocarcinoma following ileal pouch-anal 
anastomosis for ulcerative colitis: review of 26 
cases. Inflamm Bowel Dis 2009;15:295-299.
30. Al-Sukhni W, McLeod RS, MacRae H, et 
al. Oncologic outcome in patients with 
ulcerative colitis associated with dyplasia or 
cancer who underwent stapled or handsewn 
ileal pouch-anal anastomosis. Dis Colon 
Rectum 2010;53:1495-1500.
31. Selvaggi F, Pellino G, Canonico S, et al. 
Systematic review of cuff and pouch cancer in 
patients with ileal pelvic pouch for ulcerative 
colitis. Inflamm Bowel Dis 2014;20:1296-1308.
32. Stahlberg D, Veress B, Tribukait B, et al. Atrophy 
and neoplastic transformation of the ileal pouch 
mucosa in patients with ulcerative colitis and 
primary sclerosing cholangitis: a case control 
study. Dis Colon Rectum 2003;46:770-778. 
33. Veress B, Reinholt FP, Lindquist K, et al. 
Long-term histomorphological surveillance 
of the pelvic ileal pouch: dysplasia 
develops in a subgroup of patients. 
Gastroenterology 1995;109:1090-1097.
34. Gullberg K, Lindforss U, Zetterquist H, et al. 
Cancer risk assessment in long-standing 
pouchitis: DNA aberrations are rare in 
transformed neoplastic pelvic pouch mucosa. 
Int J Colorectal Dis 2002;17:92-97.
35. Gullberg K, Stahlberg D, Liljeqvist L, et al. 
Neoplastic transformation of the pelvic pouch 
mucosa in patients with ulcerative colitis. 
Gastroenterology 1997;112:1487-1492.
36. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 
2010. CA Cancer J Clin 2010;60:277-300.
37. Banasiewicz T, Marciniak R, Paszkowski J, et al. 
Pouchitis may increase the risk of dysplasia after 
restorative proctocolectomy in patients with 
ulcerative colitis. Colorectal Dis 2012;14:92-97.
6N
EO
PLA
SIA
 RISK A
FTER CO
LEC
TO
M
Y IN
 IBD
 – A
 SYSTEM
ATIC REVIEW
 A
N
D
 M
ETA
-A
N
A
LYSIS 
111
SUPPLEMENTARY MATERIAL
Reference lists of excluded duplicate publications by same institutions 
Rectal stump
1. Johnson WR, McDermott FT, Hughes ESR, 
et al. The risk of rectal-carcinoma following 
colectomy in ulcerative-colitis. Dis Colon 
Rectum 1983;26:44-46. 
2. Aylett SO. Diffuse ulcerative colitis and its 
treatment by ileo-rectal anastomosis. Ann R Coll 
Surg Engl 1960;27:260-284.
3. Aylett S. Ulcerative colitis treated by total 
colectomy and ileorectal anastomosis: a ten-year 
review. Proc R Soc Med 1963;56:183-190. 
4. Aylett S. Total colectomy and ileorectal 
anastomosis. A progress report. Dis Colon 
Rectum 1964;7:532-534.
5. Aylett SO. Three hundred cases of diffuse ulcerative 
colitis treated by total colectomy and ileo-rectal 
anastomosis. Br Med J 1966;1:1001-1005. 
6. Aylett S. Cancer and ulcerative colitis. Br 
Med J 1971;2:203-205.
7. Aylett SO. Ileorectal anastomosis: review 1952-
1968. Proc R Soc Med 1971;64:967-971.
8. Aylett SG. Rectal conservation in the surgical 
treatment of ulcerative colitis. Arch Fr Mal App 
Dig 1974;63:585-587.
9. Aylett S. Preservation of the rectum in 
surgery for ulcero-hemorrhagic rectocolitis. 
Chirurgie 1976;102:921-927.
10. Baker WN. The results of ileorectal anastomosis 
at St Mark’s Hospital from 1953 to 1968. 
Gut 1970;11:235-239.
11. Dennis CEK. Cancer risk in ulcerative colitis: 
formidability per patient-year of late disease. 
Surgery 1961;50:568-571.
12. Ehsanullah M, Naunton Morgan M, Filipe MI, et 
al. Sialomucins in the assessment of dysplasia 
and cancer-risk patients with ulcerative 
colitis treated with colectomy and ileo-rectal 
anastomosis. Histopathology 1985;9:223-235.
13. Grundfest SF, Fazio V, Weiss RA, et al. The risk 
of cancer following colectomy and ileo-rectal 
anastomosis for extensive mucosal ulcerative-
colitis. Ann Surg 1981;193:9-14.
14. Hughes ESR, McDermott FT, Masterton JP. 
Ileorectal anastomosis for inflammatory 
bowel disease: 15 year follow up. Dis Colon 
Rectum 1979;22:399-400. 
15. Jones PF, Bevan PG, Hawley PR. Ileostomy or 
ileorectal anastomosis for ulcerative colitis? Br 
Med J 1978;1:1459-1463.
16. Khubchandani IT, Trimpi HD, Sheets JA, et 
al. Ileorectal anastomosis for ulcerative and 
Crohn’s colitis. Am J Surg 1978;135:751-756.
17. Khubchandani IT, Stasik JJ Jr, Nedwich A. 
Prospective surveillance by rectal biopsy 
following ileorectal anastomosis for inflammatory 
disease. Dis Colon Rectum 1982;25:343-347. 
18. Khubchandani IT, Sandfort MR, Rosen L, et 
al. Current status of ileorectal anastomosis 
for inflammatory bowel disease. Dis Colon 
Rectum 1989;32:400-403.
19. Lavery IC, Michener WM, Jagelman DG. 
Ileorectal anastomosis for inflammatory bowel 
disease in children and adolescents. Surg 
Gynecol Obstet 1983;157:553-556.
20. Lofberg R, Leijonmarck CE, Brostrom O, et al. 
Mucosal dysplasia and DNA content in ulcerative 
colitis patients with ileorectal anastomosis: 
followup-study in a defined patient group. Dis 
Colon Rectum 1991;34:566-571.
1. Johnson WR, McDermott FT, Hughes ESR, 
et al. The risk of rectal-carcinoma following 
colectomy in ulcerative-colitis. Dis Colon 
Rectum 1983;26:44-46.
2. Oakley JR, Jagelman DG, Fazio VW. 
Complications and quality of life after ileorectal 
anastomosis for ulcerative colitis. Am J 
Surg 1985;149:23-30.
Ileorectal anastmosis
6N
EO
PLA
SIA
 RISK A
FTER CO
LEC
TO
M
Y IN
 IBD
 – A
 SYSTEM
ATIC REVIEW
 A
N
D
 M
ETA
-A
N
A
LYSIS 
112
21. Loygue J, Levy E, Michel F. Rectal preservation 
in ulcerative colitis (198 cases) [French]. 
[Faut-il conserver le rectum lors du traitement 
chirurgical de la rectocolite ulcero-emorragique? 
Etude de 198 tentatives de conservation rectale]. 
Gastroenterol Clin Biol 1981;5:1146-1154. 
22. Mignon M, Bonnefond A, Vilotte J. Indications for 
rectal preservation and ileorectal anastomosis 
in patients with ulcerative colitis [French]. [Les 
indications de la conservation du rectum dans 
les colectomies pour rectocolite hemorragique]. 
Arch Fr Mal App Dig 1974;63:541-553. 
23. Oakley JR, Lavery IC, Fazio VW. The fate of the rectal 
stump after subtotal colectomy for ulcerative 
colitis. Dis Colon Rectum 1985;28:394-396. 
24. Paris J. Anatomical evolution of the remaining 
rectum after colectomy for ulcerative colitis (author’s 
transl). Arch Fr Mal App Dig 1974;63:555-572. 
25. Ribet M, Paris J, Wurtz A, et al. Conservation 
of the rectum in hemorrhagic rectocolitis. 
Chirurgie 1973;99:474-484. 
26. Sprechler M, Baden H. Ileorectal anastomosis 
for ulcerative colitis. Br Med J 1971;2:527.
27. Thomas DM, Filipe MI, Smedley FH. 
Dysplasia and carcinoma in the rectal 
stump of total colitics who have undergone 
colectomy and ileo-rectal anastomosis. 
Histopathology 1989;14:289-298. 
28. Watts Mc KJ, Hughes ESR. Ulcerative colitis and 
Crohn’s disease: results after colectomy and 
ileorectal anastomosis. Br J Surg 1977;64:77-83. 
29. Fegiz G, Tonelli F, Paoluzi P. Ileorectal 
anastomosis in ulcerative colitis. Surgery in 
Italy 1979;9:52-62. 
30. Milito G, Brancaleone C, Nardi F, et al. Clinical, 
endoscopic and histologic review in patients 
submitted to colectomy and ileorectal 
anastomosis for ulcerative colitis. Ital J Surg 
Sci 1984;14:275-280. 
31. Johnson WR, McDermott FT, Pihl E, et al. 
Mucosal dysplasia: a major predictor of cancer 
following ileorectal anastomosis. Dis Colon 
Rectum 1983;26:697-700. 
32. Ritchie JK. Colectomy and anastomosis for 
inflammatory bowel disease. Arch Fr Mal App 
Dig 1974;63:588. 
Ileal pouch-anal anastomosis
1. Tsunoda A, Talbot IC, Nicholls RJ. Incidence of 
dysplasia in the anorectal mucosa in patients 
having restorative proctocolectomy. Br J 
Surg 1990;77:506-508.
2. Ziv Y, Fazio VW, Sirimarco MT, et al. Incidence, 
risk factors, and treatment of dysplasia in 
the anal transitional zone after ileal pouch-anal 
anastomosis. Dis Colon Rectum 1994;37:1281-1285.
3. Haray PN, Amarnath B, Weiss EG, et al. Low 
malignant potential of the double-stapled ileal 
pouch-anal anastomosis. Br J Surg 1996;83:1406. 
4. Sarigol S, Wyllie R, Gramlich T, et al. Incidence 
of dysplasia in pelvic pouches in pediatric 
patients after ileal pouch anal anastomosis 
for ulcerative colitis. J Pediatr Gastroenterol 
Nutr 1999;28:429-434.
5. O’Riordain MG, Fazio VW, Lavery IC, et al. 
Incidence and natural history of dysplasia of 
the anal transitional zone after ileal pouch-anal 
anastomosis: results of a five-year to ten-year 
follow-up. Dis Colon Rectum 2000;43:1660-1665. 
6. Remzi FH, Fazio VW, Delaney CP, et al. Dysplasia 
of the anal transitional zone after heal pouch-
anal anastomosis: results of prospective 
evaluation after a minimum of ten years. Dis 
Colon Rectum 2003;46:6-13. 
7. Saigusa N, Choi HJ, Wexner SD, et al. Double 
stapled ileal pouch anal anastomosis (DS-IPAA) 
for mucosal ulcerative colitis (MUC): is there 
a correlation between the tissue type in 
the circular stapler donuts and in follow-up 
biopsy? Colorectal Dis 2003;5:153-158. 
8. Pishori T, Dinnewitzer A, Zmora O, et al. 
Outcome of patients with indeterminate colitis 
undergoing a double-stapled ileal pouch-anal 
anastomosis. Dis Colon Rectum 2004;47:717-721.
9. Coull DB, Lee FD, Anderson JH, et al. Long-term 
cancer risk of the anorectal cuff following 
restorative proctocolectomy assessed by 
p53 expression and cuff dysplasia. Colorectal 
Dis 2007;9:321-327. 
10. Nilubol N, Scherl E, Bub DS, et al. Mucosal 
dysplasia in real pelvic pouches after 
6N
EO
PLA
SIA
 RISK A
FTER CO
LEC
TO
M
Y IN
 IBD
 – A
 SYSTEM
ATIC REVIEW
 A
N
D
 M
ETA
-A
N
A
LYSIS 
113
restorative proctocolectomy. Dis Colon 
Rectum 2007;50:825-831. 
11. Schaus BJ, Fazio VW, Remzi FH, et al. Clinical 
features of real pouch polyps in patients 
with underlying ulcerative colitis. Dis Colon 
Rectum 2007;50:832-838. 
12. Silvestri MT, Hurst RD, Rubin MA, et al. Chronic 
inflammatory changes in the anal transition 
zone after stapled ileal pouch-anal anastomosis: 
is mucosectomy a superior alternative? 
Surgery 2008;144:533-539. 
13. Vento P, Lepisto A, Karkkainen P, et al. Risk of 
cancer in patients with chronic pouchitis after 
restorative proctocolectomy for ulcerative 
colitis. Colorectal Dis 2011;13:58-66. 
14. Burdynski R, Banasiewicz T, Marciniak R, et al. 
Intestinal pouch complications in patients 
who underwent restorative proctocolectomy 
for ulcerative colitis and familial adenomatous 
polyposis in 1985-2008. Pol Przegl 
Chir 2011;83:161-170. 
15. Liu ZX, Liu XL, Patil DT, et al. Clinical significance 
of indefinite for dysplasia on pouch biopsy in 
patients with underlying inflammatory bowel 
disease. J Gastrointest Surg 2012;16:562-571. 
16. Fazio VW, Kiran RP, Remzi FH, et al. Ileal 
pouch anal anastomosis: analysis of outcome 
and quality of life in 3707 patients. Ann 
Surg 2013;257:679-685. 
17. Liu ZX, Xiao MB, Wu XR, et al. Chronic pouchitis 
is associated with pouch polyp formation in 
patients with underlying ulcerative colitis. J 
Crohns Colitis 2014;8:363-369. 
18. Zhu H, Wu XR, Queener E, et al. Clinical value of 
surveillance pouchoscopy in asymptomatic ileal 
pouch patients with underlying inflammatory 
bowel disease. Surg Endosc 2013;27:4325-4332.
6N
EO
PLA
SIA
 RISK A
FTER CO
LEC
TO
M
Y IN
 IBD
 – A
 SYSTEM
ATIC REVIEW
 A
N
D
 M
ETA
-A
N
A
LYSIS 
114
Supplementary Figure 1. Forest plot displaying pooled carcinoma prevalence in the rectal stump of 
IBD patients.
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Supplementary Figure 2. Forest plot displaying pooled carcinoma prevalence for IBD patients with IRA.
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Supplementary Figure 3. Forest plot displaying pooled carcinoma prevalence for IBD patients with IPAA.
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Supplementary Figure 4. Funnel plot analyzing publication bias of prevalence studies regarding rectal cancer 
in IBD patients with a rectal stump. Visual inspection of the funnel plot may indicate that some low prevalence 
studies are missing. Indeed, asymmetry of the plot is confirmed with the Egger test. However, because 
prevalence cannot extend below “0”, some asymmetry of the funnel plot may be expected. In addition, there 
are no outliers. 
Egger test: bias = 1.02 (95% CI, 0.05–2.00); p = 0.042.
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Supplementary Figure 5. Funnel plot analyzing publication bias of prevalence studies regarding rectal cancer 
in IBD patients with IRA. Visual inspection of the funnel plot does not indicate publication bias, although 
the Egger test showed some asymmetry of the funnel plot. Many low prevalence studies are included 
contradicting publication bias. 
Egger test: bias = 0.79 (95% CI, 0.00–1.57); p = 0.049.
6N
EO
PLA
SIA
 RISK A
FTER CO
LEC
TO
M
Y IN
 IBD
 – A
 SYSTEM
ATIC REVIEW
 A
N
D
 M
ETA
-A
N
A
LYSIS 
118
  
 
  
 
-0.10 -0.05 0.00 0.05 0.10 0.04 
0.03 
0.02 
0.01 
0.00 
Proportion 
Standard error 
Supplementary Figure 6. Funnel plot analyzing publication bias of prevalence studies regarding pouch 
cancer in IBD patients with IPAA. Both visual inspection of the funnel plot and the Egger test showed no 
indication for publication bias. 
Egger test: bias = –0.14 (95% CI, –0.45 to 0.16); p = 0.346.
Supplementary Figure 7. Forest plot displaying effect of colorectal dysplasia before colectomy on 
development of IPAA carcinoma. I2 (inconsistency) = 0%. 
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Supplementary Figure 8. Forest plot displaying effect of type of anastomosis on development of IPAA 
carcinoma. I2 (inconsistency) = 0.1%.
Supplementary Figure 9. Forest plot displaying effect of type of anastomosis on development of IPAA 
neoplasia. I2 (inconsistency) = 0%.
Supplementary Table 1. Full search strategy that was used to identify studies for inclusion.
MeSH terms (inflammatory bowel diseases OR colitis, ulcerative OR Crohn disease) AND 
(anastomosis, surgical OR colectomy OR proctocolectomy, restorative OR colonic 
Pouches OR ileostomy) AND (colorectal neoplasms OR rectal neoplasms OR colonic 
neoplasms OR  anus neoplasms)
Emtree terms (inflammatory bowel disease (exploded) OR ulcerative colitis OR Crohn disease OR colon 
Crohn disease) AND (colon resection (exploded) OR proctocolectomy (exploded) OR 
ileum pouch OR ileostomy OR continent ileostomy) AND (colorectal tumor (exploded) 
OR anus tumor (exploded))
Title/abstract 
words
(inflammatory bowel OR IBD OR ulcerative colitis OR colitis ulcerosa OR indeterminate 
colitis OR Crohn* OR idiopathic proctocolitis OR regional Enteritis OR granulomatous 
enteritis OR granulomatous colitis OR ileocolitis OR terminal ileitis OR regional ileiti*) 
AND (colectom* OR ileostom* OR restorative proctocolectom* OR pouch* OR IPAA OR 
ileoana* OR ileo-ana* OR ileal stoma* OR ileorect* OR ileo-rect* OR ileosigmoid OR ileo-
sigmoid OR IRA OR rectoileal ) AND (neoplas* OR dysplasia* OR tumor* OR tumour* OR 
carcinoma* OR cancer* OR malignanc* OR adenocarcinoma)
PubMed, Web of Science, and Cochrane search strategies were based on MeSH terms and title/abstract words. 
Emtree terms combined with title/ abstracts words were used for the Embase search. 
MeSH, Medical Subject Headings.
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TO THE EDITOR
With great interest, we read the systematic review by Selvaggi et. al.1 regarding cuff and 
pouch cancer in patients with ulcerative colitis (UC). Using clear study selection criteria, 
the authors evaluated epidemiology and risk factors of pouch-related malignancies after 
ileal pouch-anal anastomosis (IPAA) for UC. Main findings were a low pooled cumulative 
incidence of pouch and cuff cancer (0.35%, 20 y after IPAA) and the identification of prior 
colorectal neoplasia as the predominant risk factor (odds ratio, 8.8) for developing pouch-
related carcinoma. The authors then propose an endoscopic surveillance strategy of 
the pouch but based on our interpretation of the data, we suggest an alternative approach.
First, the authors recommended routine surveillance pouchoscopy starting 10 years after 
UC diagnosis followed by annual surveillance. However, the risk of pouch-related cancer is 
low and should be placed in perspective. For example, cumulative colorectal cancer risk 
from birth to 75 years is 1.96% in the general population, compared with a defined pooled 
cumulative incidence of pouch-related malignancies of 0.33% for 50 years after UC diagnosis 
and 0.35% for 20 years after IPAA.1 The early starting point and subsequent high surveillance 
frequency as recommended is at odds with the low risk.
Second, the authors suggest a delayed surveillance strategy in patients who underwent 
mucosectomy. This proposed risk stratification for pouch surveillance does not take into 
account the single most important risk factor, neoplasia of the colectomy specimen. In our 
opinion, patients with prior colorectal neoplasia do require an intensified pouch surveillance 
program.
Third, no surveillance strategy was proposed for patients with Crohn’s disease or 
indeterminate colitis because these subgroups were excluded from analyses. We advocate 
a pouch surveillance program for all patients with inflammatory bowel disease. Crohn’s 
disease and indeterminate colitis patients do carry a pouch-related cancer risk,2 and no 
evidence is available to support a separate surveillance strategy.
We applaud the efforts by Selvaggi et. al. because this will contribute toward 
the development of evidence-based pouch surveillance programs. By contrast, we favor 
a limited pouch surveillance program for all patients with inflammatory bowel disease 
with IPAA given the low pouch-related carcinoma incidence. Patients with prior colorectal 
neoplasia should be subjected to a more intensified pouch surveillance strategy with special 
attention for the anal transitional zone where most carcinomas are localized. Whether pouch 
surveillance prevents pouch and cuff cancer or improves clinical outcomes remains an area 
of future research.
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CLINICAL VIGNETTE 
Case 1
Following 2 years of rectal blood loss, a 31-year-old male was diagnosed with ulcerative 
pancolitis in 1978. Initial treatment consisted of both topical and systemic 5-aminosalicylic 
acids (5-ASA), and remission was achieved. In both 1984 and 1986 he was hospitalised due to 
exacerbations necessitating treatment with intravenous corticosteroids. The following years 
went well, without disease activity, under treatment with 5-ASA. In 1997, at the age of 50 
years, a surveillance colonoscopy showed a stenotic process with a macroscopic irregularity 
in the sigmoid region. Histology revealed at least high-grade dysplasia (HGD) and signs 
of an invasive growth pattern which could indicate colorectal cancer (CRC). The patient 
underwent restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). Histology 
of the resection specimen confirmed active inflammation in the colon and rectum and 
a carcinoma in situ was identified in the sigmoid colon without invasive growth. This 
patient did not have significant comorbidities, for example primary sclerosing cholangitis 
(PSC), and the CRC family history was negative. What pouch surveillance strategy should 
be recommended?
Case 2
A 34-year-old man presented at our inflammatory bowel disease (IBD) center with ulcerative 
proctitis. Ten years later, after an initially mild disease course, his disease progressed to 
a pancolitis. An 11-year period with multiple exacerbations (on average every 2 year, 
including hospitalization followed and treatment consisted of topical and systemic 5-ASAs 
with intermittent corticosteroids. In 1998, at the age of 65 years, a two-stage restorative 
proctocolectomy with IPAA was performed due to disease activity refractory to systemic 
corticosteroids. The colectomy specimen confirmed the diagnosis of ulcerative pancolitis 
without evidence for colorectal dysplasia or carcinoma. Other than steroid-induced diabetes 
mellitus, this patient had no comorbidities. His father died from CRC at unknown age. What 
pouch surveillance strategy should be recommended?
BACKGROUND
Although clear and well-accepted surveillance guidelines exist for inflammatory bowel 
disease (IBD) patients with an intact colon, several controversies exist with respect to 
endoscopic surveillance of the ileal pouch-anal anastomosis IPAA. Following from our clinical 
vignettes, it could be questioned whether pouch surveillance is necessary at all, whether 
and how risk stratification should be performed, and which pouch surveillance intervals 
should be followed. Both the British Society of Gastroenterology (BSG) and American 
Gastroenterology Association (AGA) recommend regular surveillance in IBD patients with 
an intact colon, tailored to the individual patient’s risk profile.1, 2 These strategies may reduce 
colorectal cancer (CRC) incidence and mortality.3, 4 However, for IBD patients who had 
undergone a colectomy, guidance is less clear.
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Pouch surveillance recommendations in the current IBD surveillance guidelines are 
lacking (AGA guideline), incomplete (American Society for Gastrointestinal Endoscopy 
(ASGE) guideline) or not up to date in the light of new available evidence (BSG guideline; 
European Crohn’s and Colitis Organisation (ECCO) guideline) as shown in Table 1.1, 2, 5, 
6 The British surveillance guidelines distinguish low (no high risk factors) and high risk 
(primary sclerosing cholangitis (PSC), previous colorectal neoplasia, atrophic mucosa) 
groups following colectomy, and recommend surveillance intervals of 5 years and 1 
year, respectively.1 However, new data with respect to risk factors for pouch carcinoma 
development became available in recent years. The ECCO guidelines only identify previous 
CRC as a very important risk factor, but subsequently propose surveillance based on risk 
factors as in the BSG guidelines.5
Lack of clear, updated, and consistent guidelines in pouch surveillance has resulted in 
a wide variation in daily practice. Some physicians adopt very short surveillance intervals, 
which may lead to unnecessary burden for patients and increased costs. In contrast, longer 
surveillance intervals may result in interval carcinomas. The recently updated evidence to 
support pouch surveillance is limited and requires careful interpretation and discussion. 
Table 1. Overview of pouch surveillance guidelines.
Guideline 
Year of 
publication
Risk stratification
Surveillance strategyYes/no Risk categories
AGA2 2010 n/a n/a No recommendations
BSG1 2010 Yes High risk: 
• Previous rectal dysplasia
• Dysplasia/cancer at the time of  
  pouch surgery
• Primary sclerosing cholangitis
• Type C pouch mucosaa
Low risk:
• Absence of high risk factors
Yearly
5-Yearly
ASGE6 2015 Yes Highest risk: 
• History of dysplasia or cancer.
High risk:
• Primary sclerosing cholangitis
• Type C pouch mucosaa
• Refractory pouchitis
Other patients
Yearly surveillance 
should be considered
Yearly surveillance 
may be considered
No recommendations
ECCO5 2015 Yes High risk: 
• Dysplasia/cancer at the time of  
  pouch surgery
• Primary sclerosing cholangitis
• Type C pouch mucosaa
• Unremitting pouchitis
Absence of high risk factors
Yearly
No evidence that 
support routine 
surveillance
a Type C pouch mucosa is defined as exhibiting permanent persistent atrophy and severe inflammation.
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Here, we aim to discuss controversies regarding IPAA surveillance based on the currently 
available literature and suggest an approach to pouch surveillance based on up-to-date 
risk stratification.
IS POUCH SURVEILLANCE NECESSARY IN IBD 
PATIENTS?
Pro
One of the main factors that determine the benefit of a pouch surveillance strategy is the risk 
of developing pouch cancer. For example, it would be more useful to screen a population 
of which 50% will develop pouch cancer compared with a population containing almost no 
patients who will develop pouch cancer. As such, pouch surveillance may be of benefit in 
subgroups that carry a high pouch cancer risk, whereas in subgroups with a low risk profile, 
surveillance pouchoscopies will not be worthwhile.
The major determinant for pouch cancer development is the presence of colorectal 
dysplasia or carcinoma before colectomy. A recent meta-analysis showed that IBD patients 
with a history of colorectal dysplasia or CRC had a respectively 4.4- and 15.0-fold increase in 
pouch cancer risk.7 In addition, 57.1% of pouch cancer cases in the literature had preceding 
colorectal neoplasia.8 The high cumulative pouch neoplasia incidence in subgroups with 
previous colorectal neoplasia (29.5% after 15 years in patients with previous CRC) supports 
regular surveillance in these patients.9
The poor outcome of pouch carcinomas may also support pouch surveillance. In 
a previous study, 9 out of 16 patients with pouch carcinoma died within a median follow-up 
of 11 months (range 1–20 months).9 Three additional patients had metastatic disease 
at the end of follow-up. This is in line with another study, in which 3 of 11 patients with 
pouch carcinoma died within 1 year of follow-up. Furthermore, alarm symptoms for pouch 
carcinoma can be masked due to already altered defaecation patterns, which may contribute 
to delayed detection and worsened outcome. Earlier detection of pouch cancers by regular 
endoscopic surveillance may improve the outcome.
Contra
The low overall incidence and prevalence of pouch carcinoma in IBD argues against routine 
pouch surveillance in all IPAA patients. A meta-analysis showed a pooled cumulative incidence 
of pouch cancer of 3.4% 25 years after IPAA construction, which is below the general lifetime 
CRC risk.7 IPAA cancers are mostly located at the anal transitional zone, and the cumulative 
incidence of pouch cancers originating from ileal mucosa will be even lower.8 In addition, 
the incidence of precancerous lesions such as low-grade dysplasia (LGD) and high-grade 
dysplasia (HGD) is also low (3.0% after 20 years).7
When incorporating risk stratification in a pouch surveillance strategy, only those with 
a history of colorectal neoplasia could be identified as high risk patients. Evidence for 
other risk factors is less conclusive or pronounced and a combined cumulative dysplasia 
and carcinoma incidence of 2.2% after 15 years was shown in those without a history of 
colorectal neoplasia.9 Patients with a longer IBD duration and a hand-sewn IPAA may carry 
7b
148
EN
D
O
SCO
PIC PO
U
CH
 SU
RVEILLA
N
CE STRATEG
Y IN
 IBD
 
an increased pouch cancer risk, but the impact of these risk factors is much lower.7 Current 
factors that guide the ECCO and BSG pouch surveillance guidelines, including PSC and an 
atrophic pouch mucosa or pouchitis, were not identified as risk factors in the two largest IBD 
cohorts with IPAA reported (n = 3203 and n = 1200).9, 10 In addition, studies that only included 
patients with PSC pouchitis or a long-standing pouch (≥ 12 years) showed relatively low 
pouch carcinoma prevalences (1.5%–2.4%).11, 12, 13 This advocates against regular surveillance 
in these subgroups.
A low absolute risk for detecting pouch cancer and precancerous lesions will result in 
a high number needed to screen, questioning cost-efficiency of a surveillance strategy in 
those with a low risk profile. Many patients will need to undergo surveillance, but in most 
cases pouch neoplasia will not be detected. This will result in significant disadvantages, such 
as a financial burden for patients and health care providers, and discomfort for patients due 
to preparation and the endoscopic procedure. Furthermore, studies that show an improved 
detection and prognosis of pouch neoplasia with surveillance are lacking, and may never be 
performed due to the limited size of available cohorts.
DOES POUCH SURVEILLANCE IMPROVE  
THE OUTCOME OF POUCH NEOPLASIA?
Pro
In long-standing colonic IBD, current surveillance strategies are based on the concept 
of an inflammation-dysplasia-carcinoma sequence.14 This sequence may also apply to 
the pathogenesis of pouch carcinoma, since patients with subsequent LGD, HGD, and pouch 
carcinoma have been described previously.15 Regular pouch surveillance may result in earlier 
pouch neoplasia detection, with potential improved prognosis and outcome. Supportive 
evidence for this hypothesis is derived from a tertiary pouch referral center performing 
regular surveillance pouchoscopies every 1 to 3 years at the discretion of the treating 
physician.10 Of 9 patients with pouch carcinoma detected in this surveillance programme, 
only 1 (11%) had a stage IV cancer diagnosis, whereas in a nationwide study without routine 
endoscopic surveillance, 4 of 12 (33%) primary pouch carcinomas were diagnosed with 
stage IV disease.9 
Contra
Although regular surveillance may result in earlier pouch neoplasia detection, it is 
unknown whether this strategy is sufficient to find more lesions at a precancerous stage. 
Typical endoscopic features of pouch neoplasia are lacking, and in many cases there are 
no endoscopic abnormalities at all.9, 16 Difficulties with detection of dysplasia in the pouch 
were confirmed by a tertiary pouch referral center: despite regular surveillance, only 3 
out of 11 patients (27.3%) were detected with dysplastic lesions preceding pouch cancer, 
whereas in 10 (90.9%) concurrent dysplasia was subsequently identified in the pouch 
excision specimen.10 
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Furthermore, it is unknown whether detection of pouch neoplasia at an earlier stage 
will improve outcome. For example, many dysplastic lesions never show progression to 
cancer or even show spontaneous regression. A previous study reported on 22 patients with 
LGD of the pouch. Only 3 patients demonstrated persistent LGD and 3 showed progression 
after a median time of 9.5 years, whereas 16 patients showed regression of LGD.15 Similarly 
another study, including 21 patients with lesions of the pouch categorized as indefinite for 
dysplasia (IND), only showed progression to LGD in 1 patient and progression to HGD in 1 
other patient during a mean follow-up of 19.3 months. In contrast, IND was not re-detected 
in 12 patients and 7 had persistent IND.17
DISCUSSION
As in colorectal surveillance, direct evidence for the benefit of a pouch surveillance strategy 
is lacking. There are no studies evaluating the yield and the number of interval carcinomas 
of a particular pouch surveillance strategy, in contrast to previous studies on
colorectal surveillance in IBD.18 Furthermore, studies comparing surveillance strategies, 
which is for example done for colorectal surveillance recommended by the BSG and AGA 
guidelines, are lacking for pouch surveillance.19 There is a need to establish a clear and well-
accepted pouch surveillance guideline, reducing the wide variation in practice and allowing 
prospective evaluation in coming years.
Our pro-con debate has resulted in a proposed pouch surveillance strategy which 
is outlined in Figure 1. Given the available data, we propose a strategy based on risk 
stratification. Risk stratification should be based only on the presence of a history of 
colorectal neoplasia before colectomy which is the dominant risk factor for pouch cancer 
in recent studies.7 The low absolute and relative pouch carcinoma risk in patients without 
Figure 1. Proposed pouch surveillance strategy.
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previous colorectal neoplasia allows us to propose forgoing surveillance in this subgroup. 
Thus, in line with the current ECCO recommendations, routine surveillance of the pouch is 
not recommended in low risk patients.5 However, in contrast to the BSG and ECCO guideline, 
the presence of PSC, atrophic pouch mucosa, or pouchitis do not guide risk stratification.1, 5 
In our proposed strategy, patients with previous colorectal dysplasia or CRC are categorised 
into intermediate and high risk categories, respectively. The optimal surveillance interval for 
these categories still has to be defined. In our proposed strategy, surveillance intervals are 
derived from the BSG guideline for regular IBD surveillance.
One of the questions that remain is how surveillance pouchoscopy should be performed. 
We did not incorporate this in our procon debate, since data from well-designed studies are 
lacking. Only one study investigated chromoendoscopy in 44 IPAA patients and found no 
increased pouch neoplasia detection rate compared with white light endoscopy.20 In addition, 
the preparation for pouchoscopy is often insufficient and residual stool is a disadvantage 
for chromoendoscopy. By contrast, both the AGA and the BSG guidelines recommend 
chromoendoscopy with targeted biopsies for regular IBD surveillance.1, 2 Furthermore, 
evidence for a biopsy regimen in pouch surveillance is absent. Since most carcinomas arise 
at the anal traditional zone (67.3%), we endorse close and careful inspection of this region 
including random and targeted biopsies.8 Targeted biopsies in the afferent and efferent limb 
and in the pouch body may be sufficient; however, evidence underlying such a strategy is 
currently lacking.
In addition to pouch surveillance endoscopy with biopsy, previous reports have suggested 
that biomarkers may also contribute to more accurate and earlier pouch neoplasia detection. 
As such, DNA abnormalities including aneuploidy, loss of heterozygosity, and mutations of 
p53, K-ras, and adenomatous polyposis coli genes have been studied as early biomarkers 
for pouch neoplasia.21 Some studies reported DNA aneuploidy or loss of heterozygosity in 
patients with pouch dysplasia. However, these studies are small in size (≤ 5 patients with 
pouch dysplasia) and often lack a control group, not allowing us to draw clinically relevant 
conclusions from these data.
Several other questions are still open to debate with respect to pouch surveillance. 
For example, can we discontinue surveillance after a certain number of pouchoscopies 
without abnormalities? And what is the appropriate management of detected LGD or HGD? 
Although many questions remain, the implementation of a widely supported guideline for 
pouch surveillance is a first step towards improved surveillance in IBD patients following 
IPAA construction.
CLINICAL VIGNETTE
Case 1
Based on our proposed surveillance strategy, we would categorize this patient into the high 
risk category recommending yearly surveillance pouchoscopies. The history of a carcinoma 
in situ in his sigmoid colon justifies yearly surveillance. 
Indeed, this patient was followed up with pouchoscopies. He underwent a pouchoscopy 
in 1997, in 2001, and yearly since 2009 until 2014 (except in 2013). A gap without surveillance 
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of respectively 4 and 8 years was left between the first three pouchoscopies. In 2009, LGD of 
the pouch body was found, which regressed to normal in all following pouchoscopies.
Case 2
This patient would be categorised in the low risk category not requiring pouch surveillance, 
according to our proposed algorithm. Even when other factors such as a long IBD history or 
PSC are present, we do not recommend surveillance, in view of the low pouch cancer risk in 
these subgroups.
Nevertheless, this patient was frequently followed up with pouchoscopies every 2 to 3 
years. He developed pouchitis once, for which he was treated with metronidazole. This did 
not influence the surveillance intervals. During five follow-up pouchoscopies in 14 years, no 
dysplasia was detected.
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GENERAL DISCUSSION
The proportion of inflammatory bowel disease (IBD) patients with cancer is increasing. 
The aging population and improved IBD management clearly contribute to this trend. For 
IBD patients with cancer, a case-by-case approach for treatment of both cancer and IBD is 
encouraged based on the type and expected evolution of the cancer. Studies that evaluated 
the influence of IBD therapies on cancer course and treatment are scarce. As a consequence, 
the evidence that supports various strategies is limited at best.
This thesis investigated the risk of several solid cancers in patients with IBD in order 
to optimize and individualize prevention and treatment strategies for both IBD and 
cancer. It includes risk assessments and interpretation of data for different malignancies, 
such as pouch cancer, enabling case-by-case decision-making. In this chapter, our main 
findings are discussed and further interpreted. We will discuss how our findings affect daily 
practice and current thinking as well as the remaining gaps of knowledge that are open for 
further research. 
INTESTINAL MALIGNANCIES – COLORECTAL CANCER
Since a wealth of data is available on colorectal (CRC) risk in IBD patients we applied our 
research questions to CRC in specific scenarios. First, we assessed the CRC risk in patients 
suffering from both Lynch syndrome (LS) and IBD. Second, we investigated the risk to 
develop CRC after colectomy in patients with IBD.
Results of this thesis – Risk assessment 
We demonstrated that patients with both IBD and LS developed CRC at a younger age 
compared to LS patients without IBD, although cumulative CRC incidence was similar 
(Chapter 2). As such, patients with both LS and IBD developed CRC 10 years earlier. Our 
unique cohort highlights that CRC specifically developed in LS patients with ulcerative 
colitis rather than Crohn’s disease and that this subgroup has a higher cumulative CRC 
incidence. One case series describing 12 LS patients with IBD confirms these results.1 In 
addition, experimental models with MSH2 or MLH1 deficient mice, recapitulating human LS, 
also support an increased and/or accelerated carcinogenesis in those with inflammation.2, 3 
In IBD patients who underwent a colectomy, we demonstrated in a systematic review 
a relatively low CRC risk with pooled prevalences varying between 0.5% and 2.4% for 
the different surgical scenarios (Chapter 6). The lowest CRC prevalence was observed in 
patients with an ileal pouch-anal anastomosis (IPAA, 0.5%), which was significantly lower 
compared to patients with a rectal stump (2.1%) or ileorectal anastomosis (IRA, 2.4%). 
Similarly, low cumulative incidences were found in IPAA patients with after 25 years a pooled 
cumulative incidence of 3.4%. This is in line with our study in which we identified all IBD 
patients with IPAA in The Netherlands and showed a cumulative pouch carcinoma incidence 
of 3.3% after 20 years (Chapter 5).
A history of CRC prior to colectomy is the most important risk factor for CRC development 
after colectomy. We showed in our Dutch cohort that IPAA patients with prior CRC had an 
8160
G
EN
ERA
L D
ISCU
SSIO
N
approximately 25-fold increase in risk to develop pouch neoplasia. Those with a history of 
colorectal dysplasia carried a 4-fold increased risk. Similarly, we found in our meta-analysis 
a respectively 15- and 13-fold increase in CRC risk for IPAA and IRA patients with a history 
of CRC. Other identified risk factors included a longer duration of IBD and a diagnosis of 
ulcerative colitis rather than Crohn’s disease. Our analysis did not support previously 
suggested risk factors to develop pouch neoplasia, including a stapled anastomosis, primary 
sclerosing cholangitis and pouchitis.
Implications
Risk assessment for CRC development in IBD and LS is of major importance for endoscopic 
surveillance recommendations. As such, clear and well-accepted surveillance guidelines 
exist for IBD and LS patients with an intact colon, recommending regular surveillance 
tailored to the individual patients’ risk profile.4, 5 Compliance to these guidelines may reduce 
CRC incidence and mortality in IBD patients.6, 7 Indeed LS patients subjected to regular 
surveillance may benefit from 7 additional life years.4 However, endoscopic guidance is 
less clear in specific IBD subgroups including IBD patients who underwent colectomy or 
with concomitant LS. This has resulted in a wide variation in daily practice, which may lead 
to an excessive number of colonoscopies and pouchoscopies, increased costs and put 
unnecessarily burden on patients.8 By contrast, insufficient surveillance intervals may result 
in increased CRC risks and even mortality.
Results of our CRC risk assessment in specific IBD populations may contribute to 
surveillance recommendations. To this end, we translated our findings into a pouch 
surveillance strategy (Chapter 7). A surveillance strategy based on risk stratification is 
proposed, including yearly surveillance in those with prior CRC and the withholding of 
surveillance in IBD patients without a history of colorectal neoplasia. Furthermore, our data 
may aid the development of surveillance recommendations in other specific IBD subgroups, 
such as those with IRA or a rectal stump. A history of colorectal neoplasia should also be 
the major determinant indicating surveillance since this factor is the most important 
post-colectomy CRC risk factor in these subgroups as well. The higher CRC incidence and 
prevalence in IBD patients with a residual rectum (including IRA and rectal stump) compared 
to IPAA, especially in those with ulcerative colitis, may allow more frequent surveillance in this 
subgroup rather than withholding surveillance. However, similarly to colorectal surveillance, 
direct evidence regarding the benefit of surveillance is lacking. To this end, the identified risk 
factors may only assist in recommendations on surveillance.
In addition to the implications for a surveillance strategy, our data emphasize 
the importance of careful compliance to existing surveillance guidelines. For example, one 
patient with both LS and IBD in our cohort developed multiple CRC following insufficient 
endoscopic follow-up (Chapter 2). This is underlined in the literature by the observation 
that inadequate bowel preparation and inadequate surveillance intervals were 
the most important risk factors for interval CRC despite endoscopic surveillance in general 
IBD patients.9 
Finally, our findings may impact surgical decision-making. As the presence of colorectal 
neoplasia may predict new and/or recurrent CRC development post-colectomy, this may 
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guide the choice between different surgical scenarios. For example, an abdominoperineal 
resection could be preferable over IPAA construction or a residual rectum in IBD patients 
with prior CRC. Likewise, the younger age of CRC development in LS patients with IBD may 
justify a more aggressive surgical approach in these patients, although one case series 
described 4 LS patient with IBD and LGD who underwent prophylactic colectomy not 
revealing malignancy.1
Reflection
One of the main strengths of these studies are the unique, large cohorts that we established 
with PALGA. As such, we identified all IBD patients with IPAA in The Netherlands (n = 1200) and 
investigated which of them developed pouch cancer. Furthermore, we established a unique 
cohort of patients with both LS and IBD. PALGA enabled us to generate data that reflect 
the IBD population at large rather than data from single tertiary referral centers. Especially in 
rare disease entities, such as pouch cancer, proper methods for the identification of patients 
and for the establishment of a large cohort are of major importance. Another strength of 
this thesis is that we used multiple approaches to confirm and explain our findings. For 
example, a systematic review and meta-analysis, one of the highest grades of evidence, was 
performed to verify our findings regarding pouch cancer risk assessment from the Dutch IBD 
and IPAA cohort. 
Our studies also come with some limitations. These include the retrospective nature 
of PALGA studies and the small number of patients that reached the primary outcome (for 
example pouch cancer: n = 16 out of 1200). Although we presented one of the largest series 
thus far, risk factors for pouch cancer development could be missed due to lack of power. 
To this end, a meta-analysis was performed that pooled data from several cohorts. However, 
the heterogeneity of included studies, with for example different durations of follow-up 
hampered the interpretation of cancer rates and other results. Currently, an individual 
patient data meta-analysis is performed including data from several North-American centers 
and our center. One large dataset with well defined consistent variables is being created in 
order to identify risk factors for pouch cancer development with sufficient power. 
Future perspectives
One of the main purposes of our CRC risk assessment was to generate data that could 
aid surveillance recommendations. Since we both established a large nationwide cohort 
and performed a meta-analysis to assess pouch cancer risk, it is not expected that better 
epidemiological evidence will be available in the next years. To assess the need for and impact 
of potential evidence-based surveillance programs, large prospective trials with long-term 
follow-up are required. Therefore, clear, feasible and up to date post-colectomy surveillance 
guidelines with wide acceptance need to be established. This may reduce the high variation 
in practice and allows its future evaluation. Similarly as for colorectal surveillance is done, 
the yield and number of interval carcinomas of such a strategy could be assessed.6, 7 
Several questions remain with respect to surveillance that may be of interest for future 
research. These questions are related to the type of endoscopy (white light or chromo), 
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the biopsy protocol (random or targeted) and the stop criteria for surveillance. Moreover, 
the best strategy after detection of low grade dysplasia is unknown. Current colorectal 
surveillance guidelines may guide clinical practice with respect to these topics. However, 
specific knowledge in the post-colectomy setting regarding these questions may in future 
optimize endoscopic surveillance strategies after colectomy. 
Although a multi-factorial etiology of CRC development in IBD is acknowledged, 
the exact etiology and pathophysiology remains not elucidated yet. For rectal stump, 
IRA and IPAA patients, and for patients with both LS and IBD, a better understanding of 
CRC development is needed. The concept of field cancerization including premalignant 
mutated, but histologically normal fields may contribute to CRC development.10, 11 To this 
end, we are currently assessing clonality of pro-oncogenic mutations between pouch 
neoplasia and prior colorectal neoplasia in IBD. Further elucidation of the specific genetic 
steps could serve the diagnostic process and may aid the prediction of CRC development. 
In extension, the inflammatory process may be another potential factor that contributes 
to CRC development. This process could drive pro-oncogenic mutations and may impede 
repair mechanisms. Our LS cohort with IBD provides a unique opportunity to investigate 
the contributions of the inflammatory process to CRC development by comparing them 
with LS only. 
INTESTINAL MALIGNANCIES – NEUROENDOCRINE 
TUMORS
Results of this thesis – Risk assessment 
Although the prevalence of colonic neuroendocrine tumors (NET) is relatively low, we 
demonstrated an increased NET prevalence in IBD patients compared to the general 
population (Chapter 3). This may be attributed to frequent colonic resections in IBD as most 
NET are detected by coincidence during surgery. The higher NET prevalences we found in 
colonic resection specimens from diverticulitis and ischemia patients compared to those 
from patients with IBD support this hypothesis. Similarly to NET in the general population, 
the appendix was one of the anatomical preference sites. 
Implications
Since NET have an excellent prognosis if diagnosed at an early stage, awareness of NET 
coexistence in IBD is of major importance for an accurate and timely diagnosis. NET may 
clinically simulate IBD, especially in Crohn’s disease patients with ileal involvement. By 
considering NET early in the diagnostic process, early detection of NET may be facilitated and 
prognosis may be improved. However, the low absolute NET prevalence does not support 
additional colonoscopies or abdominal imaging for early NET detection.
Reflection
Although we adopted a nationwide approach, there are several limitations. One of the major 
limitations is that the total numbers of patients in the total IBD, diverticulitis and ischemia 
8163
G
EN
ERA
L D
ISCU
SSIO
N
cohorts are estimates based on extrapolated data. In addition, sampling bias may be present 
and final diagnoses are only based on individual pathology reports. Although these biases 
were inevitable for feasibility reasons to address our research questions, results of this study 
should be interpreted with caution.
Our risk assessment for NET development in IBD is very concise and does not embrace 
all potential questions. For example, the risk of NET development in the small intestines is 
not incorporated, whereas this is the anatomical location with the highest NET prevalence in 
the general population. Furthermore, potential risk factors are not explored as this was not 
allowed by our study design.
Future perspectives
Despite all raised limitations, one conclusion that stands is the low NET prevalence in IBD 
patients, although an increased NET risk is present compared to the general population. 
Future studies that also aim NET risk assessment in IBD could refine these findings. The focus 
of future studies should be shifted towards underlying pathophysiological mechanisms and 
toward the outcome of IBD and NET. Inflammation may hyperstimulate entero-endocrine cells 
leading to hyperplasia and neoplasia, however studies that firmly approve this mechanism 
are lacking. Therefore, future studies that unravel the underlying NET mechanism in IBD and 
that predict the outcome may be beneficial to optimize treatment and prevention strategies.
EXTRA-INTESTINAL MALIGNANCIES 
Results of this thesis – risk assessment
In this thesis we demonstrated an increased renal cell carcinoma (RCC) risk in IBD patients 
with a more complex phenotype, probably as a result of incidental findings (Chapter 4). 
This is supported by a high number of incidentally detected RCC (51%) and consequently 
a younger age and lower disease stage at RCC diagnosis compared to the general 
population. Subsequently, this translated into a better survival following RCC independent 
of immunosuppression and anti-TNFα use. 
Implications
Currently, IBD management following a diagnosis of cancer is a relevant topic. Case-by-
case management is recommended based on cancer characteristics, the probable impact 
of IBD therapy on cancer evolution, and IBD severity. However, the body of evidence to 
guide management after a specific cancer diagnosis is limited at best. Our nationwide study 
contributes to this field and may aid in guiding IBD management after a diagnosis of RCC. As 
no adverse effect of IBD therapy on disease free and overall survival was observed, our data 
suggest that immunosuppression and anti-TNFα use could be considered following RCC.
In addition, our data emphasize that frequent use of the health care system, including 
abdominal imaging and surgery, may yield incidental findings. Indeed, both NET and RCC 
are frequently found by incidence. When interpreting data from epidemiological studies 
that assessed cancer risk in IBD, it could be questioned whether increased cancer risks are 
the result of a higher prevalence rate or of a higher detection rate. 
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Reflection
This study is limited by the retrospective character and absence of data regarding the total 
Dutch IBD population. This hampered us to determine the absolute RCC risk in patients with 
IBD and to compare it with that in the general population. Furthermore, dose and duration 
of IBD therapy were not taken into account during risk assessment as these data could not be 
reliably retrieved for all cases in a retrospective setting. The total dose as well as the interval 
time between RCC diagnosis and IBD treatment may impact survival and outcome, however 
we were not able to assess this. Furthermore, the use of different databases and registries 
may have introduced biases, such as selection bias and slightly different defined variables. 
Future perspectives
Data for case-by-case cancer management is limited and more cancer specific data are 
not only needed for RCC, but for multiple cancer types. Therefore, several studies currently 
assess specific cancer risks including the effect of IBD therapy on cancer outcome and vice 
versa. As such, risk assessment is performed by our research group for gastric cancer, head 
and neck cancer, and melanomas, using similar databases and registries. The comparable 
study design brings the same limitations; however, many cancers are rare, which makes it 
difficult to design prospective IBD studies of sufficient size to reach meaningful conclusions.
Since the retrospective character was one of the major limitations of the RCC study, future 
studies should adopt a prospective study design. This allows for example accurate registration 
of medical treatment and subsequently evaluation of the impact on cancer outcomes. 
The CESAME study cohort in France and the South-Limburg cohort in The Netherlands are 
such prospectively established population-based IBD cohorts.12, 13 However, the numbers of 
index cancers in these cohorts are small, which impedes cancer site specific analyses. Future 
studies may benefit from comprehensive prospective registries that register all IBD patients 
with newly diagnosed cancers including medical treatment. This will allow the evaluation of 
IBD treatment on cancer outcome and vice versa, including the effect of dose and duration. 
Furthermore, the prospective registration of all IBD patients on immunosuppressive and/
or anti-TNFα therapy may aid cancer risk assessment in this subgroup of patients. Such 
a registry is recently started in The Netherlands (IB-DREAM).
It could be questioned whether IBD patients with a prior malignancy are more prone to 
develop a new cancer. In our IBD and RCC cohort we detected many patients with more than 
one cancer and it has previously been shown that patients with a history of cancer were at 
increased risk to develop new or recurrent cancer. Future studies should evaluate whether 
IBD patients are at increased risk to develop multiple cancers compared to the general 
population. One could speculate that a certain IBD genotype, and/or phenotype, in 
combination with specific IBD therapies, could underlie susceptibility to cancer development. 
CONCLUSIONS
Cancer development in IBD has become one of the growing concerns in recent decades, 
especially given the aging population. In this thesis we assessed cancer risks and outcomes 
8165
G
EN
ERA
L D
ISCU
SSIO
N
for solid intestinal (both CRC and NET) and extra-intestinal malignancies (RCC). We identified 
relatively low prevalences of post-colectomy CRC with a history of prior CRC as the most 
important risk factor for IPAA, IRA and rectal stump cancer development. Furthermore, NETs 
and RCCs were frequently detected by incidence. This translated into a better survival in IBD 
patients with RCC compared to the general population, independent of immunosuppressive 
and anti-TNFα use. In general, epidemiological studies describe disease patterns, risk factors, 
and outcomes in defined study populations, which may shape evidence-based practice and 
policy decisions. Indeed, our findings may lead to more optimized and evidence-based 
surveillance and treatment strategies in IBD management. 
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SUMMARY
Malignancies in inflammatory bowel disease
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD) 
are chronic inflammatory disorders affecting the gastro-intestinal tract. They are associated 
with both an increased intra- and extra-intestinal cancer risk, which can be mainly attributed 
to chronic inflammation as well as immunosuppressive therapies. Intestinal malignancies, 
such as colorectal cancer (CRC), are especially associated with chronic inflammation. 
Therefore, control of mucosal inflammation with (immunosuppressive) therapy is warranted. 
By contrast, these therapies may promote or inhibit the development of (extra-)intestinal 
malignancies by impairing immunosurveillance of tumor cells or inducing DNA damage. 
Further evidence is required to optimize management strategies that can achieve reduction 
of chronic inflammation with an acceptable safety profile while reducing cancer risk. To this 
end, this thesis provides epidemiological risk assessment of solid intra- and extra-intestinal 
malignancies and translation of risk profiles into recommendations for daily clinical practice.
In Chapter 2 CRC risk is assessed in patients with both IBD and Lynch syndrome (LS). 
Both conditions are associated with an increased CRC risk due to inflammatory and genetic 
factors, although it is unknown whether this risk is further increased in patients with both 
IBD and LS. In our multicenter LS cohort, consisting of 1046 patients, 15 patients also carried 
a diagnosis of IBD (1.4%). Four of these 15 patients (26.7%) developed CRC, which was 
comparable to LS patients without IBD (311/1031, 30.2%). However, patients with both IBD 
and LS were younger and thus had less time to develop CRC (median 38.0 y versus 52.0 y, p = 
0.001). Patients with both IBD and LS in our cohort developed CRC at a younger age (median 
36.0 y versus 46.0 y, p = 0.045) and especially patients with UC were at increased risk. These 
findings may contribute to surveillance and treatment recommendations, although limited 
by the relative small number of cases. For example, we recommend careful compliance to 
existing IBD and LS surveillance recommendations since one of our cases developed multiple 
CRC due to insufficient follow-up.
Chapter 3 describes neuro-endocrine tumor (NET) risk in IBD patients since inflammation 
may cause hyperstimulation of enteroendocrine cells leading to hyperplasia and neoplasia. 
Indeed, an association between IBD and NET has been described in the literature, however 
contradicting results exist. Using the Dutch Pathology Registry (PALGA) we identified 
51 IBD patients who developed colonic NET in a 20-year period (1991–2011), resulting in 
a prevalence of 60.4–89.3 per 100,000 patients. Colonic NET was more prevalent in IBD 
patients compared to the general population (prevalence rate ratio 2.8–4.1), which may 
be attributed to a high rate of incidental NET as IBD patients frequently undergo intestinal 
surgery. To this end, we compared NET prevalence in colonic resection specimens between 
IBD cases and non-IBD controls (diverticulitis and ischemia). Adjusted for resection type, sex 
and age, IBD patients had a lower NET prevalence in colonic resection specimens compared 
to diverticulitis and ischemia. This supports our hypothesis that frequent incidental NET 
detection during surgery may results in increased NET prevalences in IBD patients compared 
to the general population.
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Chapter 4 is focused on extra-intestinal malignancies since certain cancer types occur 
more commonly in IBD. We investigated renal cell carcinoma (RCC) risk and outcome in 
IBD patients, with focus on the impact of immunosuppression and anti-TNFα agents. 180 
IBD patients who developed RCC between 1991 and 2013 were identified with PALGA. 
First, clinical characteristics of these patients were compared with a population-based IBD 
cohort (IBD South Limburg cohort) to identify risk factors for RCC development. Second, 
RCC characteristics and survival were compared between IBD cases and the general 
population (identified from the Eindhoven Cancer Registry, maintained by the Netherlands 
Comprehensive Cancer Organization). This study demonstrated that IBD patients with 
a complex phenotype (including Montreal E3 UC, penetrating CD and/or IBD related surgery) 
were at increased risk to develop RCC. This may be the result of more frequent and intensive 
use of the health care system, including abdominal imaging. Consequently, IBD patients were 
significantly younger at RCC diagnosis (p < 0.001) and had a lower RCC stage (N-stage, p = 
0.025; M-stage, p = 0.020) compared to the general population. This translated into a better 
survival (p = 0.026; hazard ratio 0.7) independent of immunosuppression. As no adverse 
effect of IBD therapy on survival was observed, our data suggest that immunosuppressive 
agents may be considered following RCC.
Part II of this thesis describes CRC risk in IBD in different post-surgical scenarios following 
colectomy, including the permanent end ileostomy and rectal stump, ileorectal anastomosis 
(IRA), and ileal pouch-anal anastomosis (IPAA). Currently, the increased CRC risk in IBD patients 
with an intact colon is taken into account in endoscopic surveillance guidelines. A colectomy 
substantially reduces CRC risk, however it is unknown how this should impact surveillance 
strategies. To this end, we established risk profiles for CRC development following colectomy 
and translated this into surveillance recommendations.
In Chapter 5 the risk to develop ileoanal pouch neoplasia in patients with IBD is 
investigated. All IBD patients with IPAA in the Netherlands were identified between 1991 
and 2012 using PALGA (n = 1200). Sixteen out of 1200 patients developed pouch carcinoma 
resulting in a cumulative pouch carcinoma incidence of 0.6%, 1.4%, 2.1%, and 3.3% after 
respectively 5, 10, 15, and 20 years. Subsequently, a case control study was performed to 
identify risk factors for pouch neoplasia development. Prior colorectal dysplasia and prior 
CRC were associated with an approximate 4- and 25-fold increase in risk, respectively, to 
develop pouch neoplasia.
Chapter 6 includes a systematic review and meta-analysis establishing CRC risk in IBD 
patients post-colectomy. Based on 13 studies about CRC development in the rectal stump, 
35 IRA studies and 33 IPAA studies, we calculated CRC prevalences. The cancer prevalence 
appeared to be dependent on the type of surgery and was highest in IRA patients (2.4%), 
followed by patients with a rectal stump (2.1%), and lowest in IPAA patients (0.5%). This 
resulted in an odds ratio of 6.4 to develop CRC for patients with a residual rectum (rectal 
stump, IRA) compared to IPAA patients. In line with Chapter 5, prior CRC was the most 
important risk factor for developing rectal or pouch carcinoma (IRA group: odds ratio 12.8; 
IPAA group: odds ratio 15.0). Furthermore, we identified IBD duration and a diagnosis of UC 
rather than CD as risk factors.
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Chapter 7 translates our findings from Chapter 5 and Chapter 6 into surveillance 
recommendations for IBD patients who underwent colectomy and IPAA. Given the available 
data, we proposed a strategy comprising risk stratification based on a history of colorectal 
neoplasia before colectomy. We recommend yearly surveillance in those with prior CRC and 
the withholding of surveillance in IBD patients without a history of colorectal neoplasia. 
Although many questions remain regarding surveillance, the implementation of a widely 
supported guideline for pouch surveillance would be a first step towards improved 
surveillance in IBD patients following IPAA construction.
In conclusion, this thesis assesses cancer risks and outcomes for solid intestinal (both 
CRC and NET) and extra-intestinal malignancies (RCC) in IBD patients. Risk profiles for cancer 
development and outcome are established and subsequently translated into treatment 
and surveillance recommendations. More cancer specific data enable an individualized 
approach and may in future contribute to case-by-case management of IBD patients 
with malignancies.
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NEDERLANDSE SAMENVATTING
Maligniteiten bij inflammatoire darmziekten
Inflammatoire darmziekten (IBD) waaronder colitis ulcerosa (CU) en de ziekte van 
Crohn (ZvC) zijn chronische ontstekingsziekten van het maag-darmstelsel. Ze zijn 
geassocieerd met een verhoogd risico op zowel intra- als extraintestinale maligniteiten. 
Dit is hoofdzakelijk toe te schrijven aan chronische ontsteking en immunosuppressieve 
behandelstrategieën. Intestinale maligniteiten, zoals het colorectaal carcinoom (CRC), zijn 
met name geassocieerd met chronische ontsteking. Om deze reden is het beperken van 
de mucosale ontsteking middels (immunosuppressieve) behandeling van groot belang. 
Daarentegen kunnen deze therapieën de ontwikkeling van (extra-)intestinale maligniteiten 
ook juist stimuleren door verstoorde immuunsurveillance van tumorcellen of door het 
veroorzaken van DNA schade. Meer wetenschappelijk bewijs is nodig voor optimalisering 
van de behandelstrategieën leidend tot adequate reductie van de chronische ontsteking, 
een acceptabel veiligheidsprofiel en een verminderd risico op maligniteiten. Dit proefschrift 
omvat een epidemiologische risico analyse betreffende het ontwikkelen van solide intra- en 
extra-intestinale maligniteiten en een vertaling van deze risicoprofielen naar aanbevelingen 
voor de dagelijkse klinische  praktijk.
In Hoofdstuk 2 is het risico op CRC onderzocht bij patiënten met IBD en het Lynch 
syndroom (LS). Beide aandoeningen zijn geassocieerd met een verhoogd risico op CRC door 
inflammatoire en genetische factoren. Het is echter onbekend of dit CRC risico hoger is bij 
patiënten met zowel IBD als LS. In ons multicenter LS cohort, bestaande uit 1046 patiënten, 
hadden 15 patiënten ook IBD (1,4%). Vier van deze 15 patiënten (26,7%) ontwikkelden 
CRC, wat vergelijkbaar was met de LS patiënten zonder IBD (311/1031, 30,2%). Echter, 
de patiënten met zowel IBD als LS waren jonger en hadden dus minder tijd om CRC te 
ontwikkelen (mediaan 38,0 jaar versus 52,0 jaar, p = 0,001). De patiënten met zowel IBD als LS 
in ons cohort ontwikkelden CRC op een jongere leeftijd (mediaan 36,0 jaar versus 46,0 jaar, 
p = 0,045) en met name de patiënten met CU hadden een hoger risico. Deze bevindingen 
kunnen bijdragen aan aanbevelingen voor surveillance en behandeling, hoewel dit wordt 
gelimiteerd door het beperkte aantal cases. Ons advies is om nauwgezet de bestaande 
surveillance richtlijnen op te volgen aangezien één van onze patiënten multipele CRC 
ontwikkelde ten tijde van inadequate follow-up. 
Hoofdstuk 3 beschrijft het risico op neuro-endocriene tumoren (NET) bij patiënten met 
IBD. Inflammatie kan zorgen voor hyperstimulatie van entero-endocriene cellen, mogelijk 
leidend tot hyperplasie en neoplasie. In de literatuur wordt inderdaad een associatie 
beschreven tussen IBD en NET, hoewel er tegenstrijdige resultaten worden gerapporteerd. 
Middels de Nederlandse Pathologie Database (PALGA) hebben we 51 IBD patiënten 
geïdentificeerd die een NET in het colon ontwikkelden gedurende een periode van 20 jaar 
(1991–2011). Dit resulteerde in een prevalentie van 60,4-89,3 per 100.000 patiënten. Een NET 
in het colon kwam vaker voor bij IBD patiënten in vergelijking met de algemene bevolking 
(prevalentie ratio 2,8-4,1). Dit is mogelijk te wijten aan een hoog percentage per toeval 
gevonden NET aangezien IBD patiënten vaak darmoperaties ondergaan. Om deze reden 
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hebben we de NET prevalentie in colon resectiepreparaten van IBD patiënten vergeleken met 
die van niet-IBD controle patiënten (diverticulitis en ischemie). Gecorrigeerd voor resectie 
type, geslacht en leeftijd, hadden patiënten met IBD een lagere NET prevalentie in colon 
resectiepreparaten vergeleken met patiënten met diverticulitis en ischemie van het colon. 
Dit ondersteunt onze hypothese dat de frequente vondst van NET als toevalsbevinding 
gedurende operaties kan resulteren in een verhoogde NET prevalentie bij patiënten met IBD 
vergeleken met de algemene bevolking.
Hoofdstuk 4 is gericht op extra-intestinale maligniteiten omdat bepaalde vormen 
van kanker vaker voorkomen bij IBD. We onderzochten het risico op, en de uitkomst van 
niercelcarcinoom (Renal Cell Carcinoma, RCC) bij IBD patiënten, met specifiek aandacht voor 
de invloed van immuunsuppressiva en anti-TNFα medicamenten. 180 IBD patiënten die een 
RCC ontwikkelden tussen 1991 en 2013 werden geïdentificeerd middels PALGA. Ten eerste 
werden klinische karakteristieken van deze patiënten op bevolkingsniveau vergeleken met 
het IBD Zuid-Limburg cohort om risicofactoren te idenficeren voor het ontwikkelen van 
een RCC. Ten tweede werden RCC karakteristieken en overleving vergeleken tussen IBD 
patiënten en de algemene bevolking (geïdentificeerd middels het Integraal Kankercentrum 
Zuid, onderdeel van Integraal Kankercentrum Nederland). Onze studie liet zien dat IBD 
patiënten met een complex fenotype (waaronder Montreal E3 CU, penetrerende ZvC en/
of IBD gerelateerde operaties) een hoger risico hadden om een RCC te ontwikkelen. Dit 
kan het gevolg zijn van vaker en intensiever gebruik van de gezondheidszorg, met hierbij 
het verrichten van abdominale beeldvorming. Inderdaad waren IBD patiënten significant 
jonger ten tijde van RCC diagnose (p < 0,001) en hadden ze een lager stadium RCC 
(N-stadium, p = 0,025; M-stadium, p = 0,020) in vergelijking met de algemene bevolking. 
Dit vertaalde zich naar een betere overleving (p = 0,026; hazard ratio 0,7), onafhankelijk van 
immuunsuppressiva gebruik. Aangezien er geen nadelige effecten werden geobserveerd 
van de IBD behandeling op de overleving, suggereren onze data dat immuunsuppressiva 
overwogen kunnen worden na RCC.
Deel II van dit proefschrift beschrijft het risico op CRC bij IBD in verschillende post-
operatieve scenario’s na colectomie, waaronder het permanente eindstandige ileostoma 
met rectumstomp, de ileorectale anastomose (IRA) en de ileoanale pouch (ileal pouch-
anal anastomosis, IPAA). Momenteel zijn de huidige endoscopische surveillance richtlijnen 
gebaseerd op het CRC risico bij IBD patiënten met een intact colon. Een colectomie reduceert 
het risico op CRC substantieel, echter is het onbekend hoe dit verwerkt kan worden in een 
post-operatieve surveillance strategie. Om deze vraagstelling te beantwoorden, hebben we 
risicoprofielen opgesteld voor het ontwikkelen van CRC na een colectomie en deze profielen 
vertaald naar surveillance aanbevelingen.
In Hoofdstuk 5 is het risico op het ontwikkelen van een ileoanale pouch neoplasie 
onderzocht. Alle IBD patiënten met IPAA in Nederland tussen 1991 en 2012 werden 
geïdentificeerd middels PALGA (n = 1200). Zestien van de 1200 patiënten ontwikkelden 
een pouch carcinoom, wat resulteerde in een cumulatieve pouch carcinoom incidentie van 
0,6%, 1,4%, 2,1% en 3,3% na respectievelijk 5, 10, 15 en 20 jaar. Vervolgens werd een case-
control studie verricht met als doel het identificeren van risicofactoren voor het ontwikkelen 
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van pouch neoplasie. Een voorgaande colorectale dysplasie en een voorgaand CRC waren 
respectievelijk geassocieerd met een 4- en 25-voudige toename van het risico op het 
ontwikkelen van een pouch neoplasie.
Hoofdstuk 6 betreft een systematische review en meta-analyse waarin het risico op CRC 
bij IBD patiënten na colectomie werd onderzocht. Hierin werd de CRC prevalentie berekend, 
gebaseerd op 13 studies over CRC ontwikkeling in de rectumstomp, 35 IRA studies en 33 
IPAA studies. De prevalentie van CRC bleek af te hangen van het type operatie en was het 
hoogst in IRA patiënten (2,4%), gevolgd door patiënten met een rectumstomp (2,1%), en 
was het laagst in IPAA patiënten (0,5%). Dit resulteerde in een odds ratio van 6,4 op het 
ontwikkelen van CRC bij patiënten met een resterend rectum (rectumstomp of IRA) in 
vergelijking met IPAA patiënten. Zoals ook beschreven in Hoofdstuk 5, bleek een voorgaand 
CRC de belangrijkste risicofactor voor het ontwikkelen van een rectum of pouch carcinoom 
(IRA groep: odds ratio 12,8; IPAA groep: odds ratio 15,0). Daarnaast bleken de duur van IBD 
en een CU diagnose in plaats van ZvC risicofactoren voor CRC ontwikkeling.  
Hoofdstuk 7 vertaalt onze bevindingen in Hoofdstuk 5 en Hoofdstuk 6 naar surveillance 
aanbevelingen voor IBD patiënten die een colectomie met IPAA ondergingen. Gezien de 
beschikbare data hebben we een strategie voorgesteld met risicostratificatie op basis van 
voorgaande colorectale neoplasie. We raden jaarlijkse surveillance aan in patiënten met een 
voorgaand CRC en onthouding van surveillance bij patiënten zonder voorgaande colorectale 
neoplasie. Hoewel vele vragen resteren omtrent surveillance, zou de implementatie van een 
breed gedragen richtlijn voor pouch surveillance een goede eerste stap zijn op weg naar 
optimalisatie van de surveillance in IBD patiënten met IPAA.
Concluderend beschrijft dit proefschrift kanker risico’s en uitkomsten van solide 
intestinale (zowel CRC als NET) en extra-intestinale maligniteiten (RCC) bij IBD patiënten. 
Risicoprofielen voor de ontwikkeling en uitkomst van maligniteiten zijn opgesteld en 
vervolgens vertaald naar aanbevelingen voor behandeling en surveillance. Meer kanker 
specifieke data zijn van essentieel belang voor een geïndividualiseerde benadering. 
Dit kan in de toekomst bijdragen aan ‘case-by-case’ management van IBD patiënten met 
een maligniteit.
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Onderzoek doe je niet alleen! Juist als onderzoekers samenwerken groeit het 
wetenschappelijk inzicht en worden de mooiste resultaten behaald. Desondanks is succes 
nooit gegarandeerd en teleurstelling ligt vaak op de loer. Zowel bij het behalen van successen 
als bij het verwerken van teleurstellingen zijn familie, vrienden en collega’s van uiterst groot 
belang. Ik wil de volgende mensen bedanken die mij zowel binnen als buiten het onderzoek 
hebben gesteund:
Dr. F. Hoentjen, beste Frank, als student-onderzoeker ben ik onder jouw begeleiding van 
start gegaan met mijn onderzoekscarrière. Samen begonnen we aan het project over pouch 
neoplasieën en al gauw wist je jouw enthousiasme en gedrevenheid voor onderzoek op 
mij over te brengen. Je kritische blik en opbouwende commentaar brachten het onderzoek 
naar een hoger niveau en je stimuleerde me iedere keer opnieuw om verder te gaan. 
Helaas was niet alles zonder tegenslagen en tot ieders grote spijt werd je meerdere malen 
onverwacht getroffen door ernstige ziekte. Veerkrachtig als je was, bleef je geïnteresseerd 
en betrokken bij mijn onderzoek waarvoor mijn bewondering en waardering. Frank, ik wil je 
niet alleen danken voor je kritische input en je enthousiasme, maar ook voor alle gezellige 
overleggen en mooie voetbalwedstrijden. Met jouw flitsende voetbaltrucjes hebben een 
hoop medespelers het nakijken gehad.
Prof. Dr. J.P.H. Drenth, beste Joost, samen met Frank gaf je mij de kans mijn wetenschappelijke 
stage te vervolgen met een promotietraject. Ik wil je danken voor jouw vele inzichten hierbij, 
jouw steun en de kansen en mogelijkheden die je me hebt geboden. Altijd stond je voor 
me klaar om mee te denken, ondanks je eigen overvolle agenda. Je overzag de problemen 
binnen een project vrijwel direct en met jouw uitgebreide onderzoekservaring wist je hier 
richting aan te geven. Jouw snelheid en precisie bij het reviseren van manuscripten was 
onevenaarbaar. Ik heb onze samenwerking als zeer enerverend ervaren. Het plezier dat je 
erin stelde om mijn Brabantse tongval na te bootsen, onze felle en uitdagende discussies, 
jouw vele malen grotere fanatisme dan kunde bij de verschillende voetbalwedstrijden, het 
theeleuten op de vroege morgen nadat we vrij onverwacht samen een stapelbed mochten 
delen; ik heb genoten van alle aspecten van onze samenwerking. Vele malen dank hiervoor!
Prof. Dr. I.D. Nagtegaal, beste Iris, het begon allemaal met een PALGA zoekvraag naar 
pouch neoplasieën. Sindsdien bestaat er voor mij een onlosmakelijke verbintenis tussen 
jouw naam en PALGA zoekvragen. Je talrijke ideeën in combinatie met je enthousiasme 
zorgden binnen no time voor verschillende PALGA zoekvragen. Het motto was “even wat 
verslagen doornemen en dan zijn we zo in het bezit van een heleboel mooie data”. Dat 
dit “even wat verslagen doornemen” duizenden tot tienduizenden pathologie verslagen 
omvatte, was slechts een klein detail. Desondanks heeft het me een aantal mooie publicaties 
opgeleverd, waarvoor dank. Hiernaast wil ik je danken voor je aanstekelijke enthousiasme, 
je steun en je inzichten. Op korte termijn was er altijd een afspraak mogelijk in je kleurrijke 
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agenda, met voor ieder type afspraak een apart kleurtje. Ik heb bewondering voor je 
netwerk skills en je creativiteit bij het doen van onderzoek. Dank voor deze gezellige en 
leerzame periode.
Prof. Dr. N. Hoogerbrugge, beste Nicoline, dank voor de samenwerking binnen het IBD 
en Lynch project. Jouw motto “op zoek naar de zebra” heeft me doen inzien dat juist 
ook het herkennen van de uitzonderingen van wezenlijk belang is voor het verkrijgen 
van nieuwe inzichten. 
Zonder manuscript commissie en corona geen proefschrift en verdeging. Dank aan hen die 
deze taak op zich hebben genomen.
De samenwerking met PALGA (Pathologisch Anatomisch Landelijk Geautomatiseerd 
Archief ), de ICC (Dutch Initiative on Crohn and Colitis) en vele MDL-artsen en pathologen 
is van onmiskenbaar belang geweest bij de uitvoer van een groot aantal studies in dit 
proefschrift. Dank voor allen die hun deuren hebben opengesteld voor mijn onderzoek! 
Lucy, jou wil ik in het bijzonder bedanken voor alle hulp bij het finetunen en uitvoeren van 
de verschillende PALGA zoekvragen. 
Oud collega-onderzoekers van de buitenhoek, jullie wil ik bedanken voor alle gezellige 
momenten en support bij het opstarten van mijn onderzoekscarrière. Als student-
onderzoeker voelde ik me direct thuis in de buitenhoek, mede door de gezelligheid bij Mieke 
en Melissa, het serieuze beraad bij Polat, de humoristische anti-Brabander kamergenoten 
Robin en Frank, en dj Tom en Mark (met helaas iedere vrijdagmiddag kerstmuziek).
MDL onderzoeksgroep 2.0, jullie doen zeker niet onder voor de oud collega’s van de 
buitenhoek. Hartelijk dank voor de samenwerking, jullie input en de leerzame momenten! 
Ik heb genoten van het pubquizen, de voetbalwedstrijden, de spelletjesavonden, de 
skivakanties, en de gezamenlijke feestjes, borrels en congressen. Yasmijn, Loes, Titus, 
Hedwig, Floor, Myrte, Marten, Mark, Jos, Edgar, Wybrich, Evelyn, Simon, Karina, Angelique, 
Xavier, Isabelle, Govert, Dorian, Yannick, en René, dank hiervoor! Yasmijn, het was fijn om 
met jou te kunnen sparren over onderzoek en meer, en je input te ontvangen. Ik ben er 
trots op dat onze flexkamer gebombardeerd was tot kletskamer voor onderzoekers, AIOS en 
stafleden! Loes, collega IBD-onderzoeker, onze samenwerking heb ik als zeer prettig ervaren 
en heeft ons onderzoek tot grotere hoogte gebracht. Ik ben blij dat we onze samenwerking 
en onze goede gesprekken hebben kunnen voortzetten en dat ik je nog iedere dag mag 
treffen in het JBZ!
Collega-onderzoekers en analisten van de pathologie, dank dat jullie mij op geduldige wijze 
wegwijs hebben gemaakt bij de meer basale en pathologie-gerelateerde aspecten van het 
onderzoek. Ik heb de werksfeer bij jullie als zeer ontspannen en gezellig ervaren, dank Nikki, 
Michiel, Niek, Sabine, Monika, Annemarie, Steven, Femke, Jeroen, Elisa en Shannon. De vier 
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laatst genoemde wil ik in het bijzonder bedanken voor de hulp en praktische ondersteuning 
bij het field cancerisation project.  
Jody, Hennie en Rene, alhoewel ik bij jullie geen labervaring heb opgedaan, was ik toch 
vaak genoeg in de koffiekamer van het lab te vinden. De fanatieke wijze van jullie rikken in 
combinatie met de nonchalante “eigenlijk heb ik geen idee wat ik doe” houding van anderen 
maakten het Brabantse kaartspel tot een goede lunch besteding. Jody, samen met Titus en 
jou was het altijd gezellig om weer een nieuwe voetbalwedstrijd te mogen organiseren.
Wouter-Michiel en Lisa, als student-onderzoekers hebben jullie mij geweldig ondersteund 
waarvoor dank! De vele data die jullie vergaard hebben zijn essentieel geweest bij 
de totstandkoming van verschillende manuscripten. Lisa, super dat je jouw 
onderzoekscarrière ook hebt vervolgd met een promotietraject! 
Wietske, dank voor het sparren over de methodologische en statistische vraagstukken. 
Jouw gestructureerde werkwijze en ervaring als senior-onderzoeker zijn bij verschillende 
projecten van nut gebleken. 
Co-auteurs die ik niet eerder specifiek benoemd heb, dank voor jullie bijdrage aan de 
verschillende publicaties in dit proefschrift. 
Jesssica, als chef de corridor heb ik regelmatig verhitte, uitdagende discussies met je 
gevoerd. Onze gesprekken zaten boordevol humoristische toespelingen, met toch vaak een 
serieuze ondertoon. Dank voor al deze gesprekken, jouw interesse in mij persoonlijk en je 
waardevolle adviezen! 
Alle stafleden, AIOS, verpleegkundigen en secretaresses van de MDL afdeling in het 
Radboudumc, dank voor de ondersteuning waar nodig, de prettige sfeer en gezellige 
werkomgeving. Maria, dank voor het aandragen van patiënten die mogelijk in één van mijn 
studies pasten. 
Collega’s in het JBZ, met jullie ben ik een nieuwe uitdaging begonnen, namelijk de opleiding 
tot MDL-arts. Dank voor de fijne leeromgeving en gezelligheid. Judith, lieve buddy, dank 
voor je hulp bij de Nederlandse samenvatting van mijn proefschrift.
Lieve familieleden, vrienden en vriendinnen, vele malen dank dat ik mijn successen en 
teleurstellingen bij het onderzoek altijd uitgebreid met jullie heb kunnen delen. Evenzo 
belangrijk waren voor mij de gezelligheid, de humor en de ontspanning. Dit hielp me 
mijn gedachten te verzetten en gaf me energie om verder te gaan. Dank voor alle uitjes, 
gezelschapsavonden, bordspellen en avondjes in de kroeg, zelfs als de volgende ochtend 
weer “vroeg” een voetbalwedstrijd op het programma stond! Anne, jou wil ik in het bijzonder 
bedanken voor onze wekelijkse etentjes, waarbij ik al mijn overwegingen en frustraties 
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betreffende het onderzoek en zoveel meer kwijt kon. Allen dank voor jullie zo enorm 
waardevolle vriendschappen!
Lieve Sebastian & Chanti, Tijmen & Loes, en Dagmar, wat ongelooflijk fijn dat ik zulke lieve 
broers en (schoon)zussen heb. Jullie humoristische en nuchtere opmerkingen over mijn 
wetenschappelijke carrière waren vaak erg relativerend. Zo werd door jullie het ietswat 
serieuze “dokter Derikx” al snel omgedoopt tot “poepdokter” of “dokter A.A.P.”, gelijk aan mijn 
initialen. De door jullie aangedragen stellingen voor dit proefschrift waren zeker origineel te 
noemen, echter heeft geen enkele stelling het ook daadwerkelijk gehaald. Jammer genoeg 
kon ik slechts twee van jullie vragen mijn paranimf te zijn. Tijmen en Dagmar, fijn dat jullie 
deze taak op jullie hebben willen nemen. Dagmar, lief zusje, heel veel dank voor alle hulp bij 
de laatste (administratieve) loodjes. 
Lieve papa en mama, dank voor jullie onvoorwaardelijke steun en vertrouwen in mij. Van 
jullie heb ik geleerd om af te maken waar ik aan begonnen ben en om door te zetten. Bij 
twijfel over wat voor keuzes dan ook waren jullie altijd daar voor advies. Pap, dank voor het 
prachtige ontwerp van de kaft. Mede door jullie beiden heb ik het punt bereikt waar ik nu 
ben. Dank hiervoor lieve pap en mam!
Lauranne Derikx
Nijmegen, oktober 2016
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Lauranne Derikx werd geboren op 18 juli 1988 te 
Oud en Nieuw Gastel (Noord-Brabant). Zij behaalde 
in 2006 cum laude haar Gymnasium diploma aan het 
Norbertuscollege te Roosendaal (Noord-Brabant). In 
datzelfde jaar startte zij met de opleiding Geneeskunde 
aan de Radboud Universiteit Nijmegen. Nadat zij 
zowel haar propedeuse (2007) als bachelor (2009) had 
ontvangen met het predicaat cum laude, behaalde zij in 
2013 haar artsexamen. 
Gedurende haar opleiding volgde Lauranne een 
wetenschappelijke stage aan de afdeling Maag-, 
Darm-, Leverziekten van het Radboud Universitair 
Medisch Centrum te Nijmegen onder begeleiding 
van dr. F. Hoentjen. Ze onderzocht het risico op pouch 
neoplasieën bij patiënten met inflammatoire darmziekten en de hieruit volgende publicatie 
werd bekroond met verschillende onderzoeksprijzen (Onderwijs- en Opleidingsregio 
Oost Nederland Onderzoeksprijs 2014, PALGA prijs 2014, Best Paper Award 2014).  Na 
aanvankelijk 4 maanden werkzaam te zijn geweest als ANIOS Maag-, Darm-, Leverziekten 
in het Radboudumc, vervolgde zij haar wetenschappelijke stage met een promotietraject. 
Hierin onderzocht zij het risico op verschillende intra- en extra intestinale maligniteiten bij 
patiënten met inflammatoire darmziekten. 
In het kader van haar opleiding tot Maag-, Darm-, Leverarts, begon Lauranne op 1 
oktober 2015 aan haar vooropleiding Interne Geneeskunde in het Jeroen Bosch Ziekenhuis 
te ’s Hertogenbosch (opleider mw. dr. W. Smit).
Curriculum vitae
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LIST OF PUBLICATIONS
2013: LAAP Derikx, JT Heikens, CJHM van Laarhoven, F Hoentjen. Ileo-anale pouch voor 
inflammatoir darmlijden (Ileo-anal pouch for inflammatory intestinal disease) 
Nederlands tijdschrift voor geneeskunde 2013;157(39):A555.
2014:  LAAP Derikx, W Kievit, JPH Drenth, DJ de Jong, CY Ponsioen, B Oldenburg, AE van der 
Meulen – de Jong, G Dijkstra, MJAL Grubben, ID Nagtegaal, F Hoentjen, on behalf of 
the Dutch Initiative on Crohn and Colitis. Prior colorectal neoplasia is associated with 
increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease 
Gastroenterology 2014;146(1):119-128 e1.
2014:  LAAP Derikx, F Hoentjen. Cuff and pouch cancer in patients with inflammatory bowel 
disease: What surveillance strategy should be recommended? Inflammatory Bowel 
Diseases 2014;20:E20.
2015: LAAP Derikx, LHC Nissen, LJT Smits, B Shen, F Hoentjen. Neoplasia risk after 
colectomy in inflammatory bowel disease patients – A systematic review and meta-
analysis. Clinical Gastroenterology and Hepatology 2015;14(6):798-806.
2015: LAAP Derikx, LHC Nissen, B Oldenburg, F Hoentjen. Controversies in pouch 
surveillance for patients with inflammatory bowel disease. Journal of Crohn’s and 
Colitis 2015;10(6):747-751.
2015: LAAP Derikx, LHC Nissen, JPH Drenth, CM van Herpen, W Kievit, RHA Verhoeven, 
PFA Mulders, CA Hulsbergen-van de Kaa, MJ Boers-Sonderen, TRA van den Heuvel, 
M Pierik, ID Nagtegaal, F Hoentjen, on behalf of the Dutch Initiative on Crohn and 
Colitis, PALGA group, and IBD and RCC group. Better survival of renal cell carcinoma 
in patients with inflammatory bowel disease. Oncotarget 2015;6(35):38336-38347.
2015: M Boers-Sonderen, SF Mulder, ID Nagtegaal, LAAP Derikx, G Wanten, P Mulders, WTA 
van der Graaf, F Hoentjen, CML. van Herpen. Endoscopy in patients with diarrhea 
during treatment with vascular endothelial growth factor receptor tyrosine kinase 
inhibitors: is the cause in the mucosa. Acta oncologica 2015;55(4):444-448.
2015: LHC Nissen, ID Nagtegaal, DJ de Jong, W Kievit, LAAP Derikx, PJ Groenen, HJ van 
Krieken, F Hoentjen. Epstein-Barr virus in Inflammatory Bowel Disease: the spectrum 
of intestinal lymphoproliferations. Journal of Crohn’s and Colitis 2015;9(5):398-403.
2016: LAAP Derikx, WMAM Vierdag, W Kievit, S Bosch, F Hoentjen, ID Nagtegaal. Increased 
prevalence of colonic neuroendocrine tumors in inflammatory bowel disease. 
International Journal of Cancer 2016;139(3):535-542.
LIST OF PUBLICATIONS
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2016: LAAP Derikx, LA Dieleman, F Hoentjen. Probiotics and prebiotics in ulcerative colitis. 
Best Practice & Research: Clinical Gastroenterology and Hepatology 2016;30(1):55-57.
2016: LAAP Derikx, LJT Smits, S van Vliet, E Dekker, CM Aalfs, MCA van Kouwen, FM 
Nagengast, ID Nagtegaal, N Hoogerbrugge, F Hoentjen. Colorectal cancer risk in 
patients with both Lynch syndrome and inflammatory bowel disease. Clinical 
Gastroenterology and Hepatology; Epub ahead of print.
2016: LJT Smits, LAAP Derikx, DJ de Jong, RS Boshuizen, AAJ van Esch, JPH Drenth, F 
Hoentjen. Clinical outcomes following a switch from Remicade® to the biosimilar 
CT-P13 in inflammatory bowel disease patients: a prospective observational cohort 
study. Journal of Crohn’s and Colitis 2016; Epub ahead of print.
2016: LHC Nissen, EL Assendorp, RS van der Post, LAAP Derikx, DJ de Jong, W Kievit, M 
Pierik, TRA van den Heuvel, R Verhoeven, LIH Overbeek, F Hoentjen, ID Nagtegaal, 
on behalf of the Dutch Initiative on Crohn and Colitis, PALGA group, and IBD and 
gastric cancer group. Impaired gastric cancer survival in inflammatory bowel disease 
patients. Journal of Gastrointestinal and Liver Diseases 2016; Epub ahead of print.
2016: MM van de Meeberg, LAAP Derikx, HAM Sinnige, L Schipper, P Nooijen, LHC 
Nissen. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn’s disease patient 
on thiopurine monotherapy. World Journal of Gastroenterology 2016; Epub ahead 
of print.
2016: SL Bosch, SJ van Rooijen, GMJ Bökkerink, HJW Braam, LAAP Derikx, CAM Marijnen, 
JHW de Wilt, ID Nagtegaal. Acute toxicity and surgical complications after neo-
adjuvant (chemo)radiotherapy for inflammatory bowel disease related rectal 
cancer. Submitted.
2016: LHC Nissen, M Pierik, LAAP Derikx, E de Jong, W Kievit, TRA van den Heuvel, AR van 
Rosendael, EI Plasmeijer, P Dewint, ID Nagtegaal, F Hoentjen, AE van der Meulen – 
de Jong, on behalf of the Dutch Initiative on Crohn and Colitis, PALGA group, and 
IBD and melanoma group. No impaired melanoma survival in inflammatory bowel 
disease patients. Submitted.
2016:  LHC Nissen, LAAP Derikx, A Jacobs, CM van Herpen, W Kievit, R Verhoeven, E 
van den Broek, E Bekers, TRA van den Heuvel, M Pierik, J Rahamat-Langendoen, 
R Takes, W Melchers, ID Nagtegaal, F Hoentjen, on behalf of the Dutch Initiative 
on Crohn and Colitis, Dutch Head and Neck Society, PALGA group and IBD/HNC 
group. Poor survival of oral cavity carcinoma in patients with inflammatory bowel 
disease. Submitted
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LAAP Derikx, W Kievit, JPH Drenth, DJ de Jong, CY Ponsioen, B Oldenburg, AE van der 
Meulen – de Jong, G Dijkstra, MJAL Grubben, ID Nagtegaal, F Hoentjen, on behalf of 
the Dutch Initiative on Crohn and Colitis. Prior colorectal neoplasia is associated with 
increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease. 
• Oral presentation Digestive Disease Week, 2013, Orlando (USA)
• Gastroenterology 2013;144(5):S136-S137
• Oral presentation Dutch Society of Gastroenterology (NVGE), 2013, Veldhoven 
(The Netherlands)
• Oral presentation Dutch Pathology Days, 2014, Zeist (The Netherlands)
• PALGA award 2014
• Best paper award 2014,  Awarded by the Radboud University Theme: “tumors of 
the digestive tract”
• Education Region East Netherlands Research award 2014
LAAP Derikx, LHC Nissen, JPH Drenth, CM van Herpen, W Kievit, RHA Verhoeven, PFA 
Mulders, CA Hulsbergen-van de Kaa, MJ Boers-Sonderen, TRA van den Heuvel, M Pierik, ID 
Nagtegaal, F Hoentjen. Better survival of renal cell carcinoma in patients with inflammatory 
bowel disease.
• Poster presentation Digestive Disease Week, 2014, Chicago (USA)
• Gastroenterology 2014;146(5):S631-632
• Poster presentation United European Gastroenterology Week, 2014, Vienna (Austria)
• United European Gastroenterology Journal 2014:2 (Supplement 1)
• Oral presentation Clinical PhD retreat 2014, Radboud University Medical Centre, 
Wageningen (The Netherlands)
LHC Nissen, ID Nagtegaal, DJ de Jong, W Kievit, LAAP Derikx, PJ Groenen, HJ van Krieken, 
F Hoentjen. Epstein-Barr virus in Inflammatory Bowel Disease: the spectrum of intestinal 
lymphoproliferations.
• Poster presentation Digestive Disease Week, 2014, Chicago (USA)
• Gastroenterology 2014;146(5):S378-379
LAAP Derikx, LHC Nissen, LJT Smits, B Shen, F Hoentjen. Neoplasia risk after colectomy in 
inflammatory bowel disease patients – A systematic review and meta-analysis.
• Poster presentation Digestive Disease Week, 2015, Washington DC (USA)
• Gastroenterology 2015;148(4):S469
• Poster presentation United European Gastroenterology Week, 2015, Barcelona (Spain)
• United European Gastroenterology Journal 2015:2 (Supplement 1)
ABSTRACTS AND 
CONFERENCES
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LAAP Derikx, LJT Smits, S van Vliet, E Dekker, CM Aalfs, MCA van Kouwen, FM Nagengast, ID 
Nagtegaal, N Hoogerbrugge, F Hoentjen. Colorectal cancer risk in patients with both Lynch 
syndrome and inflammatory bowel disease.
• Oral presentation United European Gastroenterology Week, 2015, Barcelona (Spain)
• United European Gastroenterology Journal 2015:2 (Supplement 1)
• UEG Week 2015 Travel Grant
• Oral presentation Dutch Society of Gastroenterology (NVGE), 2015, Veldhoven 
(The Netherlands)
LAAP Derikx, SB van Tilburg, ID Nagtegaal, LHC Nissen, F Hoentjen. Colorectal cancer risk in 
a nationwide inflammatory bowel disease cohort with low grade dysplasia.
• Oral presentation United European Gastroenterology Week, 2016, Vienna (Austria)
• United European Gastroenterology Journal 2015: In press
• UEG Week 2016 Travel Grant
• Oral Free Paper Prize
• Oral presentation Dutch Society of Gastroenterology (NVGE), 2016, Veldhoven 
(The Netherlands)
